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Abstract 
In Vitro Evaluation of Anthracycline-induced Cardiotoxicity and 
Mitigation by Perturbation of Angiotensin Signalling 
Key words: Cardio-oncology, cardiotoxicity, anthracyclines, angiotensin signalling, hypertrophy, 
xCELLigence, doxorubicin, angiotensin receptor blockers, toxicity mitigation. 
Cardiotoxicity is a major complication of many anticancer therapies, particularly anthracyclines, which 
impacts the quality of life and overall survival of patients. Manifesting as both an acute toxicity and more 
frequently a chronic toxicity occurring months or years after conclusion of therapy, there is an urgent 
need for greater understanding of the molecular mechanisms responsible for these toxicities and 
identification of therapeutic strategies to mitigate and overcome this issue. Improved in vitro models for 
accurate prediction and modelling of these cardiac liabilities is therefore of crucial importance. 
Recently, clinical studies have demonstrated that drugs which perturb angiotensin signalling may reduce 
the cardiotoxicity of anthracyclines. However, despite showing promise, the mechanism of toxicity is 
unresolved and the molecular relationship to angiotensin signalling in the heart is currently unknown. 
Furthermore, the majority of in vitro cardiotoxicity studies to date have either used inappropriate cell 
models or utilised end-point assays, both strategies that fail to account for the physiological parameters 
of cardiac cells and the progressive nature of human toxicity development. 
This study has qualified the use of hiPSC-derived cardiomyocytes and the human AC10 cardiomyocyte cell 
line paired with impedance-based systems (xCELLigence technology) for detection of both structural and 
functional cardiotoxicity. A range of pharmacological and biological mediators were used to qualify these 
technologies, with both structural hypertrophy and physiological contractility monitorable. A major 
advantage of these systems over others is that longer-term real-time non-invasive experiments can be 
conducted, thus allowing recapitulation of the progressive nature of human toxicity development and 
subsequently a robust clinically relevant method for assessing drug-induced cardiotoxicity. 
Using these models and technologies, this study demonstrates induction of cardiomyocyte hypertrophy 
by anthracyclines which is reduced by blockade of angiotensin signalling, thus implying a relationship at 
the cardiomyocyte level between anthracycline-induced cardiotoxicity and angiotensin signalling. 
Furthermore, anthracycline-induced elevated expression of the angiotensin type I receptor and several 
genes implicated in angiotensin II signalling in this study provides further evidence for a direct molecular 
relationship between anthracycline-induced cardiotoxicity and angiotensin signalling, with clear 
translational potential for clinical mitigation of this dose-limiting toxicity in the treatment of cancer. 
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Chapter 1: Introduction 
1.1 Cancer 
Cancer is a broad and complex family of diseases that can affect all tissues of the body.  There 
are more than 100 distinct types of cancer, and subtypes of tumours can be found within specific 
organs.  Although cancer has multiple causes and exhibits a wide range of genetic, physiological 
and histological features, an acceptable clinical definition states that cancer is a set of diseases 
characterised by upregulated cell growth leading to invasion of surrounding tissues and 
metastasis to different parts of the body.1,2 
 
1.1.1 Increasing prevalence of cancer survivors 
There are reportedly over 200 different pathological types of human cancer affecting all tissues 
of the body, with approximately 350,000 new cases of adult and paediatric cancers diagnosed 
per year in the UK. Furthermore, cancer is the second major cause of mortalities, responsible 
for the deaths of approximately 163,000 people in the UK per year. Consequently, it is now 
estimated that one person in two will be diagnosed with cancer during their lifetime and one in 
four will die of cancer.3  However, as a consequence of extended life expectancy and an increase 
in the global population, it is predicted that over the next decade the prevalence of cancer would 
significantly increase, but due to better prediction and treatment the number of deaths from 
cancer should hopefully decrease. In this context, an upwards trend in both cancer incidence 
and survival has been observed in the United Kingdom in recent years, with today’s cancer 
patients benefitting from life expectancies ten times longer than their counterparts 40 years  
ago.4 In addition, future mortality rates are envisaged to decrease by 15.3% from 2014-2035,5 
thereby further increasing the size of the cancer survivor group. The improved prognosis that 
cancer patients now possess is prospectively due to both the general growth of the aging 
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population as a result of improved treatments for life shortening conditions, and more crucially, 
advancements in cancer screening, diagnosis and treatments.6 
The total number of cancer survivors in the United Kingdom has been predicted to escalate by 
one million each decade from 2010 – 2040, assuming existing trends continue. According to 
these predicted trends there will be three million cancer survivors in the United Kingdom in 
2020, with varied and often complex care needs bringing additional challenges to healthcare 
professionals.7 
 
1.2 Management of cancer 
Chemotherapy is the most widely used type of treatment for cancer and can be used at different 
stages of disease progression. Conventionally chemotherapy is directed at disrupting cell 
proliferation, targeting one or more of the hallmarks of cancer.1 Currently, the majority of agents 
in clinical use are systemic anti-proliferative agents that target cells undergoing rapid growth by 
attacking DNA or the processes involved in DNA replication.8 These established 
chemotherapeutic agents can be categorised according to their mode of action including DNA 
interacting agents, antimetabolites, antimicrotubule agents and topoisomerase inhibitors, 
described below.  
However, although these drugs are able to kill large numbers of tumour cells their efficacy is 
limited by the damage they cause to proliferating normal cells such as in the cardiovascular 
system, gastrointestinal tract and bone marrow.8  The therapeutic window for tumour versus 
normal tissue is modest with anti-proliferative compounds, toxic side effects are the norm and 
the development of resistance often occurs.9 
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1.2.1 DNA interacting agents 
Alkylating agents such as cyclophosphamide, together with the platinum based agents such as 
cisplatin, act by covalently binding alkyl groups of cellular macromolecules such as DNA and 
protein.  Such agents react covalently with DNA bases to form DNA adducts and cross links which 
disrupt the structure and processing of DNA leading to inhibition of replication, DNA mispairing 
and consequently the induction of cell death pathways.10 
Cyclophosphamide is used to treat a variety of cancers including haematological cancers and 
solid tumours originating from the lung, breast, ovaries and brain. Due to the inability of these 
drugs to differentiate from rapidly dividing tumour cells and rapidly dividing healthy cells, many 
acute toxicities occur due to the drug’s effects on proliferating healthy cells. Reduction in the 
numbers of white blood cells, platelets and red blood cells can cause an increased risk of 
infection, bruising and anaemia respectively. Similarly, mucosal membranes are associated with 
a high turnover rate and hence toxicities such as bladder irritation, mouth ulcers and vomiting 
are also common. The hair, skin and nails can also be affected with side effects including hair 
loss, dry skin, skin rashes, brittle nails, nail discolouration occurring in most patients.11  
More serious side effects include decreases in fertility, development of secondary cancers and 
disturbances in heart function. Cardiac toxicity is a less common side effect, and generally occurs 
after a single cycle of a high dose regimen; causing a haemorrhagic necrosis that can be life 
threatening and, on rare occasions, fatal. In contrast to the usual progressive nature of heart 
failure, cardiac failure associated with cyclophosphamide can be seen as early as several days 
following administration, which illustrates the severity of this side effect.11,12 
 
1.2.2 Topoisomerase interactive agents 
Nuclear topoisomerase enzymes play a crucial role in the normal replication of DNA.  In its 
physiological state in the chromosome, the DNA helix is supercoiled and replication requires 
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transient relaxation and unwinding of the parent DNA.  In order to achieve this, cleavage of the 
DNA is required. This is mediated by the formation of a cleavable complex consisting of a 
covalent intermediate between topoisomerase and DNA, allowing passage of the intact strand 
and subsequent DNA unwinding, followed by re-ligation of the DNA strands.13  This is crucial for 
protein synthesis where strands of the DNA double helix must be uncoiled for transcription to 
take place and subsequently recoiled.   
Topoisomerase inhibitors prevent the re-ligation of the DNA strands by stabilising the complex 
of topoisomerase enzyme and DNA. The most common class of topoisomerase inhibitor used in 
the clinic are the anthracycline-class of topoisomerase II inhibitors. The DNA damage and 
fragments produced by these agents directly block cell replication and trigger cell death 
pathways.14 Anthracyclines such as doxorubicin are among the most effective anti-cancer agents 
introduced in the past 50 years, and are commonly used in treatment of cancers of the breast, 
stomach and lung and also in haematological malignancies. Due to their inhibitory effect on DNA 
replication, and therefore on all rapidly proliferating cells, anthracyclines are associated with 
many of the acute toxicities associated with cyclophosphamide treatment described above.15 
More serious side effects include peripheral neuropathy, development of secondary cancers and 
disturbances in heart function.15 The most severe side-effect associated with anthracyclines is 
the development of cardiotoxicity, so much so that it is considered the prototypical anti-cancer 
drug to cause permanent therapy-induced cardiotoxicity. Unlike cyclophosphamide induced 
toxicity which can occur rapidly, anthracycline induced cardiotoxicity is cumulative and related 
to the maximum lifetime dose. Usually manifesting as left ventricular dysfunction, cardiotoxicity 
can occur acutely, or more frequently the damaging effects are dormant until many years after 
the completion of therapy and can culminate in heart failure.16,17 Both the acute toxicities 
associated with chemotherapy, and the more severe permanent cardiac liabilities have 
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prompted the search for therapies that are more specific towards tumour cells whilst sparing 
healthy cells from toxicities. 
 
1.2.3 Molecular targeted therapies 
Over the past decade, a more advanced, although still primitive, understanding of the molecular 
biology of cancer has contributed to the process of discovery and development of anticancer 
agents from classical cytotoxic drugs to target-led, rationally designed agents. These compounds 
are designed to expand beyond disrupting DNA replication and exploit defined abnormalities 
responsible for the causation, maintenance or progression of human tumours such as genetic 
instability, aberrant cell cycle control, invasion, angiogenesis and the ability to metastasise.18 
The identification of aberrant signalling pathways in cancer has led to the development of 
therapies that target specific oncogenic processes.  The initial wave of molecular therapeutics 
favour the receptor tyrosine kinase (RTK)- Ras- Raf-1- extracellular signal-regulated protein 
kinase (ERK) signal transduction pathway.19  This pathway was one of the earliest pathways to 
be understood and is frequently deregulated in human cancer. Both epithelial growth factor 
receptors (EGFR) and Ras genes often possess activating mutations which lead to the persistent 
stimulation of downstream pathways essential for cancer progression. A number of RTK 
inhibitors have been directed towards the EGFR and other RTKs implicated in signalling 
pathways important in cancers.20  Several RTK inhibitors are now used in the clinic: Trastuzumab 
(Herceptin) for the treatment of HER2 positive breast cancers, Imatinib (Gleevec) for the 
treatment of chronic myelogenous leukaemia (CML), gliomas and gastrointestinal-stromal 
tumours, and Gefitinib (Iressa) for the treatment of non-small cell lung cancer (NSCLC). Other 
agents currently undergoing phase I/II clinical trial in NSCLC include Nazartinib (EGF816) and 
Avitinib (AC0010). The occurrence of developing resistance to RTK inhibitors is unfortunately 
commonplace, often due to the acquisition of mutations that prevent the inhibitors binding to 
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their target.21 Nazartinib and Avitinib are third generation inhibitors and will hopefully remedy 
issues of resistance associated with the existing RTK inhibitors used to treat NSCLC.22 
In contrast to expectations, these molecular targeted agents exhibit a range of toxicities, albeit 
different to the conventional DNA interacting agents. Often, the toxicities that occur are specific 
to the class of targeted therapy. For example, inhibitors of the EGFR such as gefitinib (Iressa) are 
associated with the development of skin, nail and hair reactions which occur in approximately 
50% of patients. The most common of these adverse effects is an acneiform rash that usually 
appears on the face or upper body.23 Within the epidermis of the skin the EGFR plays a critical 
role and is highly expressed in keratinocytes which form the majority of the epidermis.24 
Inhibition of EGFR signalling is thought to alter keratinocyte behaviour including proliferation, 
differentiation, attachment and migration. Due to the importance of EGFR signalling in the skin, 
the coincident inhibition of EGFR signalling in the skin may be responsible for the occurrence of 
dermatological toxicities in cancer patients treated with EGFR inhibitors.25 
Specific toxicities also occur with therapies that target the vascular endothelial growth factor 
receptor (VEGFR), termed angiogenesis inhibitors, such as Bevacizumab (Avastin).  The primary 
side-effect of this drug class is hypertension which occurs so frequently it is considered a 
biomarker of therapeutic efficacy.26 VEGFR signalling is important in the normal vasculature and 
plays a role in vascular density and generation of the vasodilatory mediator nitric oxide (NO). 
Inhibition of this signalling by angiogenesis inhibitors used in cancer management results in 
vascular rarefaction and decreased NO which both contribute to hypertension by increased 
peripheral resistance and vasoconstriction.27  
Although usually not life-threatening, the toxicities that arise from targeted therapies can 
decrease the quality of life for patients and can also require temporary treatment interruptions 
which could reduce therapeutic efficacy. Fortunately, the toxicities are usually reversible, and 
disappear upon the completion of treatment.  This is especially pertinent with the occurrence 
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of toxicity to the cardiovascular system as the therapy-induced toxicity is less likely to adversely 
affect their long-term health, and is associated with a more favourable prognosis compared to 
cardiotoxicity induced by some chemotherapies. 
 
1.3 Cancer therapy induced cardiotoxicity 
Although increased understanding of the molecular basis of cancer over the past decade has 
advanced cancer chemotherapy, and many of these medicines have significantly improved 
cancer treatment and patient survival, it is now clear that their benefit is counterbalanced by 
adverse toxic effects, particularly upon the cardiovascular system.28,29 The improved success of 
cancer treatment has in itself created issues regarding cardiovascular toxicity, as the prolonged 
patient survival allows the patient to live long enough to encounter the long-term detrimental 
effects of the particular therapeutic. The risk of patients developing cardiovascular related 
health problems post cancer treatment represents an extra hurdle for both patients and health 
professionals and can pose more of a threat to patients than the development of cancer 
recurrence.30,31 A situation then arises in which cardiovascular toxicity can be the main 
determinant of quality of life and potentially be responsible for premature death, as opposed to 
cancer. In fact, the risk of death from cardiac related toxicities may exceed the risk of recurrence 
for many forms of cancer32 and cancer survivors are estimated to be 15 times more likely to 
develop heart failure and 10 times more likely to develop coronary disease than their siblings.33 
Both the probability of developing cancer therapy induced cardiotoxicity and the severity of the 
problem depends on various patient specific factors such as age, sex and the presence of 
cardiovascular co-morbidities. Consequently, challenges exist with respect to identifying, 
managing or at least monitoring cancer-therapy related cardiovascular toxicity, to provide the 
most beneficial cancer treatment, and ultimately improve patient outcomes and longer-term 
healthcare.34 
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1.3.1 Emergence of cardio-oncology  
Increases in the survival rate of patients with cardiovascular diseases have also been observed 
during the past three decades, which can be attributed to improved treatments and greater 
awareness of risk factors.35 As a result of the increased incidence and prevalence of both 
cardiovascular disease and cancer, the number of patients that present with both conditions is 
increasing.36 Human diversity further complicates the issue, with cancer patients coming from 
wide-ranging health backgrounds with varied baseline susceptibilities to cardiovascular toxicity. 
Common risk factors for development of cardiovascular disease include hypertension, stress, 
diabetes mellitus, obesity, lack of exercise and poor diet.37 Based on these environmental and 
health factors, a higher likelihood for cardiovascular disease exists in the cancer population than 
the general population.38  
Cardiovascular co-morbidities such as heart disease and hypertension can amplify the problem 
of drug-induced cardiotoxicity, as patients already have a reduced cardiac reserve, making them 
already one stop closer to developing complications with their heart function even before the 
challenge of cancer and administration of a potentially cardiotoxic therapy. For these reasons it 
is important that cardiovascular issues are identified and the associated risks are managed, 
minimised and evaluated throughout a patients’ cancer treatment and beyond. This includes 
assessment of cardiovascular risk factors at baseline and tailoring of a suitable treatment plan 
that takes in to account both the existing damage and the amount of additional insults to the 
cardiovascular system that could be tolerated. This information would allow for a more informed 
decision on the type and amount of cancer therapy that could be given without causing 
additional cardiovascular harm, whether administration of cardioprotective drugs is necessary 
and how frequently monitoring of heart function and biomarkers indicative of early cardiac 
damage should be assessed.39   
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This forms the basis of the emerging discipline termed cardio-oncology, which aims to develop 
interdisciplinary expertise to effectively treat a patients cancer whilst minimising any collateral 
damage to the cardiovascular system.40,41 Although cardiotoxicity is prevalent  in the cancer 
survivor group in general, sensitivity can vary greatly between individuals, suggesting differing 
genetic variations or predispositions to drug-induced cardiovascular toxicity within the cancer 
patient population.42 Therefore, in order to create safer yet still effective cancer treatments, a 
much greater appreciation of the underlying molecular mechanisms by which current therapies 
cause adverse effects upon the cardiovascular system and how to predict these toxicities before 
they arise in the clinic is required. 
 
1.4 The cardiovascular system 
The average human body contains approximately five litres of blood that is constantly travelling 
around the vascular system to provide an adequate supply of oxygen and nutrients to the 
organs, whilst simultaneously removing waste products. Also responsible for the transport of 
hormones and immune cells to their required sites of action; the cardiovascular system is multi-
functional and essential for sustaining life. As such, it is the first functional organ to develop 
during embryonic development,43 with a spontaneous heart beat arising by week four of 
development. Within the cardiovascular system the heart and the peripheral vasculature form 
a closed circulatory system where the heart is the central component. Structurally composed of 
four chambers, the heart is formed from specialised striated cardiac muscle surrounded by a 
dense coronary microvascular network that ensures the high metabolic requirements of the 
myocardial tissue are met.44 A heterogeneous mixture of support cells and cardiomyocytes 
complete the myocardial tissue; in which the cardiomyocytes are the cell type responsible for 
the generation of contractile force.  
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1.4.1 Cardiomyocytes: The contractile unit of the heart  
The heart fulfils its role of maintaining constant circulation of blood through the vascular system 
by its ability to continuously pump without interruption, cycling between relaxing (diastole) and 
contracting (systole).44 The capability to contract in this rhythmic manner is due to the close co-
ordination of cardiomyocytes which represent 30% of cells in the myocardium, the others being 
cardiac fibroblasts, microvascular endothelial cells and pericytes (described below). Due to the 
large size of cardiomyocytes, although they only constitute 30% of cell type, they are estimated 
to make up approximately 85% of the volume of the myocardium.45 During embryogenesis the 
appropriate signals initiate the differentiation of these specialised cells from stem cells, which 
in their mature form contain an abundance of mitochondria and highly organised repeating 
arrangements of myofilaments called sarcomeres (Figure 1.1).46  The main components of 
sarcomeres are thin actin filaments and thick myosin filaments, which shorten sarcomere length 
by sliding past each other. This forms the basis of the sliding filament theory of muscle 
contraction whereby the co-ordinated multi-sarcomere shortening triggers contraction of the 
cardiomyocyte.47 As the myocardium exists as a syncytium, co-ordinated cardiomyocyte 
contractions occur which culminate in ventricular contraction and the expulsion of blood around 
the body.  
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Figure 1.1 Ultrastructure of cardiomyocytes 
Cardiomyocytes are specialised muscle cells composed of myofibrils that contain repeating 
arrangements of myofilaments called sarcomeres. T-tubules and sarcoplasmic reticulum are 
specialised organelles required for contraction that can form a diad structure. Adapted from 
reference.48 
 
 
 
 
 
 Diad 
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1.4.2 Generation of contractile force: Excitation-contraction coupling 
Cardiac excitation-contraction coupling describes the series of events required to translate an 
electrical impulse into mechanical contraction (Figure 1.2). This process is ultimately regulated 
by of adenosine triphosphate (ATP) and calcium ions (Ca2+), where presence of the ions elicit 
contraction, and subsequent dissociation causes relaxation of the myocardium.49  
The pacemaker cells of the heart spontaneously initiate an electrical impulse in the form of an 
action potential which propagates through the heart causing membrane depolarisation. The 
action potentials utilise gap junctions to jump through cells, travel along the sarcolemma, and 
penetrate the cells in deep invaginations of the sarcolemma known as transverse tubules (T-
tubules). The highly specialised extensive T-tubule network that cardiomyocytes possess allow 
the action potentials to travel into the centre of the cell and facilitate entry of Ca2+ through L-
type Ca2+ channels (LTCC) which open due to membrane depolarisation. The Ca2+ are then 
sequestered by the ryanodine receptors (RyRs) of the nearby sarcoplasmic reticulum which acts 
as a Ca2+ storage unit within the cell.50 Activation of the RyRs via extracellular Ca2+ binding 
triggers the sarcoplasmic reticulum to open, thereby releasing a much greater amount of Ca2+ 
into the cell.51 This process known as calcium induced calcium release (CICR), results in a rapid 
increase in the level off free cytosolic Ca2+ that activates myofilaments to initiate contraction of 
the myocardium.52  
Initially the myosin binding sites of the actin filaments are uncovered as the inhibitory troponin 
I is freed due to Ca2+ binding to troponin C and triggering an allosteric change. The myosin heads 
of the thick filaments can now form a cross-bridge to the binding sites of the thin filaments and 
perform power strokes with the assistance of ATP hydrolysis. This results in the thick and thin 
filaments sliding past each other, thereby shortening the sarcomere.47,49 
The contraction of the myocardium described above represents the systole phase where blood 
is forced out of the heart. Following this the diastole phase occurs where relaxation of the 
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myocardium allows the heart to re-fill with blood. Here, Ca2+ dissociates from troponin C and is 
either removed from the cell via sodium-calcium exchangers (NCX) which trade one Ca2+ for 
three sodium ions (Na+) or put back into storage in the sarcoplasmic reticulum by the 
sarcoplasmic reticulum Ca2+ATPase (SERCA). The reduction of free Ca2+ inhibits cross-bridge 
formation and relaxation of the myocardium occurs.49 
As the process of cardiac excitation-contraction coupling is a tightly regulated process involving 
co-ordinated movement of ions, release of calcium and cross-bridge formation, any 
perturbations to this process can result in disturbances to the cardiomyocyte contraction and 
therefore cardiac rhythm, which compromises the function of the heart at pumping blood 
around the body.  
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Figure 1.2 Cardiac excitation-contraction coupling 
1. Action potentials (AP) travel along the sarcolemma and enter T-tubules causing membrane 
depolarisation 2. This opens L-type Ca2+ channels (LTCC), Ca2+ ions enter the cardiomyocytes and 
bind to the ryanodine receptors (RyR) of the sarcoplasmic reticulum (SR) to cause Ca2+ release 
(Calcium induced calcium release - CICR).  3. The Ca2+ binds to troponin C of the myofilaments 
which initiates cardiomyocyte contraction. Upon repolarisation Ca2+ are loaded back into the SR, 
transported out of the cell and Ca2+ dissociates from troponin C causing cardiomyocyte 
relaxation. The inset graph shows the relationship between AP, [Ca2+]i and cellular contraction.  
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1.4.3 Multicellular composition of the myocardium 
Although cardiomyocytes are the contractile unit of the heart and therefore represent the 
primary cell involved in maintaining cardiac rhythm, other cell types constitute 70% of cells in 
the heart numerically45 and also play important roles in myocardial regulation and homeostasis. 
Cardiac function is reliant upon the dynamic interaction between the extracellular matrix (ECM) 
and the various cell types that compose the heart. 
 
1.4.3.1  Cardiac fibroblasts 
Cardiac fibroblasts have been previously reported to constitute the majority of the support cells 
of the heart, however more recent evidence suggests that they are less prominent and have an 
abundance of 15%.53 These spindle shaped connective tissue cells are crucial for cardiac 
remodelling and maintenance of the extracellular matrix (ECM); and are responsible for the 
production of the majority of myocardial ECM proteins. Situated between cardiomyocytes, their 
close proximity teamed with the capacity to influence ECM composition provides fibroblasts 
with the ability to influence the phenotype of cardiomyocytes.54 Historically fibroblasts have 
been considered a uniform collagen secreting cell type throughout the body, and therefore 
compared to cardiomyocytes cardiac fibroblasts received only minor attention.   
Recent studies have challenged this dogma, and cardiac fibroblasts are now thought to play a 
more varied role in the heart, facilitating a plethora of events associated with the response of 
the myocardium to mechanical, electrical, and chemical signals. Furthermore, communications 
between cardiomyocytes may be supported by cardiac fibroblasts as they are reported to 
possess unique contractile transduction abilities, a quality absent from non-cardiac fibroblasts.55 
Although cardiomyocytes have been the classic target for drug-induced cardiotoxicity, due to 
the close relationship between cardiomyocytes and fibroblasts with respect to signal 
transduction and the response of the myocardium to various stimuli, damage to fibroblasts 
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could also indirectly impair cardiac contractility and function without a drug directly damaging 
the cardiomyocytes. Cardiac fibroblasts may also play a role in receiving and responding to 
distress signals from neighbouring cardiomyocytes following tissue damage. Rohde et al., have 
shown that following tissue damage ischaemic cardiomyocytes release the Ca2+ binding protein 
S100A1 as a distress signal. This is then internalized by local cardiac fibroblasts which attempt 
to maintain homeostasis by assuming an immunomodulatory role and activate anti-fibrotic 
pathways. This interaction with local fibroblasts promotes the maintenance of tissue 
homeostasis and protects against fibrosis.56 This illustrates the important interplay that exists 
between cardiomyocytes and cardiac fibroblasts to maintain stability within the myocardium 
even when challenged with environmental stress.  
 
1.4.3.2  Cardiac microvascular endothelial cells 
The cardiac microvascular endothelial cells are present both within the endocardium that forms 
the inner lining of the heart chambers and in intramyocardial capillaries. Their primary function 
is to supply cardiomyocytes with nutrients and oxygen and to ensure their high metabolic 
demands are met.57 Recent evidence suggests that cardiac microvascular endothelial cells are 
present at a higher abundance than previously reported, and have been estimated to be the 
most prominent cell type in the myocardium accounting for 40% of the cells.53 In addition, it has 
been estimated that there are three endothelial cells for each single cardiomyocyte in the 
myocardium, which ensures a minimum distance for quick cellular diffusion and exchange of 
oxygen and waste products.57  Other roles of cardiac endothelial cells include aiding the 
adherence of immune cells, allowing inter-cellular signalling factors to be communicated and to 
impede thrombus formation.58 Due to the crucial role of cardiac microvascular endothelial cells, 
any damage would adversely affect cardiac contractility as the supply of oxygen, nutrients and 
cellular signalling factors to cardiomyocytes would be compromised. The constant cycle of 
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cardiac excitation-contraction coupling requires uninterrupted energy, which in part relies on 
healthy endothelial cells allowing quick and efficient diffusion of oxygen. 
 
1.4.3.3  Pericytes 
Pericytes are contractile cells which wrap their elongated cellular processes around the 
microvasculature to provide structural integrity.   Located adjacent to endothelial cells, they 
provide support to the microvasculature by means of direct physical contact and paracrine 
signalling. In addition to providing structural integrity, pericytes are involved in vascular 
homeostasis and are important regulators of vascular permeability, blood flow and 
coagulation.59 The study referenced above by Pimto et al. revisited the cellular composition of 
the myocardium, however pericytes were not included in their analysis. Nees et al. conducted 
an extensive study on pericyte characterisation from various species and have suggested that 
they are the second most abundant cell type In the heart after endothelial cells and that each 
pericyte is associated with up to three endothelial cells.60 Given the prominence of this cell type 
in the heart and their physiological significance with respect to regulating blood flow to the 
extensively vascularised myocardium, these cells are a  potential target with respect to 
cardiotoxicity,61 as damage to the cells could compromise the provision of an adequate blood 
supply to the heart. 
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1.4.4 Myocardial cellular communications 
1.4.4.1  Physical communications 
The ability of the heart to rhythmically contract in a co-ordinated manner is aided by the 
extensive number of cellular connections that the cells within the myocardium possess. Gap 
junctions represent a major type of intercellular connection that are present on both 
cardiomyocytes and support cells; where both homotypic (between same cell type) and 
heterotypic connections occur. In virtually all human cells that touch each other, gap junctions 
act as channels that permit direct intercellular transfer of ions and small molecules.62 
Gap junctions are important within the heart as rapid transfer of oxygen and nutrients from the 
microvasculature to cardiomyocytes is essential to meet the energy requirements of this large, 
highly demanding organ.57 In addition, gap junctions facilitate the conduction of electrical 
impulses between cardiomyocytes that precede myocardial contraction. The connexin family of 
gap junction proteins are critical in the rapid conduction of electrical impulses. Connexin-43 
(Cx43) is the most abundant gap junction protein in cardiomyocytes and its presence is essential 
for normal action potential propagation.63 As co-ordinated electrical activity is essential for 
synchronous contractile activity of the heart, impairments to gap junctional communication 
between neighbouring cardiomyocytes could result in disturbance to action potential 
propagation and arrhythmias. Indeed mutations of Cx43 have been associated with atrial 
fibrillation and more recently, sudden infant death.64 
 
1.4.4.2  Chemical communications  
The role of gap junctions in cardiac cells is not limited to the spread of electrical currents through 
the myocardium; exchange of chemical signals also occur in an autocrine and paracrine manner 
which is vital for tissue function. A wide array of molecules are secreted through the dense 
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complicated network that exists between cardiomyocytes and support cells that ultimately 
regulate cardiac structure, function and performance.  
A key example is nitric oxide (NO) which is a small gaseous signalling molecule that passively 
diffuses into cells and regulates intracellular signalling.65 A regulator of vascular and cardiac 
function, the physiological actions of cardiac NO include initiation of positive inotropy, 
(increased myocardial contractility), modulation of intra-cardiomyocyte Ca2+ movements, 
accelerated ventricular relaxation, vasodilation and regulation of cardiac metabolism.66 The 
actions of NO in cardiac physiology are supported by tight regulation of the enzymes responsible 
for its production – NO synthases.  There are three NO synthases which act in unison to increase 
and decrease the influence of NO as required. Loss of this balance by production of a high 
amount of NO could result in cellular disturbances which could lead to heart failure.65 
 
1.4.5 Intracellular signalling pathways in cardiac cells 
In addition to the extracellular communications and interdependencies between cell types 
within the heart, cardiac contractility and physiological function is further regulated by cell-
surface receptors and their interaction with the local cellular environment. A plethora of specific 
receptors and corresponding intracellular signal transduction machinery provides the heart with 
a sophisticated mechanism to respond to extracellular stimuli. Signal transduction is crucial 
during normal physiological functioning of the heart and perturbations of this signalling can lead 
to pathological situations.67 The G-protein coupled receptors (GPCR) represent the largest group 
of cell surface receptors that are heavily involved in signalling in the heart. Examples of GPCRs 
include the angiotensin receptor, α- and β- adrenergic receptor and the ET1B receptors, and 
signalling which is orchestrated through these receptors can alter contractile strength, heart 
rate and vascular tone.68 As GPCRs are expressed by both cardiomyocytes and the vasculature, 
aberrant signalling through these receptors can promote atherosclerosis, hypertension and 
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cardiac hypertrophy.69 Figure 1.3 outlines the process of signal transduction through GPCRs, 
specifically relating to signalling via the angiotensin type 1 receptor (ATR1). 
Phosphorylation of proteins is an important component of all signal transduction cascades, 
including GPCR signalling. Kinases phosphorylate protein substrates whereas phosphatases de-
phosphorylate them; a fine balance exists between activity of these signalling elements as 
dysregulation can cause mayhem within the cells that can contribute to clinical disease. The 
majority of signal transduction in eukaryotic cells can be attributed to protein kinases, of which 
serine/threonine kinases represent a major group that add phosphate groups to either serine or 
threonine amino acid residues; this results in a conformational change to the protein and 
consequently a change in function or location.67 For instance, protein kinase G (PKG) is a cyclic 
guanosine monophosphate (cGMP) dependent kinase that is central to the regulation of the 
pathway through which NO causes vasodilation. This involves, in part, the phosphorylation of 
voltage dependent calcium channels which reduces intracellular Ca2+ levels and therefore 
deteriorates the ability of the vessel wall to contract.70 Protein phosphatases remove phosphate 
groups from target proteins and hence reduce the signal transduction through kinase 
pathways.67 
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Figure 1.3 Process of G-protein coupled receptor (GPCR) signal transduction 
  showing ATR1 signalling as an example 
The GPCR signalling system contains a receptor, a heterotrimeric G-protein and an effector 
molecule. The specific type of all of these components is dependent upon cell type, receptor 
and agonist. In cardiovascular cells, angiotensin II binding to the ATR1 causes activation of the 
Gq/II heterotrimeric G-protein, which stimulates activity of the effector molecule - 
phospholipase C (PLC), whose enzymatic activity hydrolyses a membrane phospholipid to 
generate inositol (1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG). These second messengers 
cause an increase in the intracellular Ca2+ levels and activate protein kinase C (PKC). This then 
leads to phosphorylation of intracellular proteins and a cellular response to the stimulus. The 
physiological effects of angiotensin II on the heart are shown inset on the figure. 
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1.4.5.1  Adrenergic signalling pathways in cardiomyocytes 
The adrenergic receptor signalling pathway mediates the response of cardiac cells to adrenaline, 
involving β-adrenergic GPCRs. There are four subtypes of β-adrenergic receptors, β1 and β2 are 
found in the heart and comprise approximately 75% and 25% of cardiac β-adrenergic receptors 
respectively. Each receptor type is associated with distinct signalling pathways and subsequent 
cellular responses. For instance, β1- adrenergic receptor stimulation of the heart is associated 
with increased myocardial contractility and heart rate.71 
Following receptor activation, adenylate cyclase (effector molecule) generates increased cyclic 
adenosine monophosphate (cAMP) levels (second messenger) which activates Protein kinase A 
(PKA). PKA then co-ordinates the response and phosphorylates various substrates including 
troponin I, ryanodine receptors and ion channels. This facilitates depolarisation and increases 
intracellular Ca2+ levels, thereby culminating in increased myocardial contractility and heart 
rate.72 The β2 adrenergic receptor is thought to have a similar role in increasing contractility, 
however utilising mitogen-activated protein kinase (MAPK) signalling and phospholipase A2 
rather than adenylate cyclase and cAMP.67 
Due to the known effects of adrenergic stimulation on the heart, disruption of this signalling is 
a known pharmacological target, with drugs targeting these receptors being used clinically for 
treatment of congestive heart failure (CHF). Reduced cardiac output in CHF, caused by a 
reduction in the heart’s ability to pump efficiently, is followed by compensatory mechanisms 
leading to increased heart rate and remodelling of the heart. The purpose of the remodelling is 
to return cardiac output to the required level, however puts more strain on the myocardium, 
further deteriorates pumping efficiency and increases the risk of arrhythmias and cardiac 
arrest.73 
Beta-blockers are a class of drugs that disrupt adrenergic signalling and have utility in the 
management of CHF. By decreasing the rate of myocardial contraction, β-blockers such as 
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carvedilol, decrease the work-load on the heart which curbs remodelling, improves ventricular 
filling and reduces further deterioration of cardiac function.74  
 
1.4.5.2  Angiotensin signalling pathways in cardiomyocytes 
The angiotensin receptor signalling pathway mediates the response of cardiac cells to 
angiotensin II, this involves angiotensin receptors (ATR), of which there are two subtypes – ATR1 
and ATR2. The majority of the known physiological effects of angiotensin II are mediated by the 
ATR1 which are widely expressed throughout the body including the heart. Angiotensin II 
mediates a myriad of physiological and pathological processes in the cardiovascular system 
including vasoconstriction and blood pressure regulation, inflammation, atherosclerosis, 
hypertension, and cardiac hypertrophy/remodelling.75 The physiological importance of 
angiotensin II in the cardiovascular system is paramount, as it is responsible for controlling 
minute to minute changes in vascular tone and blood flow, therefore ensuring adequate 
perfusion of the organs. Prolonged activation of ATR1 can cause the pathological effects of 
angiotensin II such as hypertension and cardiac hypertrophy to develop.76 The complex activities 
of angiotensin II are facilitated by a number of signalling mechanisms including classical G-
protein signalling (as outlined above in figure 1.3) and transactivation of other receptor types 
and pathways (discussed below in section 1.4.5.3).  
Due to the known effects of angiotensin II on the heart and vasculature, disruption of this 
signalling is a known pharmacological target, with drugs targeting this pathway being used 
clinically for congestive heart failure (CHF). Reduced cardiac output in CHF, caused by a 
reduction in the heart’s ability to pump efficiently, is followed by compensatory mechanisms 
leading to remodelling of the heart and increased heart rate. The purpose of the remodelling is 
to return cardiac output to the required level, however puts more strain on the myocardium, 
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further deteriorates pumping efficiency and increases the risk of arrhythmias and cardiac 
arrest.73 
Angiotensin receptor blockers (ARB) which prohibit the binding of angiotensin II to the ATR1, 
thereby disrupting angiotensin signalling, have utility in the management of CHF as they can 
curb the remodelling of the heart and reduce blood pressure.77 Interestingly, the ARB valsartan 
has been shown to simultaneously block signalling of ART1 and β2 adrenergic receptors in mice, 
suggesting further complex receptor interactions and perhaps more use for angiotensin 
signalling modulators in CHF.78   
 
1.4.5.3  Receptor cross talk within cardiac cells 
Increasing evidence suggests that cross talk exists between GPCRs and receptor tyrosine kinases 
(RTKs) which are another type of cell surface receptor. Growth factor receptors, such as those 
for vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) are members 
of the RTK family, where ligand binding promotes cell growth, proliferation and survival. Unlike 
GPCR’s, these receptors possess intrinsic kinase activity which allows them to 
autophosphorylate and recruit other proteins to trigger their downstream signalling pathways. 
Within the cardiovascular system, RTKs are involved in signalling related to cellular 
differentiation, proliferation and growth.67  
Evidence suggests that RTKs and GPCRs expressed on cells in the cardiovascular system can 
‘‘talk’’ to each other as a means to co-ordinate intracellular signalling. Known as transactivation, 
this novel form of signal transduction allows GPCRs to hijack the signal transduction machinery 
of growth factor receptors for their own use. For example activation of the ATR1 GPCR by 
angiotensin II can directly induce cardiomyocyte growth by transactivating the EGFR which 
triggers specific signalling events related to the regulation of hypertrophic gene transcription. 
The specific signalling employed is the activation of a major protein kinase cascade called the 
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mitogen activated protein kinases (MAPK) cascade, which allow for crosstalk, amplification and 
branching of signals.67,79  
The examples in this section aim to highlight the complex nature of the signalling that occurs 
within the myocardium, and represent the tip of the iceberg of what are very intricate regulatory 
mechanisms. The vast network is important as it allows cells to rapidly respond in unison to 
environmental changes and maintain homeostasis, even subtle changes to this network by 
cardiotoxic drugs could be detrimental to cardiac function.  
 
1.5 Drug-induced cardiotoxicity 
In general, cardiotoxicity is drug induced damage to the heart that occurs either by direct 
damage to the heart muscle or disturbances in cardiac electrophysiology or cellular pathways, 
resulting in either cardiac failure or cardiac arrest.80 The disruption of the electrical machinery 
of the heart ultimately culminates in the inability of cardiac muscle to sustain a progressive 
contraction, resulting in dysrhythmia and eventually cardiac arrest.81 Conversely, drug effects 
causing a perturbation in cardiomyocyte (or supporting cell) shape, orientation, or morphology 
causes alterations in cardiac structure and function in terms of contractility and ability to 
efficiently pump blood around the body. In this latter case, cardiomyocytes eventually lose 
sufficient ability to contract effectively, leading to reductions in left ventricular ejection fraction 
(LVEF) and potentially heart failure.82 
  
1.5.1 Implications of drug-induced cardiotoxicity for drug development 
In addition to drug-induced cardiotoxicity being a serious health problem, it is also the primary 
cause of drug withdrawal and attrition during drug development,83 which has significant 
financial implications for the pharmaceutical industry. For instance, the non-steroidal anti-
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inflammatory drug (NSAID) rofecoxib  is one of the most widely used drugs ever to be withdrawn 
from the market,  and was used worldwide by an estimated 80 million people to treat pain 
conditions such as arthritis and dysmenorrhea.  It was withdrawn from the market in 2004 due 
to increased risk of heart attack and stroke; and its long term use is attributed to have caused 
between 88,000 and 140,000 reports of serious heart disease.84,85 Later research suggests that 
the basis for rofecoxib toxicity may be related to its metabolism, specifically causing increases 
in the oxidative modification of cell membrane lipids and human low density lipoprotein (LDL) 
which is associated with the development of atherosclerosis,86 which can lead to heart attack or 
stroke.  In addition to being responsible for significant health problems in patients, rofecoxib 
caused controversy for Merck and cost billions of dollars in legal expenses. 
Similarly, the first marketed non-drowsy anti-histamine, terfenadine, was also removed from 
the market in the 1990s. In this case, the drug induced significant effects upon cardiac 
electrophysiology as a consequence of blocking specific ion channels in cardiomyocytes which 
disrupts the electrical rhythm of the heart. Terfenadine blocks the hERG potassium ion channel; 
a common mechanism of cardiotoxicity for withdrawn medicines, it results in cardiac 
arrhythmias caused by prolongation of the QT interval. Whilst terfenadine is cardiotoxic at high 
doses, its major active metabolite is not. Therefore toxicity is more likely when the body’s ability 
to remove terfenadine is reduced, possibly as a result of interaction with other medicines. The 
resulting increase in plasma concentration of terfenadine can result in ventricular tachycardia 
and the fatal condition Torsades de Pointes (TdP).87 
 
1.5.2 Drug-induced cardiotoxicity of oncology therapeutics 
As described previously, cardiotoxicity is becoming a major issue in cancer therapy. Although 
significant therapeutic success is now associated with the new generation of molecular targeted 
therapeutics, it is very important to remember that the classical antiproliferative cytotoxic 
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agents still underpin many treatment regimens, and are commonly delivered concurrently to 
these revolutionary therapeutics. In this context, it is well established that these classical agents 
have a broad range of systemic toxicities, often associated with an elevated risk for 
cardiotoxicity. Subsequently, this led to the viewpoint that the observed cardiovascular toxicity 
was purely a result of the generalised activity of the cytotoxic agent within the regimen 
(commonly an anthracycline), and that the toxic effects would be removed with increased 
targeting of cancer therapies. However, this simplistic hypothesis has now been invalidated due 
to our greater understanding of molecular pharmacology and improved understanding of drug-
induced cardiovascular toxicity in cancer patients. Consequently, we now know that drug-
induced detrimental effects upon the heart are not limited to cytotoxic therapies or a single type 
of therapeutic but are an inherent problem with many oncology agents.88 
The range of possible cardiovascular damage caused by cancer therapies is broad (table 1.1), 
and the mechanisms by which conventional chemotherapy and molecularly targeted therapies 
cause cardiotoxicity appear to be distinct, and can be characterised into type I and type II 
cardiotoxicity depending on the effect of the drug on the heart.29,89 
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 Examples of drugs 
Mechanism of 
action 
Examples of 
cardiovascular damage 
Conventional 
chemotherapy 
Anthracyclines 
DNA 
intercalation 
CHF, LVD, acute myocarditis, 
arrhythmia 
Capecitabine 
DNA 
antimetabolite 
Ischemia, pericarditis, CHF 
Paclitaxel 
Tubulin 
binding agent 
hypotension, CHF, ventricular 
tachycardia 
Molecularly 
targeted 
therapies 
Imatinib TKI Arrhythmias, CHF, angioedema, LVD 
Sorafenib TKI Hypertension, arrhythmias 
Sunitinib TKI Hypertension, arrhythmias 
Trastuzumab MAb Arrhythmias, CHF, angioedema, LVD 
 
Table 1.1 Possible cardiovascular damage caused by conventional 
  chemotherapies and molecularly targeted therapies  
CHF = congestive heart failure, LVD = left ventricular dysfunction, TKI = tyrosine kinase inhibitor, 
MAb = monoclonal antibody 
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1.5.2.1  Type I Cardiotoxicity: Structural changes 
Conventional chemotherapies reduce the growth and proliferation of all rapidly dividing cells 
within the body. Due to their non-specific mechanism of action, unwanted toxicities in many 
different organ systems often occur.90 Conventional chemotherapies are labelled as type I 
cardiotoxicants, which cause irreversible dose-dependent morphological damage to 
cardiomyocytes through necrosis or apoptosis. Myocardial injury may arise due to oxidative 
stress, structural modifications to cells or changes in calcium homeostasis. The loss of viability 
or decrease in functionality of cells within the myocardium can affect the pumping activity of 
the heart which may lead to heart failure. The anthracycline class of anticancer chemotherapy 
is strongly linked with the development of type I cardiotoxicity, so much so that it is considered 
the prototypical anti-cancer drug to cause permanent therapy-induced cardiotoxicity.16,91 The 
mechanism and manifestation of anthracycline-induced cardiotoxicity is discussed in detail in 
section 1.7.  
 
1.5.2.2  Type II Cardiotoxicity: Functional changes 
Type II cardiotoxicity is caused by the newer generation of molecularly targeted therapies. These 
therapies aim to be less destructive than conventional cytotoxic chemotherapy as they 
specifically target cancer cells by inhibiting the action of proteins that are mutated or 
overexpressed in cancer, thereby limiting toxicities to healthy cells.18 Although revolutionary in 
the treatment of cancer, these treatments were not as specific as originally hoped and 
unexpected toxicities including cardiotoxicity still occur.92 Rather than causing permanent 
structural damage to cells within the myocardium, type II therapies cause cardiotoxicity by 
perturbation of signalling pathways that are important for normal myocardial function and 
survival, thereby causing acute alteration of myocardial function.89 An important difference 
between the two types of cardiotoxicity is that type II is usually reversible, and cardiovascular 
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effects can disappear upon termination of treatment. Although this transient nature of 
cardiotoxicity poses less of a long-term threat than permanent damage caused by type I 
cardiotoxicants, the development of treatment related arrhythmias and the possibility of 
targeted therapies accentuating the cardiotoxic effects of type I therapies makes this type of 
cardiotoxicity a considerable problem.  
 
Figure 1.4 Comparison of the characteristics of type I and type II cardiotoxicity 
 
  
1.6 Type II cardiotoxicity: Molecularly targeted therapies 
The development of targeted therapies has dramatically shifted the approach to cancer 
treatment and for many patients has changed this once fatal disease into a survivable condition. 
Due to their specific inhibition of proteins that are mutated or overexpressed in cancer, 
unwanted toxicities are minimized in healthy cells. Although revolutionary in the treatment of 
cancer, many targeted therapies were not as specific as originally hoped and unexpected 
toxicities including cardiotoxicity still occur.93  
The Bcr-Abl tyrosine kinase inhibitor imatinib was the first oncology therapeutic that showed 
promise for such targeted action, and has a remarkable 90% success rate in treating Philadelphia 
chromosome positive chronic myelogenous leukaemia (CML).94 Approximately five years after 
the introduction of imatinib in 2001, reports of cardiotoxicity began to emerge starting with 
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Kerkela et al. who reported ten individuals had developed CHF whilst taking imatinib. Upon 
closer inspection, cardiac biopsies of two patients revealed mitochondrial abnormalities and 
vacuoles within the sarcoplasmic reticulum suggestive of toxic cardiomyopathy. Comparative 
histological findings were also detected in imatinib treated mice and imatinib induced death in 
isolated cardiomyocytes.95 
Unfortunately, imatinib is not the only targeted therapy where unexpected cardiotoxicity 
followed the initial cancer eradication triumph. Many more targeted therapies are now available 
that treat a wide range of tumours, however clinicians often need to be vigilant to catch 
potentially harmful cardiovascular effects.   
 
1.6.1 Sunitinib: Mechanism of action 
The process of angiogenesis is required to facilitate tumour growth, making the signalling 
pathways involved in this process a popular target for new inhibitory drugs. The multi-targeted 
tyrosine kinase inhibitor sunitinib is used primarily in the treatment of advanced renal cell 
carcinoma (RCC) and gastrointestinal stromal tumors (GIST).96 
In order to sustain proliferation and metastasise around the body tumours must establish their 
own blood supply, this is achieved by secretion of a number of pro-angiogenic factors including 
VEGF which cause nearby blood vessels to sprout and vascularise the tumour. This process is 
intrinsic to tumours becoming malignant and is hampered by sunitinib which inhibits multiple 
receptor kinases including the primary target vascular endothelial growth factor receptors 
(VEGFR) and platelet-derived growth factor receptors (PDGFR). Therefore sunitinib is both anti-
angiogenic and anti-proliferative, which has a cytostatic effect as tumours are starved of oxygen 
and therefore unable to maintain adequate nourishment.1,97 
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1.6.1.1  Cardiotoxicity of sunitinib 
As a broad spectrum multi-targeted kinase inhibitor sunitinib is designed to inhibit a selection 
of kinases that contribute towards the angiogenic process in tumours. However due to the 
decreased selectivity of the drug and similarities in the structure of all kinases, sunitinib can 
unintentionally inhibit other kinases, causing ‘off-target’ kinase inhibition.  
Myocardial biopsies from patients who suffered from sunitinib induced cardiotoxicity have 
revealed mitochondrial swelling which suggests that cardiac production of ATP may have been 
compromised which could be linked to the toxicity.98 Cardiovascular energy homeostasis is 
regulated mainly by protein kinases and any perturbations to the balance of energy production 
and use can have consequences to cardiac function as beating cardiomyocytes require constant 
energy supply. Adenosine monophosphate activated kinase (AMPK) plays a key role in 
maintaining energy homeostasis in cardiomyocytes and is an ‘off-target’ kinase that is inhibited 
by sunitinib. In times of cellular stress when energy levels are depleted, AMPK acts as a sensor 
and is responsible for kick-starting production of energy to sustain normal functioning of the 
cell.99 Studies using rat neonatal ventricular myocytes found that gene transfer of an activated 
mutant of AMPK partially rescued the toxicity in the cells, suggesting that inhibition of AMPK 
contributes to the cardiotoxicity.100 
As the heart is very demanding in terms of energy requirements, inhibition of AMPK by sunitinib 
could lead to blips in the supply of ATP which is needed to supply sarcomeres and ion channels 
with the energy required to play their role in contraction. This could cause electrophysiological 
abnormalities and ultimately lead to arrhythmias, which would be in addition to other adverse 
effects of sunitinib on the heart.  
Although inhibition of kinases relating to angiogenesis is beneficial with respect to halting 
tumour progression, many of the target kinases of sunitinib play essential roles within the 
cardiovascular system, therefore their inhibition is related to expected cardiotoxicity. 
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Myocardial biopsies from patients who suffered from sunitinib induced cardiotoxicity have also 
revealed hypertrophy of cardiomyocytes,98 which generally occurs as a result of an increased 
pressure load, such as during hypertension. Hypertension is a common cardiovascular effect of 
sunitinib which occurs due to inhibition of sunitinib’s primary target VEGF in the cardiovascular 
system where it plays a crucial role in blood pressure regulation.  Consequently, hypertension is 
considered a biomarker of therapeutic efficiency,34 with anti-VEGF induced hypertension being 
initiated by effects on endothelial cells such as reduced density, increased stiffness and 
increased vascular resistance.101 In terms of evidence, a study conducted by Chu et al. found 
that out of 75 patients 47% developed hypertension whilst taking sunitinib. As hypertension 
causes an increased workload for the heart, it is thought to be responsible for the less common 
but more severe cardiac toxicities of sunitinib which are reduced LVEF and heart failure which 
were reported to occur in 19% and 8% of patients respectively.98 
Inhibition of PDGFR (a secondary target of sunitinib) may also contribute to the cardiotoxicity of 
the drug. PDGFR signaling has recently been implicated as a regulator of the compensatory 
cardiac response, with its expression increasing in the hearts of mice exposed to pressure 
overload stress. In mice lacking PDGFR, exposure to pressure overload stress caused accelerated 
cardiac remodeling, cardiac dysfunction and heart failure.102 As hypertension caused by VEGF 
inhibition is a mechanism of pressure overload and PDGFR inhibition reduces the hearts ability 
to adapt to the stress, it is likely that one or both of these factors plus the energy deficiency 
caused by off-target AMPK inhibition contribute to clinical presentation of cardiotoxicity 
accompanying sunitinib treatment.   
34 
 
 
Figure 1.5 Cardiotoxicity mechanism of the multi-targeted tyrosine kinase 
  inhibitor sunitinib 
1. Sunitinib disrupts VEGF signalling in endothelial cells causing impaired vascular function, 
hypertension and thrombosis. 2. Sunitinib inhibits the PDGFR which affects the myocardial stress 
response in cardiomyocytes. 3. Off-target inhibition of AMPK by sunitinib disrupts the regulation 
of metabolism and energy homeostasis in cardiomyocytes. 
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1.6.2 Trastuzumab: Mechanism of action 
The human epidermal growth factor receptor 2 (HER2) specific monoclonal antibody 
trastuzumab is a treatment for aggressive HER2-positive breast and gastric cancers.103 The HER2 
receptor belongs to the EGFR family of receptors, which dimerizes with other members of the 
EGFR family (EGFR3/HER3 and EGFR4/HER4) causing autophosphorylation of tyrosine residues 
within the cytoplasmic tail of the receptors which initiates a variety of signalling pathways 
involved in cellular proliferation.104 
Over-expression of HER2 is observed in 20% of breast and gastric cancers leading to increased 
signaling and subsequent activation of MAPK and phosphoinositide 3-kinase (PI3K) pathways 
and increased cellular proliferation. Blocking these signaling pathways using trastuzumab 
provides a treatment alternative in patients who otherwise would have had a poor prognosis, 
however cardiotoxicity became evident during clinical trials for breast cancer where incidence 
of heart failure was 5-8.5%.105  
 
1.6.2.1  Cardiotoxicity of trastuzumab 
Although inhibition of the HER2 receptor is beneficial for halting caner progression in tumours 
overexpressing HER2, inhibiting these receptors in the heart may interfere with cardiac function 
as the receptors have a crucial function in this location. The proposed mechanism responsible 
for trastuzumab induced cardiotoxicity is thought to involve the neuregulin (NRG) signalling 
pathway. Neuregulins are a ligand of the EGFR receptors, and NRG-EGFR signalling is involved in 
cardiac development and physiology.106 In genetically engineered mice disruption of this 
signalling leads to failure of cardiac development including lack of ventricular trabeculation (a 
process necessary for development of the ventricular wall) and improper formation of heart 
valves. Research in to the function of NRG-EGFR signalling in adult hearts was spurred by 
occurrence of trastuzumab induced cardiotoxicity, and it was found that the signalling continues 
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to play vital roles in the adult cardiovascular system relating to the physiological adaption to 
stress, cardiomyocyte maintenance and vascular homeostasis. Conditional gene knockout mice 
models were used to study the effects of a loss of NRG signalling in adult mice, with observations 
such as spontaneous dilated cardiomyopathy, increased susceptibility to stress such as pressure 
overload, thin myofilaments and increases in ventricular repolarisation time noted with loss of 
EGFR2 and EGFR4.107,108 This suggests that the signalling pathway is related to the physiological 
adaptation of the heart to changes in cardiac demand, which is supported by the potential for 
neuregulins to be used as a treatment for heart failure.106 
As an individual therapy trastuzumab carries a relatively low risk of cardiotoxicity, and because 
the perturbation of signalling in the heart causes myocardial dysfunction (not damage), this type 
of toxicity has a high likelihood of being reversible and a low likelihood of causing late effects on 
the cardiac system. However, the situation is different when used in combination with 
chemotherapies such as anthracyclines, where the rate of cardiac dysfunction increased from 
5% to 27%105 (discussed later in section 1.7.1).  
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Figure 1.6 Cardiotoxicity mechanisms of the HER2 targeted therapy trastuzumab 
1. Endothelial cells secrete neuregulin (NRG). 2. NRG-HER2 tyrosine kinase (TK) signalling is 
required for normal cardiomyocyte growth, survival and homeostasis. 3. Trastuzumab prevents 
HER2/HER4 coupling and therefore disrupts NRG-HER2 TK signalling and cardiomyocytes have 
impaired myocardial response to stress.  
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1.7 Type I cardiotoxicity: Anthracyclines 
Anthracyclines (e.g. doxorubicin, epirubicin and daunorubicin) are probably the most common 
cytotoxic treatments used in the clinic, which are used to treat a wide range of paediatric and 
adult cancers.15 Originally derived from the Streptomyces peucetius bacterium, daunorubicin 
was the first member of the anthracycline family to be identified – followed by doxorubicin 
which was found to be a more efficacious anticancer agent.109,110 Anthracyclines exert their anti-
proliferative effects on cancer cells by intercalating between DNA base pairs, generating 
damaging oxygen free radicals and inhibiting topoisomerase IIα (TopIIα), thereby causing DNA 
double strand breaks. This culminates in an array of cellular injury including damage to cellular 
components and disruption of DNA synthesis and replication.15,111  Doxorubicin exhibits broad 
spectrum activity against many different tumour types and therefore remains one of the 
mainstays of oncological treatment (Figure 1.7). 
However, despite this class of agent being potent and widely used cancer therapeutics, their use 
is undeniably associated with detrimental effects upon the cardiac system and significant 
concerns are now being raised regarding the aftermath of anthracycline-treatment.16  
 
Figure 1.7 Malignancies commonly treated with doxorubicin 
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1.7.1  Cardiotoxicity of anthracyclines 
The cardiotoxic effects of anthracyclines were first reported in 1973 by Lefrak et al., who 
observed transient electrocardiographic changes in 11% of patients treated with doxorubicin, 
with an additional 3% developing severe congestive heart failure (CHF).112 The importance of 
cumulative dose as a determinant for development of CHF was identified shortly after by Von 
Hoff et al. who conducted a retrospective analysis of over 4000 patients treated with 
anthracyclines. The major risk factor for development of doxorubicin-induced cardiac 
dysfunction is now known to be the cumulative drug exposure, with the incidence of congestive 
heart failure increasing from 1.7% at a cumulative dose of 300 mg/m2 to almost 50% at 650 
mg/m2.113 Although the initial Von Hoff study has been critiqued due to sole utilisation of 
clinician identified symptoms of CHF, a sudden rise in the prevalence of CHF was observed at a 
cumulative dose of 550mg/m2, which is slightly higher than the current maximum recommended 
cumulative lifetime dose of 450mg/m2.15 
A retrospective analysis of three clinical trials conducted by Swain et al. further investigated the 
importance of cumulative dose in relation to anthracycline-induced cardiotoxicity (AIC), and 
reported the prevalence of CHF in patients who were exposed to a range of cumulative doses of 
anthracycline. The incidence of CHF was found to increase with cumulative dose, with estimated 
incidence of 5%, 26% and 48% with 400mg/m2, 550mg/m2 and 700mg/m2 cumulative dose 
respectively. Interestingly, the study also found an increased risk of cardiotoxicity with lower 
amounts of doxorubicin (<300 mg/m2) which were previously not linked with left ventricular 
dysfunction.17 Although the most significant risk factor for anthracycline-induced late onset 
cardiotoxicity is the cumulative dose, other contributory risk factors include the dosing rate and 
schedule, patient age, female gender, hypertension, and previous cardiovascular disease 
(Discussed in section 1.7.13). 
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1.7.1.1  Doxorubicin cardiotoxicity mechanisms 
Although AIC has been classified as the most noted chemotherapy-induced cardiotoxicity to 
date,114 it is still unclear as to how anthracyclines cause irreversible damage to cardiomyocytes. 
The cardiotoxicity appears to be distinguishable from the therapeutic mechanism of action of 
anthracyclines as cardiomyocytes in general are not proliferative, and TopIIα (a primary target 
of anthracyclines) is expressed at much lower levels in quiescent tissues such as the heart.115 
Collective evidence suggests that the cardiomyopathy initiated by doxorubicin is a progressive 
and multi-factorial process. Microscopy has indicated that treatment with doxorubicin causes 
cytoplasmic vacuoles, mitochondrial membrane disruption and disorder of myofibril 
arrangement.116 Possible mechanisms of doxorubicin-induced cardiomyopathy include impaired 
calcium handling, altered gene and protein expression, DNA breakage via inhibition of 
topoisomerase IIβ (TopIIβ), and the formation of oxygen free radicals that damage the 
mitochondria of the cells.16,34  
 
1.7.1.1.1 Iron and free radical hypothesis 
The iron and free radical hypothesis is the most widely accepted, whereby the formation of 
doxorubicin-iron complexes causes free radical formation on the inner membrane of 
cardiomyocytes mitochondrion. It is estimated that cardiac mitochondria occupy 40% of the 
volume of cardiomyocytes,117 making these organelles powerhouses for the generation of 
reactive oxygen species (ROS) from doxorubicin. 
Doxorubicin binds to the mitochondrial membrane protein cardiolipin which leads to 
mitochondrial accumulation of the drug. Here, redox cycles occur which generate a substantial 
amount of ROS including .O2- which is converted to H2O2. In the presence of iron (Fe2+), H2O2 is 
converted into the extremely reactive .OH.111,118 
41 
 
Perturbations to cellular iron metabolism are an important feature of this toxicity whereby 
doxorubicin and its metabolite doxorubicinol interfere with iron homeostasis, resulting in 
increased formation of doxorubicin-iron complexes and availability of Fe2+ to facilitate 
generation of .OH.119,120 Specifically, doxorubicin disrupts the activity of iron regulatory proteins 
(IRPs) which regulate the activity of intracellular iron. As a consequence of the increased 
intracellular iron, levels of the iron carrier protein transferrin have been found to increase 
following doxorubicin treatment which is thought to protect against oxidative injury and ROS 
formation. Due to the increased polarity of doxorubicinol it accumulates at higher levels than 
doxorubicin in the heart and is also more potent at dysregulating iron homeostasis which 
contributes to the generation of ROS.118,120 
Cardiomyocytes are especially prone to damage by ROS as the myocardium possesses a limited 
capacity for detoxification. Doxorubicin further hinders this detoxification capacity as it inhibits 
glutathione peroxidase and catalase which are necessary for the breakdown of H2O2 into water 
and oxygen.121 This entire process leads to a surge in oxidative stress which is extremely harmful 
to cardiomyocytes. The cellular damage includes oxidative modifications of cellular components, 
degradation of the sarcomere, mitochondrial dysfunction, DNA damage and the induction of 
apoptotic pathways.91 The significance of this cardiotoxicity mechanism has been demonstrated 
using transgenic mice, where overexpression of the detoxification enzyme superoxide 
dismutase 2 (SOD2) attenuated the cardiotoxic effects of doxorubicin, whilst deletion of SOD2 
potentiated them.122 
 
1.7.1.1.2 Topoisomerase-dependent cardiotoxicity hypothesis 
DNA topoisomerases are enzymes involved in the unwinding of DNA necessary for transcription 
and DNA replication to occur. Topoisomerase IIα (TopIIα) is a marker of cellular proliferation, 
and its overexpression in tumour cells is a major target for the anticancer activity of 
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doxorubicin.115,123 Unlike TopIIα that has low expression in quiescent cells, topoisomerase IIβ 
(TopIIβ) is present in non-proliferating cells including cardiomyocytes. Here, a complex is formed 
consisting of doxorubicin – TopIIβ – DNA that cause double strand breaks in the DNA and 
ultimately cardiomyocyte death. Studies in cardiomyocyte specific TopIIβ knockout mice treated 
with doxorubicin showed that cardiomyocytes were protected from DNA double strand breaks 
and changes in transcription of genes that may be related to ROS formation and apoptosis.124 In 
addition, more recent research has investigated the role of mitochondrial topoisomerase I 
(Top1mt) in doxorubicin induced cardiotoxicity.  
The mitochondria within mammalian cells contain their own DNA genome (mtDNA), as well as 
specific processes for DNA replication and protein synthesis. The mtDNA encodes important 
proteins that are part of the mitochondrial electron transport chain responsible for oxidative 
phosphorylation and therefore production of ATP in the cell. Relaxation of the circular, double-
stranded mtDNA relies on the presence of topoisomerase activity within the mitochondria, 
which enables transcription and protein synthesis to occur.125 Therefore any perturbations to 
topoisomerase activity could impede energy production in cardiomyocytes which would affect 
the normal functioning of the myocardium. As mitochondrial dysfunctions and mtDNA lesions 
are a feature of human hearts exposed to doxorubicin126 and Top1mt is involved in mtDNA 
homeostasis, it is possible that Top1mt is also a target for doxorubicin in the heart.   
Khiati et al. investigated the role of Top1mt using TopImt knockout (KO) mice and found that 
after 8 weeks treatment with doxorubicin the Top1mt KO mice had increased mtDNA damage, 
mitochondrial cristae disorganisation and were unable to maintain the mitochondrial electron 
transport chain. These mitochondrial defects also caused an increase in damaging ROS and 
myofibrillar damage. These results suggest that Top1mt is critical for cardiac tolerance to 
doxorubicin and the adaptive response to doxorubicin cardiotoxicity.127  
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1.7.1.1.3 Alterations in multidrug resistance efflux proteins 
The ATP-binding cassette (ABC) family of membrane transporters are responsible for 
translocation of substances across membranes. Multidrug resistance (MDR) proteins are a 
member of the ABC family that remove foreign potentially harmful substances from cells and 
are involved in regulating the efflux of anthracyclines from cardiomyocytes. Polymorphisms of 
the MDR1 gene have been associated with cardiotoxicity, and reduced expression of the gene 
was detected in cancer patients who later developed AIC.128 As patients may be taking other 
medications that can block the MDR proteins, this has clinical significance as the intracellular 
levels of anthracyclines may be increased further, thereby increasing the risk of cardiotoxicity.  
 
1.7.1.1.4 Impaired calcium handling  
Doxorubicinol is a metabolite of doxorubicin that accumulates in cardiomyocytes, causing 
inhibition of Ca2+ uptake into the sarcoplasmic reticulum by the sarcoplasmic reticulum 
Ca2+ATPase (SERCA).129 As efficient calcium recycling is required for successful contraction and 
relaxation of cardiac muscle, this causes a considerable delay in the activation and inactivation 
of cardiomyocyte contractility. 
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Figure 1.8 Anthracycline cardiotoxicity mechanisms 
Anthracyclines damage cardiomyocytes through a variety of mechanisms: 1. Oxidative stress 
induces production of damaging reactive oxygen species (ROS) in the mitochondria which are 
damaging to cells, 2. Disrupted topIIβ and topImt activity causes double strand breaks in the 
DNA, 3. Increased intracellular concentration of anthracyclines due to alterations in MDR efflux 
proteins, 4. Decreased uptake of Ca2+ into the sarcoplasmic reticulum (SR) causes disturbances 
to myocardial contractility and 5. Decreased mesenchymal and circulating progenitor cells 
reduces the regenerative capacity of the heart following damage. 
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1.7.1.1.5 Impact of anthracycline metabolism and metabolites on cardiotoxicity 
Upon clinical administration doxorubicin is rapidly cleared from the blood and widely distributed 
into tissues. The drug undergoes triphasic elimination with mean half-lives of 12 minutes, 3.3 
hours and about 30 hours. Doxorubicin is metabolised primarily by the liver, and the main 
metabolite is doxorubicinol which is an active metabolite.15 Doxorubicinol is important with 
respect to cardiotoxicity as due to its polarity it more readily accumulates in cardiomyocytes 
where it causes dysregulation of iron homeostasis and alterations in calcium handling119,129 (see 
section 1.7.1.1.1 and 1.7.1.1.4). The impact of doxorubicinol on cardiotoxicity is exemplified by 
studies which have shown that genetic polymorphisms in the enzymes that form doxorubicinol 
lead to increased levels of cardiotoxicity.130 
Other anthracyclines follow similar metabolism and elimination patterns. For example the 
primary metabolites of daunorubicin and epirubicin are daunorubicinol and epirubicinol which 
are both pharmacologically active.131,132 Epirubicinol is also an active metabolite however it has 
been reported to be formed in lower quantities than doxorubicinol in the human myocardium 
which may relate to the more favourable toxicity profile of epirubicin.133 Epirubicin also has a 
different pharmacokinetic profile to doxorubicin characterised by a higher clearance rate and a 
shorter half-life, which may also contribute to the reduced toxicity of the drug clinically.131 
  
1.7.1.2  Clinical manifestation of anthracycline induced cardiotoxicity 
In terms of clinical presentation, AIC is classified into three types (discussed in detail below): 
symptomatic acute toxicity occurring soon after administration, and early- and late-onset 
chronic toxicity, occurring before or after one year of treatment, respectively.  
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1.7.1.2.1 Clinical manifestation of chronic anthracycline induced cardiotoxicity 
Early- and late-onset chronic progressive cardiotoxicity are associated with electrophysiological 
changes and left ventricular dysfunction (LVD), and tend not to be reversible. However, if 
undetected or not-treated, these chronic forms of cardiotoxicity will progress and lead to a 
reduction in cardiac function with time.134 
Early-onset chronic cardiotoxicity is the most prevalent manifestation of AIC. Symptoms usually 
present approximately one year following treatment as dilated cardiomyopathy which can lead 
to heart failure.  Recently, Cardinale et al. conducted a clinical study whereby patients receiving 
anthracycline treatment underwent heart function monitoring at regular intervals in an attempt 
to elucidate the incidence and clinical features of early-onset chronic AIC. A key finding was that 
9% patients developed AIC, with 98% of these cases occurring within the first year after 
treatment. Upon clinical recognition of significant reductions in left ventricular ejection fraction 
(LVEF) indicative of AIC (primary endpoint), treatment with the heart failure therapy enalapril 
was initiated and the potential for recovery from AIC was determined (secondary end point). 
The study demonstrated that initiation of heart failure therapies is beneficial for restoration of 
cardiac function with 71% patients demonstrating partial recovery and 11% demonstrating 
complete recovery.135  
Delayed cardiotoxicity (also called late onset chronic cardiotoxicity) is particularly relevant in 
adult survivors of childhood cancer, whereby cardiotoxicity arises decades after exposure to 
doxorubicin after a long asymptomatic period.136 Due to their younger age at the time of 
treatment, childhood survivors are in a developmental stage that makes them more vulnerable 
to adverse health effects from potentially toxic therapies, which become clinically apparent 
years later. Recent evidence suggests that anthracyclines decrease the number of cardiac 
mesenchymal and circulating progenitor cells, thereby reducing the regenerative capacity of the 
heart in response to damage (Figure 1.8). This may provide an explanation for the delayed 
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cardiotoxicity observed in children who are treated with anthracyclines.137,138 In these survivors, 
cardiovascular related disease has been identified as the leading cause of morbidity and 
mortality after development of cancer recurrence,31 with echocardiographic abnormalities 
indicative of impairments to left ventricular contractility estimated to occur in up to 65% of 
patients.139 
A retrospective analysis of the childhood cancer study conducted by Mulrooney et al. assessed 
the incidence and risk of cardiovascular events in 14,358 five year survivors of childhood 
cancers.30 Compared to their siblings, cancer survivors were more likely to suffer from cardiac 
events including CHF, pericardial disease and valvular disease. For example, at an average age 
of 27 years old 248 cancer survivors reported CHF and 101 had suffered a myocardial infarction; 
this is of particular note as such events are generally rare in young adults. The probability of 
developing CHF was identified to be related to cumulative dose as the risk increased from 2.4 
fold higher risk at doses of up to 250mg/m2 to 5.2 fold higher risk at doses >250mg/m2.30 
A similar study investigated the long-term cardiac mortality among 34,489 childhood cancer 
survivors diagnosed and treated across seven decades (1940-2006) in the United Kingdom. In 
concordance with the findings of Mulrooney et al.; the number of cardiac deaths was 3.4 times 
the expected amount and the risk of developing CHF was 5.9 times greater than expected. 
Interestingly, the risk of death due to heart failure was greatest amongst survivors who were 
diagnosed 1980-1989; with 28.9 times more excess deaths reported than those diagnosed from 
1990. This decline in the risk of cardiac death that was observed post-1990 suggests that the use 
of alternative drugs, lower cumulative doses and more frequent monitoring for cardiac liabilities 
has proved beneficial as a means to reduce cardiotoxicity.140 
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1.7.1.2.2 Clinical manifestation of acute anthracycline induced cardiotoxicity 
Due to the often asymptomatic nature of acute cardiotoxicity, which presents as rhythm 
disturbances, transient reductions in myocardial contractility, and/or hypotension, and the fact 
that it is reversible by discontinuation of treatment, this adverse effect is commonly not 
identified. 
Acute toxicity as a consequence of anthracycline treatment is rare and typically occurs in the 
two weeks succeeding a single treatment; usually manifesting as pericarditis, transient 
arrhythmias or LVD.141,142 In contrast to the chronic and delayed cardiotoxicity discussed above, 
the deterioration to left ventricular function is not permanent as improvements in cardiac 
function have been documented in some patients.142 In addition, the mechanism of acute 
cardiotoxicity may differ from delayed cardiotoxicity as it is thought to involve an inflammatory 
response.16 
 
1.7.1.3  Risk factors for anthracycline-induced cardiotoxicity   
Several risk factors have been reported to increase susceptibility to developing AIC including 
extremes of age, concurrent treatments and pre-existing cardiac disease. A retrospective 
analysis of three clinical trials identified age as an important risk factor related to doxorubicin 
induced CHF as at a cumulative dose of 400mg/m2 patients over 65 years old showed a greater 
incidence of CHF than younger patients.143 Similarly, paediatric patients are more susceptible to 
delayed cardiotoxicity, and it is estimated that more than 50% childhood cancer survivors 
treated with doxorubicin develop some form of cardiotoxicity years after finishing cancer 
treatment136. Concurrent treatment  with other cancer drugs can also exacerbate cardiotoxicity, 
for example the combination of anthracyclines with the monoclonal antibody trastuzumab 
increases cardiotoxicity risk,105 as does concurrent radiation therapy.144 In 1977 Minow et al. 
identified heart disease which results in an increased cardiac work-load, such as hypertension 
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as a risk factor for doxorubicin induced cardiotoxicity. Hypertension can cause the heart to 
hypertrophy; thereby reducing contractile capacity which may lower the dose of doxorubicin 
required to cause CHF.145 
The lower cumulative doses required for patients with pre-existing risk factors can decrease 
oncological efficacy; which creates a challenge for clinicians to ensure a balance between 
antineoplastic effects and minimising cardiotoxicity.  
 
1.7.1.4  Detection of anthracycline-induced cardiotoxicity   
AIC is usually detected post cancer treatment when patients show signs and symptoms of heart 
failure. The loss of functionality becomes evident as cardiomyocyte injury or impairment has 
occurred to a level whereby the heart can no longer compensate for the loss of contractility and 
so becomes a less efficient pump.146,136 
The lack of consensus regarding the definition of cardiotoxicity adds to the problem of detection 
and management of AIC. Cardiotoxicity is generally defined as “toxicity that affects the heart”  
although a more precise definition is lacking overall.34 The cardiac review and evaluation 
committee overseeing the supervision of clinical trials for the molecular targeted 
chemotherapeutic trastuzumab provided perhaps the most accurate definition of drug-
associated cardiotoxicity to date, whereby a patient must have one or more of the following:147 
 
1) Cardiomyopathy characterised by a reduction in LVEF, either globally or specific to the septum 
2) Signs or symptoms related to CHF  
3) Reduced LVEF from baseline that is 5% to < 55% alongside accompanying HF signs or 
symptoms 
4) A reduced LVEF of 10% to <55% without any additional HF signs or symptoms.  
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This definition relies narrowly upon changes in LVEF and development of symptomatic CHF 
which are indicative of systolic function; however does not encompass subclinical cardiotoxicity 
that occurs with AIC, where patients can develop cardiac abnormalities histologically but remain 
asymptomatic under general observations. Detection of damage at the earlier subclinical stage 
would allow for appropriate risk assessments to be made and interventions to be put in place to 
prevent further cell loss and resulting impairments to heart function.148 Frequent imaging using 
techniques such as echocardiograms (ECHO) and radionuclide ventriculography multi-gated 
acquisition scan (MUGA) may assist with earlier detection of cardiotoxicity as they allow 
clinicians to check the structure of the heart and assess ventricular function.146  
A new promising echocardiographic approach, Doppler myocardial imaging (DMI), has been 
shown to detect abnormal myocardial activity as early as one week after completion of an 
anthracycline therapy.149  Analysis of biomarkers, such as cardiac troponins also represent a 
means to identify cardiotoxicity. The wide diagnostic window, high specificity and high 
sensitivity make cardiac troponins an ideal biomarker that can be assessed quickly using a simple 
blood test. This is highlighted by Cardinale et al. (2006) who identified cardiac troponin I (cTnI) 
as a useful biomarker in terms of identifying patients at high risk of developing AIC.150,151 
 
1.7.2  Mitigation of anthracycline-induced cardiotoxicity 
In recent years, there has been a shift in focus from the recognition and treatment of 
cardiotoxicity to prevention. Understanding the aetiology of AIC has driven the development of 
preventive strategies to protect the heart from permanent cardiac damage caused by 
anthracyclines.28,152,153 
Dexrazoxane is the first and only drug to be licensed for anthracycline related cardioprotection. 
Dexrazoxane contains EDTA within its structure; EDTA is a chelating agent that can sequester 
metal ions such as Ca2+, Mg2+ and Fe2+ which causes a decrease in their activity. When co-
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administered with anthracyclines, dexrazoxane chelates iron which reduces the amount of iron 
that can complex with the anthracycline. This interferes with iron-mediated free radical 
generation that is thought to play a role in the development of AIC.154  Although a recent meta-
analysis concluded that adjuvant dexrazoxane treatment is associated with a decreased risk of 
heart failure,155 use is restricted to adult patients as controversial clinical trial data has been 
generated including increasing the rate of secondary malignancies and acute myelogenous 
leukaemia (AML) in paediatric patients.156 
Other strategies that have been explored for mitigation of AIC include the use of statins and β-
blockers.28 Statins possess both anti-inflammatory and anti-oxidative properties and are 
routinely used for the prevention of cardiovascular diseases. Thought to interfere with the 
generation of ROS and inhibition of TopIIβ associated with AIC, a small randomised controlled 
trial (RCT) found prophylactic atorvastatin protected patients from declines in LVEF,157 and a 
larger RCT called ‘Preventing anthracycline cardiovascular toxicity with statins (PREVENT)’ is 
currently underway.158 
β-blockers such as carvedilol are used for the treatment of CHF and angina. Carvedilol 
antagonises beta (β1, β2) and alpha (α1) adrenergic receptors and is unique amongst β-blockers 
as it also possesses anti-oxidant properties.74,159 Whereas selective β-blockers decrease the rate 
and force of myocardial contraction, the additional α1 blockade properties of carvedilol are 
related to vasodilation, this is associated with reduced blood pressure and as a result carvedilol 
is more effective at treating CHF than the conventional selective β-blockers. With respect to 
reduction of AIC, the anti-oxidant properties of carvedilol may also be beneficial. Studies 
comparing the efficacy of carvedilol and atenolol at protecting cultured rat cardiomyocytes from 
AIC in vitro showed that carvedilol was able to decrease the production of damaging free radicals 
and prevent apoptosis of cardiomyocytes, whereas atenolol was not.160 This suggests that 
carvedilol may possess the ability to protect the heart from AIC and as such it has been employed 
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in a number of small studies where its prophylactic effects on AIC have been investigated with 
encouraging results.152 The first such study was conducted by Kalay et al. who concluded that 
carvedilol may protect both systolic and diastolic functions of the left ventricle in patients 
undergoing anthracycline therapy.161  
 
1.7.2.1  Angiotensin blockade for cardioprotection 
There is a growing body of evidence that administration of angiotensin converting enzyme 
inhibitors (ACEi) or angiotensin receptor blockers (ARB) can also protect the heart from the 
deleterious effects of anthracyclines (See table 1.2 below). ACEi are routinely used for the 
treatment of CHF and hypertension, and ARB are used for the treatment of hypertension and to 
prevent cases of stroke and myocardial infarction.162,163  Both prevent the physiological activity 
of angiotensin II (angII); ACEi prevent the formation of angiotensin II whereas ARB stop 
angiotensin II binding to the ATR1 (figure 1.9). Angiotensin signalling has a variety of effects 
within the cardiovascular system including vasoconstriction and blood pressure regulation, 
inflammation, atherosclerosis, hypertension, and cardiac hypertrophy/remodelling.75 (See 
section 1.4.5.2). 
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Figure 1.9 Angiotensin II synthesis and pharmaceutical inhibition 
Following formation of angiotensin I by cleavage of angiotensinogen by renin, angiotensin I is 
cleaved by angiotensin converting enzyme (ACE) to form angII. The production of angII can be 
prevented using angiotensin converting enzyme inhibitors (ACEi), and the activity of angII can 
be inhibited using angiotensin receptor blockers (ARB) which prevent angII from binding to the 
ATR1.  
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Table 1.2 summarizes the methods and findings of a selection of clinical studies that have 
assessed anthracycline containing chemotherapy regimes in combination with either an ACEi or 
ARB alone, or with adjuvant β-blocker therapy.  
Studies using Angiotensin converting inhibitors (ACEi) 
Study Study objective Prophylaxis 
Cardiac 
assessment 
modalities 
Study findings 
Cardinale 
et al. 
(2006)150 
To examine the 
effects of 
enalapril 
treatment in 
patients with 
high cTnI 
following one 
month of Cx        
C = 58, T = 56 
Enalapril 
Physical 
examination, ECG, 
ECHO at  baseline 
and 1, 3, 6, and 12 
months after the 
end of Cx. cTnI 
measurements 
performed regularly 
during Cx 
In high-risk patients 
with increased cTnI 
levels, early 
treatment with 
enalapril prevented 
the development of 
late cardiotoxicity 
Bosch  
et al. 
(2013)164 
OVERCOME 
To investigate 
the efficacy of 
carvedilol and 
enalapril at 
preventing LVSD 
in patients with 
haematological 
malignancies       
C = 45, T = 45 
Enalapril, 
carvedilol 
ECHO and CMR 
imaging studies 
were performed at 
baseline and 6 
months. cTnI and 
biomarker analysis 
was also performed 
regularly during Cx 
Enalapril and 
carvedilol protected 
patients from 
significant declines 
in LVEF that were 
seen in the control 
group at 6 months 
Janbabai  
et al. 
(2017)165 
To investigate 
the efficacy of 
enalapril in the 
prevention of AIC                     
C = 35, T = 34 
Enalapril 
ECHO performed at 
baseline and 6 
months. cTnI 
measured 1 month 
after the initiation of 
Cx 
LVEF did not change 
in enalapril group at 
6 months, but 
significantly 
decreased in control 
group 
 
Table 1.2A Summary of clinical studies investigating the use of ACEi for 
  cardioprotection during anthracycline containing regimens 
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Studies using Angiotensin receptor blockers (ARB) 
Study Study objective Prophylaxis 
Cardiac  
assessment 
modalities 
Study findings 
Nakamae 
et al. 
(2005)166 
To investigate 
whether valsartan 
can inhibit acute AIC 
in patients with non-
Hodgkin’s lymphoma           
C = 20, T = 20 
Valsartan 
ECHO and ECG at 
baseline and on 
days 3, 5, and 7 
Valsartan prevented 
transient changes to 
the left ventricular 
end-diastolic 
diameter and QT 
interval that were 
observed in the 
control group  
Cadeddu 
et al. 
(2010)167 
To assess the 
protective effects of 
telmisartan on EPI 
induced early 
ventricular 
impairment using 
escalating doses                          
C = 24, T = 25 
Telmisartan 
ECHO, tissue 
Doppler, strain 
rate imaging and 
ROS were 
assessed at 
baseline and 7 
days after every 
new EPI dose of 
100mg/m2 
As the dose of EPI 
increased, strain 
rate (indication of 
ventricular 
impairment) 
deteriorated in 
control group but 
normalised in the 
telmisartan group. 
Increases in ROS 
were not observed 
in the telmisartan 
group 
Gulati  
et al. 
(2016)168 
PRADA 
To investigate if 
candesartan (Cn) or 
metoprolol (M) can 
alleviate declines in 
LVEF associated with 
anthracycline-
containing regimens 
in breast cancer 
patients C = 30, (T: 
Cn/M = 28, Cn = 32, 
M = 30 
Candesartan 
Metoprolol 
CMR, blood 
samples, physical 
examinations, and 
ECHO performed 
at baseline, after 
first and final 
cycles of Cx, and 
for those 
concerned, at 
completion of 
trastuzumab or 
radiation therapy 
Adjuvant breast 
cancer treatment is 
associated with a 
decline in LVEF that 
is alleviated by 
concomitant 
blockade with 
candesartan. No 
improvement to 
LVEF were observed 
with metoprolol 
 
Table 1.2B Summary of clinical studies investigating the use of ARB for  
  cardioprotection during anthracycline containing regimens 
AIC = anthracycline-induced cardiotoxicity, C = number of patients on control arm of trial, CMR 
= cardiac magnetic resonance, cTnI = cardiac troponin, Cx = chemotherapy, ECG = 
electrocardiogram, ECHO = echocardiogram, EPI = epirubicin, LVEF = left ventricular ejection 
fraction, LVSD = left ventricular systolic dysfunction, ROS = reactive oxygen species, T = number 
of patients on experimental treatment arm of trial. 
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Limitations of the studies outlined include short follow up time of patients (ranging from 1 week 
– 1 year) and the low number of patients enrolled. A follow on study aimed to address the short 
follow up time of patients and assess if the cardioprotective effects of telmisartan observed by 
Cadeddu et al. would be maintained long-term. Their results showed that telmisartan exhibited 
protective effects for at least 18 months and so may be useful in preventing anthracycline-
induced early onset chronic cardiotoxicity which typically presents 1-2 years following 
treatment.169 The authors have indicated that this study is still ongoing and they intend to 
continuously monitor the patients for at least 3 years to evaluate whether the global cardiac 
function is similar between the two groups or whether the telmisartan group have better global 
cardiac function and thus a better clinical outcome.  
Larger phase II and phase III clinical studies are currently underway that aim to assess the 
cardioprotective potential of ACEi/β-blocker combinations170 and ACEi alone171 in breast cancer 
patients receiving anthracycline treatment. These clinical trials will hopefully support the 
findings of the smaller studies and provide additional information regarding the optimal 
cardioprotective strategies and monitoring schedules for detection of sub-clinical damage.  
The potential for reversal of AIC by ACEi has also been investigated in long-term cancer survivors.  
Enalapril therapy commenced seven years after completion of doxorubicin chemotherapy in 
survivors of childhood cancer reported benefits initially, however these improvements 
deteriorated after six years.172 These transient benefits exemplify the permanent nature of 
damage caused by doxorubicin and supports the current view that concomitant angiotensin 
blockade alongside anthracycline treatment is the most effective way to use these agents as 
cardioprotectors.   
The mitigation of AIC with therapeutics that limit angiotensin signalling suggests a role for the 
angiotensin signalling pathway in mediating this toxicity; therefore it is imperative to understand 
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downstream signalling events of the ATR1 and how these signalling events may interplay with 
mechanisms of AIC. This is discussed in chapter 6 of this thesis.  
 
1.8 Combination therapies 
Using a combination of therapies represents a potent method of cancer treatment as cancer 
cells are attacked using a variety of mechanisms. For example the regimen ‘R-CHOP’ consists of 
the targeted therapy rituximab, the conventional chemotherapies cyclophosphamide, 
doxorubicin hydrochloride, vincristine (Oncovin) and the steroid prednisolone. Rituximab is a 
monoclonal antibody used to treat leukaemia and lymphomas and specifically targets the CD20 
cell surface receptor that is present on both healthy and cancerous B cells, leading to apoptosis 
of the cells.  Cyclophosphamide, doxorubicin and vincristine are conventional chemotherapies 
that attack proliferating cells by interacting with DNA, inhibiting enzymes required for DNA 
replication and preventing microtubule assembly respectively.173 All of these therapies 
individually are associated with different cardiotoxicities such as acute arrhythmias and 
progressive development of heart failure. Although beneficial for reducing tumour burden, 
combination therapies may have a synergistic effect which increases the severity and likelihood 
of developing therapy induced cardiotoxicity.153 
 
1.8.1 Clinical effect of co-administration of type I and type II cardiotoxic 
 therapies 
In clinical trials of trastuzumab the incidence of heart failure was 5-8.5%, a figure which 
increased dramatically to 27% with concurrent anthracycline therapy.105  Following analysis of 
the pivotal clinical trials in this therapeutic area, previous anthracycline exposure and 
concurrent anthracycline use were listed as risk factors related to trastuzumab cardiotoxicity.174  
58 
 
As discussed previously, anthracyclines such as doxorubicin cause direct damage to 
cardiomyocytes which leads to impairment of cardiomyocyte function (See section 1.7.1). 
Anthracyclines are an example of a type I cardiotoxicant, whereby the agent causes permanent 
dose-related structural damage to cardiomyocytes which can impact the pumping ability of the 
ventricles therefore causing left ventricular dysfunction. In contrast trastuzumab is a type II 
cardiotoxicant, which causes cellular dysfunction (not damage) of cardiomyocytes which is not 
dose-dependent and usually reversible upon termination of treatment. An important distinction 
between the cardiotoxicity of the two drugs is that anthracyclines are associated with chronic 
and delayed forms, where patients are asymptomatic for years before disturbance to ventricular 
function becomes apparent, whereas trastuzumab is generally not associated with causing long-
term cardiac sequelae.16,89,105 
A cumulative lifetime dose of doxorubicin has been established at 450mg/m2 in attempt to 
reduce the risk of cardiotoxicity in patients.15 However before alterations to cardiac function 
become clinically apparent, sub-clinical cardiomyocyte injury occurs that creates a population 
of vulnerable cardiomyocytes that are reliant on repair mechanisms to minimise the damage 
and resume normal function.29 The mechanism of trastuzumab cardiotoxicity has been 
postulated to involve inhibition of neuregulin signalling which has vital roles in the adult 
cardiovascular system relating to the physiological adaption to stress and cardiomyocyte 
maintenance (See section 1.6.2.1). Conditional gene knockout mice models were used to study 
the effects of a loss of neuregulin signalling in adult mice, with observations such as spontaneous 
dilated cardiomyopathy, increased susceptibility to stress such as pressure overload, thin 
myofilaments and increases in ventricular repolarisation time noted.108 This suggests that the 
signalling pathway is related to the physiological adaptation of the heart to changes in cardiac 
demand, which is a change that occurs with anthracycline therapy. Therefore trastuzumab’s 
interference with this critical survival signalling pathway in cardiomyocytes which reduces the 
repair capacity of vulnerable cardiomyocytes may increase severity of anthracycline toxicity as 
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the cells are less able to repair the sub-clinical damage caused by the type I cardiotoxicant.175 
Consistent with this proposed mechanism of toxicity, disrupted HER2 signalling in mice 
exacerbates anthracycline cardiotoxicity and myocardial HER2 is up-regulated following 
anthracycline exposure in humans.176 
 
1.9 Current in vitro models for identification and study of drug-
 induced cardiotoxicity 
Cardiotoxicity is assessed during all stages of the drug development process, starting in the early 
pre-clinical stages of drug discovery. As defined in the ICH S7 guidelines, pre-clinical assessment 
of drug-induced cardiac liabilities is a regulatory requirement.177 Historically, cardiac liabilities 
were initially determined via assessment of drug effects upon the hERG potassium channel, a 
known toxicity target with relationships to clinical effects. This assay utilised an in vitro cell 
system whereby a non-cardiac cell line was engineered to artificially express a functional hERG 
channel.177 The in vitro evaluation against hERG was then followed by assessment of the drug in 
vivo against a larger mammalian species, primarily dog. However, although successfully 
identifying several drugs with cardiac liabilities, the complexity of the cardiac system and 
involvement of several ion channels in cardiomyocyte contractility was such that many drugs 
progressed into animal studies, and occasionally clinical trials, unnecessarily.178,179 
Consequently, there is an urgent need for development of in vitro assays to robustly detect such 
effects reliably. This has now led to the development of the CiPA initiative (comprehensive in 
vitro proarrhythmia assay).180 
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1.9.1 The CiPA initiative and pre-clinical evaluation of drug-induced 
 cardiotoxicity 
The ICH S7B guidelines have proven successful in preventing the introduction of drugs that are 
potentially torsadogenic to the market, however the focus on the ability of drugs to block the 
hERG potassium channel and cause QT prolongation as the sole determinants of cardiotoxicity 
risk needs revising.181 The cardiac action potential is governed by activity of many ion channels, 
and cardiotoxicity itself can be caused by other factors (e.g. structural damage); as such 
potential cardiotoxicants could slip under the radar with the current screen if they cause 
structural damage, whereas others may appear hazardous with respect to hERG block but pose 
little actual risk for TdP in the clinic.  
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative aims to develop a new 
paradigm for assessing proarrhythmic risk, utilising new technologies and an expanded 
understanding of cardiotoxicity beyond hERG block.181 Development and validation of a set of 
predominantly pre-clinical assays is currently underway that is envisaged to enable a more 
precise prediction of clinical proarrhythmia risk using the three pillars of CiPA.  
These are:  
i)  Assessment of drug effects on the critical human ventricular ion channel currents 
ii)  in silico integration of the ion channel effects to determine the net effects on the 
 cardiac  action potential 
iii)  A check for discrepancies in fully integrated biological systems (in vitro cardiomyocyte 
 models). 
The third pillar of CiPA involves evaluating the acute effects of drugs on the electrical activity of 
induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs) using high throughput 
approaches such as microelectrode arrays and impedance technology that enable more 
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comprehensive and robust assessments earlier in the drug discovery process. These cell types 
and approaches are discussed in detail in the following sections.  
 
1.9.2 In vitro cardiomyocyte cell line models 
A variety of models are available including primary cells, cell lines and induced pluripotent stem 
cell derived cardiomyocytes (iPSC-CMs).182 Perhaps the most frequently used model, the 
immortalised rat cardiomyoblast H9c2 cell line was derived in 1976 and has since been widely 
used to assess cardiac biology and electrophysiology. Although morphologically distinct from 
cardiomyocytes and without contractile ability, they do express relevant contractile proteins, 
ion channels and fuse to form multinucleated myotubes.183 The cells have been successfully 
utilised as an in vitro model to measure the cardiac hypertrophic effect of several agents such 
as doxorubicin and sunitinib.184,185 This is because the H9c2 cells showed almost identical 
hypertrophic responses to those observed in primary cardiomyocytes.186 
Another cell model is the HL-1 murine atrial cardiomyocyte cell line model. This cell line 
expresses relevant ion channels and forms organised sarcomeric structures and therefore 
spontaneously contracts in vitro, whilst maintaining proliferative capacity.187 Their energy 
metabolism differs from cardiomyocytes and due to the differences between the mouse and 
human cardiac action potential limited toxicity screening has been conducted.  
Although growing in culture, the major issue with these cell lines is their rodent derivation, 
degree of maturity, originating cell type, and their subsequent inability to fully represent or 
recapitulate a human cardiac cell model. In this context, a series of cell lines (AC1, AC10, AC12, 
AC16) were created via fusion of immortalised SV40 protein transformed human fibroblasts with 
primary human ventricular cardiomyocytes.188 Based on their human origin and immortality 
these cells were postulated as being useful as an in vitro screening model.  However current data 
remains limited, the cells are reportedly in a pre-contractile state, but with expression of many 
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cardiac specific transcription factors, contractile proteins and functional gap junctions.188 As a 
series of immortalised cell lines, AC cells may be applicable for use in high-throughput screening 
assays for detection of structural toxicity, and complement data obtained for the more 
physiologically relevant induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs). 
 
1.9.2.1  Induced pluripotent stem cell derived cardiomyocytes 
The discovery that somatic cells can be reprogrammed into pluripotent stem cells,189 and the 
subsequent development of the processes required to differentiate these cells into functional 
human cardiomyocytes190 instigated the growing preference of human iPSC-CMs for pre-clinical 
cardiotoxicity assessment of new drugs.  Although iPSC-CMs possess many favourable features 
such as the ability to spontaneously contract, responsiveness to cardioactive drugs and 
expression of important cardiac ion channels and receptors;191 It is has been frequently noted 
that these cells resemble embryonic cardiomyocytes and are described as having an immature 
phenotype. Robertson et al. reviewed this subject in depth and discussed the differences 
between embryonic and adult cardiomyocytes.192  
With reference to size, embryonic cardiomyocytes are approximately 30µm in length making 
them approximately 80% smaller than adult cardiomyocytes that are large, cylindrical and 
approximately 150μm long. Differences in organelle size and number have also been noted, for 
example adult cardiomyocytes are usually bi- or multinucleated, whereas embryonic 
cardiomyocytes are mononucleated. In adult cardiomyocytes the contractile apparatus and 
mitochondria constitute around two thirds of the cytoplasmic space, this is reduced in 
embryonic cells where much smaller sarcomeres and fewer mitochondria are seen. With respect 
to contractile function, contractile strength is reduced due to the lack on an extensive T-tubule 
network in embryonic cells.192 This results in slower excitation-contraction coupling and calcium 
entry primarily through the sarcolemma rather than released from the sarcoplasmic reticulum 
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through CICR. Long term experiments appear to improve the phenotype to having a higher level 
of maturity, including increased use of the sarcoplasmic reticulum, increased multinucleation 
and improved myofibrillar arrangement.193  
Despite the immature phenotype of human iPSC-CMs, they are still considered more clinically 
and physiologically relevant than other in vitro models such as the rat H9c2 cell line. In addition, 
these cells represent a source of human adult cardiomyocytes that can be cultured easily for 
long periods of time and are readily available for routine drug testing - A feature absent from 
other human derived in vitro models.194 Therefore these cells have become fundamental to 
many in vitro cardiotoxicity assays, and have shown considerable promise to accurately detect 
cardiac liabilities in drugs with known cardiac effects on a number of platforms. Another 
potentially exciting advancement, is the development of patient-specific iPSC-CMs which can be 
used to study drug effects in the context of a particular risk factor or disease.195  
Although commonly used as a confluent spontaneously beating monolayer, the use of iPSC-CMs 
is now expanding to 3D models. Various types of 3D cell culture techniques have been 
developed, some use scaffolds, whilst others rely upon the innate interactions of cells. All of 
these models were developed with the aim of more accurately recapitulating in vivo cellular 
morphology and physiology than that of the more commonly used 2D cell models.196 Although 
3D cell culture techniques have existed for some time, it is only since the recent development 
iPSC-CMs that efforts have been directed towards utilizing these techniques to potentially 
increase model maturity for cytotoxicity screening. Many 3D models incorporate different cell 
types, often cardiomyocytes, fibroblasts and endothelial cells which usually approximate the 
ratios found in the human heart (See section 1.4.3)197 Such models have been used to measure 
cardiac hypertrophy and structural cardiotoxicity; where increases in the size of spheroids and 
perturbations to mitochondrial function (measured as ATP level) in response to cardiotoxicants 
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are visible using microscopy. Therefore 3D spheroid models have applications in improving pre-
clinical cardiotoxicity screening.198  
 
1.9.3 In vitro cardiotoxicity assays  
The requirement of in vitro cardiac cell assays and the identification of new cardiac cell lines and 
advent of iPSC-CMs has led to a surge in the development of new high-throughput assays that 
allow the structural and functional activity of cardiomyocytes to be assessed. The driving 
principle of these assays is the measurement of electrophysiological changes that precede 
contraction or quantification of the contraction itself. Traditionally, monitoring 
electrophysiological fluctuations of excitable cells was carried out using patch clamping.199 
Although this technique allows for the activity of single ion channels to be assessed, it is labour 
intensive, limited to isolated cardiomyocytes, and evaluates cell effects at a snapshot in time, 
making this technique unsuitable for high-throughput screening. 
 
1.9.3.1  Microelectrode arrays  
Microelectrode arrays (MEAs) are plate based assays whereby electrically active cells such as 
iPSC-CMs are seeded into the wells of specialised plates that have a series of electrodes on the 
bottom of the wells. Once the cells form a cohesive monolayer and begin to spontaneously 
contract, their electrophysiological profile is captured by the electrodes in real-time allowing 
parameters such as beat rate, field potential duration, amplitude and conduction velocity to be 
assessed.200 In contrast to the traditional patch-clamp approach, MEAs measure the total 
extracellular change of ions and therefore assess changes in all major ion channels implicated in 
the action potential. A recent blinded study by Blinova et al. assessed the ability of iPSC-CMs to 
detect drug-induced arrhythmias using an MEA platform. The results were promising, drugs that 
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block key potassium and calcium channels were positively identified, there was however more 
variable success at detecting sodium channel blockers.201  
 
1.9.3.2  IonOptix 
Cardiac tissue is characterised by the appearance of bands within the individual cardiomyocytes 
known as sarcomeres. These are the basic unit of muscle and contain the contractile proteins 
and molecular machinery responsible for cardiac contractility (See section 1.4.1). The rate and 
size of sarcomere shortening and lengthening provide important information relating to cellular 
contractility and changes in inotropy and chronotropy induced by drugs. Changes in 
cardiomyocyte contractility can be monitored using the IonOptix cell geometry system which 
monitors sarcomere movements in real-time using video-based detection.202 A perfused 
cardiomyocyte monolayer is observed using a microscope which collects optical intensity data 
representing the light and dark bands present within the sarcomere. Contraction of the cells 
results in the movement of these bands which translates into transients of peaks and troughs 
which are then analysed to provide quantification of contractility. This technique was recently 
used by Pointon et al. who evaluated the ability of iPSC-CMs to detect changes in contractility 
by 11 reference compounds (8 negative inotropes, 2 positive inotropes and 1 inactive 
compound). All of the negative isotopes and the inactive compound were positively detected, 
however although the positive inotropes were detected by the system, they exhibited a negative 
rather than positive inotrope response.203 
 
1.9.3.3  Calcium fluctuation  
As Ca2+ is intrinsically involved in cardiomyocyte contraction, measurement of intracellular Ca2+ 
transients can also be used as a surrogate measure of contraction. Calcium specific fluorescent 
dyes are added to monolayers of cells in a plate based format, and as the iPSC-CMs 
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spontaneously beat and their intracellular Ca2+ levels fluctuate, the peaks and troughs in 
fluorescence intensity are recorded.204 This technique allows changes in contraction force and 
frequency to be quantified, however it should be noted that compounds which affect the 
contractile machinery, such as the myosin II inhibitor blebbistatin will not be detected and the 
toxicity of the dyes limits how long drug effects can be monitored.  
 
1.9.3.4  Cellular impedance assays 
 Cellular impedance technology allows for real-time, label free monitoring of cardiomyocyte 
viability and beating over sustained periods. Minute cardiomyocyte movements that occur 
during contraction cause transient changes in impedance; these small morphological changes to 
cardiomyocytes are detected by electrodes which creates a surrogate pattern based on the 
contractility of the cells. In addition to changes in contractility, this technology can detect 
changes in cellular viability and morphology as impedance readings also provide a measure of 
overall cell health and therefore may be useful in detecting structural changes.  These features 
allow for sensitive and robust monitoring of the effects of compounds on cardiomyocyte 
function and health in a high-throughput approach that is reflective of clinical exposures.205,206 
As cardiomyocyte contraction is downstream of the cardiac action potential and calcium flux in 
cardiac excitation-contraction coupling (See section 1.4.2 and figure 1.2), the surrogate 
measurement of contractility generated by cellular impedance technology has the potential to 
detect drug induced disturbances to the action potential, calcium flux and mechanical 
contraction. For example, the reduced contraction strength caused by the myosin II inhibitor 
blebbistatin can be demonstrated using impedance technology, however effects of the drug are 
absent using both MEAs and calcium fluctuation assays which measure endpoints higher in the 
cascade.207  
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As a result, cellular impedance technology has the potential to detect both functional and 
structural drug-induced cardiotoxicity, which could lead to earlier cardiovascular hazard 
identification in the drug development process. A recent study by Doherty et al. assessed if a 
multi-parameter in vitro screen could detect cardiotoxicity across multiple drug classes with 
known clinical cardiac risks. A range of studies were carried out, however the most sensitive test 
was the impedance based xCELLigence cardio system which detected 16/18 known 
cardiotoxicants as cardiotoxic.208 Similarly Gou et al. compared the utility of MEA and the 
impedance based xCELLigence cardio system to detect functional changes in iPSC-CMs following 
treatment with 28 different compounds with known cardiac effects and attained comparable 
results from both sytems,207 therefore highlighting illustrating the utility of impedance-based 
technology at accurately detecting cardiac liabilities in iPSC-CMs. 
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1.10 Rationale and aims 
The cardioprotective potential of therapies that act on the angiotensin signalling pathway has 
been demonstrated in recent clinical studies, which strongly suggests that a relationship exists 
between anthracycline-induced cardiotoxicity and angiotensin signalling. Although a number of 
in vivo studies have added further support for the cardioprotective nature of these drugs, there 
is a lack of in vitro studies, and the molecular mechanisms underpinning the cardioprotective 
mechanisms are currently unclear.  
The aim of this study was to investigate the structural and functional cardiotoxicities caused by 
anthracyclines using in vitro models paired with novel impedance-based technologies, and to 
ascertain if toxicity mitigation was detectable in these models upon concomitant administration 
of angiotensin receptor blockers.  
This thesis is divided into four sections: 
i) Development and qualification of in vitro cardiac cell models (AC10 cardiomyocyte cell 
line (AC10-CMs) and hiPSC-CMs) for the in vitro assessment of drug-induced cardiotoxicity, using 
impedance-based methodologies. Changes in cellular viability, morphology and functionality will 
be assessed using impedance-based detection (xCELLigence technology) in response to drugs 
and cardiac regulatory factors. 
ii) Assessment of the mechanistic basis for cardiotoxicity induced by anthracyclines  
iii) Assessment of the potential for the adverse toxicological effects of anthracyclines to be 
mitigated by perturbation of the angiotensin signalling pathway. 
iv)  Identification of the mechanistic basis for the effects of anthracyclines upon the cardiac 
system and the impact of angiotensin signalling in mediating this toxicity 
Specific aims are detailed in each section.
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Chapter 2: Materials and Methods 
All reagents were obtained from Sigma-Aldrich Company Ltd (UK) unless otherwise stated. 
Plastic tissue culture materials were supplied by Sarstedt (UK). 
2.1 Cell lines and tissue culture  
2.1.1 Cell lines 
The proliferating human cardiomyocyte cell line AC10 was originally derived by fusion of adult 
ventricular heart cells with SV40 transformed fibroblasts as described by Davidson et al.;188 these 
cells were kindly donated by Dr Barbara Savoldo from Texas Children’s Hospital, Texas, USA. The 
H460 cell line is an immortalised human cancer cell line from non-small cell lung cancer (NSCLC) 
origin that was originally obtained from American tissue culture collection (ATCC).  
 
2.1.2 Cell culture and maintenance of cells 
Cell lines were grown as monolayers in vitro and incubated at 37°C in a constant humidified 
atmosphere of 5% carbon dioxide. The AC10 cell line was maintained in Dulbecco’s modified 
eagle medium (DMEM) -F12 medium (Life technologies) supplemented with 12.5% foetal bovine 
serum (FBS), 1% L-glutamine and 1% penicillin/streptomycin. The H460 cell line was maintained 
in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% FBS and 1% L-
glutamine. Cells were passaged when flasks were ~75-80% confluent by washing the monolayer 
with hanks balanced salt solution (HBSS) and addition of 0.25% trypsin-EDTA, a pellet was then 
obtained by centrifugation at 1000g for 5 minutes and the cells were re-suspended in fresh 
medium and passaged into a new flask or cell pellets were stored at -20°C for molecular analysis.  
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2.1.3 Cell counting  
Cell number was determined using a haemocytometer where 10μl of cell suspension was 
pipetted under a coverslip and the number of cells counted in five 1mm2 sections. Due to the 
dimensions of the haemocytometer the average value of cells (N) in the five sections equates to 
N x104 cells/ml.  
 
2.1.4 Cryopreservation of cells 
Cells that were not passaged were frozen for future use. Confluent AC10 cells were trypsinised 
and centrifuged at 1000g for 5 minutes, the supernatant was then removed and the cells were 
re-suspended in 1ml of fresh medium. Cells were transferred to a 1.5ml cryovial and 10% 
dimethyl sulfoxide (DMSO) was added before the tubes were placed in a cryogenic freezing 
container in a -80°C freezer. The following day cells were transferred to a liquid nitrogen storage 
dewar for long term storage.  
 
2.2 Cellular viability assays 
The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay is a 
colourimetric assay that relies upon mitochondrial conversion of a soluble tetrazolium dye to 
insoluble purple formazan crystals, whereby the amount of purple crystals created reflects the 
number of viable cells.209  
Following determination of the optimum cell seeding density (AC10 exponential = 2x103 
cells/well; AC10 plateau = 3.5 - 4x104 cells/well; H460 exponential = 5x102/well) cells were 
seeded in flat-bottomed 96 well plates which were left in the incubator to adhere overnight, one 
lane of the plate contained medium only to act as a cell blank control. The cells were then 
treated with drug solutions and a vehicle control as required throughout the experiment, with 
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the DMSO vehicle concentration being no higher than 0.1% per well. Following the total 
incubation period for the experiment the medium was removed and replaced with medium 
containing a 1:10 dilution of MTT (5mg/ml), and incubated for an additional 4 hours to allow the 
formation of formazan crystals. Following removal of the MTT solution the crystals were 
dissolved in DMSO and the absorbance of each well was read at 550nm using a UV-Vis 
spectrophotometer plate reader. A vehicle control lane of 0.1% DMSO was used to ensure that 
any observed effect was due only to the drugs added and not an effect of the vehicle. Analysis 
of absorbance readings was conducted using Microsoft excel; the average absorbance for each 
treatment group was determined from which the average of the blank lane was deducted, and 
average absorbance’s relating to treatment with a compound expressed as a percentage of the 
vehicle control (0.1% DMSO). 
All experiments were performed in triplicate, IC50 values were determined by implementing 
curve fitting by non-linear regression on GraphPad Prism (Version 7.04, GraphPad Software, 
Inc.).  Statistical analysis on IC50 values was conducted where necessary using a One way analysis 
of variance (ANOVA) test, and a post-hoc Dunnett’s test when required on GraphPad Prism 
(Version 7.04, GraphPad Software, Inc.). 
 
2.3 xCELLigence real-time cell analyser 
The xCELLigence DP16 real-time cell analyser (RTCA) is an in vitro impedance-based cell analysis 
system that allows changes in cell survival, morphology and drug response to be evaluated on 
adherent cell lines in real time using 16 well electrode plates (E-plates).210  In wells containing 
only medium the electric current can flow freely, thus completing the circuit between the 
electrodes. However as cells adhere and begin to proliferate on the electrode the current flow 
between the electrodes is impeded – This provides very accurate information relating to 
changes in cell number, morphology and attachment (Figure 2.1).  
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Figure 2.1 Principle of impedance based cell detection 
In wells containing only medium the electric current can flow freely, thus completing the circuit 
between the electrodes (left). However when cells are added and adhere to the bottom of the 
wells the current flow between the electrodes is impeded (right). Once cells begin to proliferate 
on the electrode the current flow between the electrodes is impeded further, therefore 
impedance increases. Image courtesy of ACEA biosciences.  
 
2.3.1 Experimental set-up 
The RTCA software was started and experiments were set up as per manufacturer’s guidance 
notes (ACEA Biosciences, San Diego). The layout of the plate was outlined with information 
including cell type, cell number and compounds to be added to each well. The length of the 
experiment and number and frequency of impedance readings to be taken (sweeps) was also 
input into the experimental schedule page.  
 
2.3.2 Cell seeding 
Prior to cell seeding 100μl of DMEM-F12 medium was added to all wells of a 16 well E-plate 
which was then put to one side to allow the medium and E-plate to achieve equilibrium.  A 
suspension of AC10 cells was then created and the number of cells contained in the solution was 
determined using a haemocytometer.  The cell concentration was then adjusted to contain 
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5x104cells/ml for experiments examining cells in the exponential growth phase or to 
10x104cells/ml for experiments requiring cells to be in the plateau phase of growth.  
The 16 well E-plate was transferred in to the cradle of the RTCA instrument and the background 
impedance reading was taken. After completion of the background measurement 100μl of cell 
suspension was to the wells, with one pair of wells left with medium only. The E-plate was then 
left for 30 mins at room temperature to allow the cells to settle in an evenly distributed manner 
at the bottom of the wells. Following this the E-plate was transferred back into the cradle and 
impedance measurements were recorded every 30 mins.  
 
2.3.3 Cell maintenance and compound addition 
Following attachment of the cells compounds were added as required. For experiments 
examining the effects of compounds to cells in exponential growth phase compounds were 
added at 24 hours and after. For experiments examining the effects of compounds to cells in 
plateau growth phase compounds were added once the growth and therefore impedance 
readings (designated as cell index) became stable (Usually around 72 hours). When the effects 
of a single compound were to be assessed, double strength compounds were prepared and 
added by removing 100µl of medium from the wells and replacing with 100µl of the double 
strength compound. On all subsequent additions of that compound 100µl of drug solution was 
removed from the wells and replaced with 100µl of single strength compound.  
All experiments were performed in triplicate unless stated otherwise. Statistical analysis on 
normalised cell index values was conducted where necessary using a one way analysis of 
variance (ANOVA) test, and a post-hoc Dunnett’s test when required on GraphPad Prism 
(Version 7.04, GraphPad Software, Inc.). 
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Figure 2.2 Cell growth monitoring using the xCELLigence impedance-based system 
Schematic showing the output on the xCELLigence impedance-based system when monitoring 
cellular growth and response to cytotoxic drugs, whereby cell index (measurement of 
impedance) is related to the phase of cellular growth and the cell density in the wells. 
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2.4 xCELLigence cardio system 
The xCELLigence RTCA Cardio is an in vitro impedance-based cell analysis system that allows 
changes in cell survival, morphology, drug response and contractility to be evaluated in human 
iPSC-derived cardiomyocytes (hiPSC-CMs).205,211 Experiments were conducted as per 
standardised protocol produced by Axiogenesis, who supplied the hiPSC-CMs used throughout 
these studies.212 
 
2.4.1 Experimental set-up 
The RTCA Cardio software was started and experiments were set up as per manufacturer’s 
guidance notes (ACEA biosciences, San Diego). The layout of the 96 well Cardio E-plate was 
outlined with information including cell type, cell number and compounds to be added to each 
well. The length of the experiment and number and frequency of impedance readings to be 
taken (sweeps) was also input into the experimental schedule page.  
 
2.4.1.1  Fibronectin coating of E-plate 
Prior to cell seeding the E-plate was coated with fibronectin to facilitate cellular adhesion. A 
10µg/ml fibronectin coating solution was prepared by diluting 60µl fibronectin stock solution 
(1mg/ml) in 6ml PBS with Ca2+ and Mg2+, 50µl of which was added to each well of the E-plate 
and incubated overnight at 4˚C. 
 
2.4.1.2  Background measurement  
The following day the fibronectin coating solution was carefully aspirated from the E-plate and 
180 µl pre-warmed Cor.4U culture medium (axiogenesis) was added to each well using a multi-
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channel pipette. The E-plate was then transferred into the cradle of the RTCA Cardio instrument 
and incubated for 5 minutes before the background reading was taken. 
 
2.4.1.3  Seeding of cardiomyocytes 
A vial containing 4 x 106 Cor.4U hiPSC-CMs (axiogenesis) was removed from liquid nitrogen and 
transferred on ice to a 37˚C water bath and thawed for approximately 2 minutes. The cell 
suspension was then carefully pipetted into 3ml of pre-warmed Cor.4U medium, and the cryovial 
washed with a further 1ml of medium, resulting in a total cell suspension volume of 5ml.  
The number of live cardiomyocytes was ascertained by performing a cell count with trypan blue. 
A 1:1 mixture of trypan blue and cell suspension was created and 10µl was applied to a 
haemocytometer and the number of viable (clear) and dead (blue) cells was determined.  
The number of cells in the suspension was then calculated taking into account the chamber 
factor (1x104), dilution factor (2) and total volume (5). The cell suspension was adjusted to 
contain 3 x106 viable cells in 18ml of Cor.4U medium. 
The E-plate was disengaged from the RTCA cardio instrument and put inside the cell culture 
cabinet. The medium in the wells of E-plate was carefully aspirated and 180µl of the cell 
suspension was added to each well from a sterile reagent reservoir using a multi-channel 
pipette. This equates to a plating density of 3 x104 cardiomyocytes per well. The E-plate was then 
left for 30 mins at room temperature to allow the cells to settle in an evenly distributed manner 
at the bottom of the wells. Following this the E-plate was transferred back into the cradle and 
the recording of impedance measurements was initiated.   
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2.4.2 Maintenance of cardiomyocytes 
The following day the culture medium was exchanged twice – Once in the morning 
approximately 18 hours after seeding and then again in the evening approximately 26 hours 
after seeding. For each medium change a 100% medium replacement was performed in four 
steps – Whereby 90µl of medium was removed from all wells and the same amount of fresh 
medium was added from a sterile reagent reservoir. For a complete medium change 36ml of 
pre-warmed of Cor.4U culture medium was required to repeat the process four times. 
Subsequently a 100% medium change was performed once daily until the addition of 
compounds.  
 
2.4.3 Compound treatments 
Compounds were added to the cardiomyocytes once the cell growth had plateaued and stable 
baseline beating was observed. The following criteria were checked before commencing with 
compound addition: An absolute cell index >3, beat rate of 40-100bpm and beat amplitude of 
>0.02.   
Approximately 2 hours prior to compound addition a 100% medium change was performed as 
described above. The compounds to be added were prepared at double the concentration 
required in Cor.4U growth medium, and at least 110µl of compound was added to each well of 
a 96 well plate in the defined plate layout. The 96 well plate containing the compounds was put 
in to the cell culture incubator for 30 minutes to equilibrate, and immediately prior to addition 
of the compounds an 11 minute baseline beating measurement was performed. The E-plate was 
then disengaged and taken to the cell culture cabinet together with the compound plate; 
compounds were added by removal of 90µl medium from the top each well followed by addition 
of 90µl  of the appropriate double concentrated compound. Once all compounds were added 
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the E-plate was transferred back into the cardio instrument and the measurements were 
resumed.  
On subsequent days compounds were added again by removing 90µl compound solution from 
the top of the well followed by addition of 90µl of the appropriate single concentrated 
compound, or compounds were washed out using the four step medium change method.  
 
2.4.4 Data analysis 
Parameters relating to contractility of hiPSC-CMs such as beat frequency and beat amplitude 
were analysed using the data analysis function of the RTCA Cardio software V1.0.  
Statistical analysis on normalised cell index, normalised beat rate and normalised beat 
amplitude were conducted using a one way analysis of variance (ANOVA) test, and a post-hoc 
Dunnett’s test when required. Where only two data groups were compared a paired T-test was 
used. Statistical analysis was performed using GraphPad Prism (Version 7.04, GraphPad 
Software, Inc.). 
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Chapter 3: Qualification of In Vitro Models 
for Cardiotoxicity Evaluation  
 
3.1 Introduction 
Cardiotoxicity is a leading cause of drug attrition and withdrawal, and is categorised as the 
second leading toxicity responsible for 16% of withdrawals according to the WITHDRAWN 
database.213 The current method of pre-clinical testing for cardiac liabilities outlined by the ICH-
S7B guidelines focusses narrowly on the ability of compounds to block the human ether-à-go-go 
related gene (hERG) potassium channel in vitro, followed by evaluation of the ability to prolong 
ventricular repolarisation and therefore prolong the QT-interval in vivo.177 
Contractility of cardiomyocytes involves coordinated regulation and activity of a multitude of 
ion channels, transferring potassium, calcium and sodium ions into and out of the cell, resulting 
in an action potential and cardiomyocyte contraction (Figure 3.1). One of these channels, the 
rapid delayed rectifier potassium current (IKr) or hERG1 channel, is essential for ventricular 
repolarisation and therefore essential to maintain normal cardiac rhythmicity. Prevention of the 
flow of potassium ions through this channel can result in arrhythmogenicity and possible 
development of fatal disorders such as long QT syndrome and Torsades de pointes (TdP) 214,215 
(Figure 3.2).  These conditions can both occur due to drug inhibition of the hERG channel, with 
several drugs such as terfenadine and cisapride now withdrawn from the market due to 
prolongation of the QT interval via hERG channel inhibition.80 
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Figure 3.1 Relationship between the ventricular action potential and ionic  
  currents 
Schematic representation of the ventricular action potential with phases 0-4 indicated and the 
ionic currents responsible for the action potential phases. Adapted from reference.216 
 
 
Figure 3.2 Effect of hERG channel inhibition on cardiac rhythm 
Schematic representation of a normal ECG trace and an ECG trace with a prolonged QT interval, 
with waves, segments, and intervals labelled (Left). Schematised ECG strip showing a normal 
rhythm and a Torsades de Pointes rhythm (Right). Adapted from reference.217 
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3.1.1 Limitations of hERG channel screening during drug development 
Although inhibition of the hERG channel is responsible for approximately half of drug 
withdrawals related to appearance of cardiac adverse effects,80 drugs can disturb cardiac 
function in a host of other ways including structural damage to the myocardium, perturbation 
of signalling pathways relating to cardiac homeostasis, function and survival, and modulation of 
other ion channels important for generating the cardiac action potential that precedes 
cardiomyocyte contraction.80  
Such cardiotoxicities are overlooked as the hERG channel screen is too simplistic, as it evaluates 
a single channel in isolation, and therefore not representative of the complex nature of 
cardiomyocyte electrophysiology and function. Although many of these disturbances, if not 
detected via hERG screening, could be identified using subsequent telemetric analysis in vivo if 
they culminate in a change to cardiac rhythm. However, in vivo models are costly, and are 
somewhat of an unethical substitute for a poor in vitro assay,218 which do not always translate 
to humans due to differences in electrophysiology.219 As such, there is an urgent need for better 
pre-clinical models that are able to accurately capture information on a compound’s ability to 
cause both functional and structural cardiotoxicity, which would ideally start during the in vitro 
phase of safety testing.181 
 
3.1.2  Pre-clinical evaluation of cardiac effects during development of 
  oncology drugs 
In contrast to development of ‘conventional’ drugs, a degree of toxicity risk is generally accepted 
during the development of oncology drugs. By definition these agents do not have a safety 
margin and therefore must be screened using a paradigm focused on mechanism of action and 
monitorability, as defined in the ICHS9 guidelines.220 Such a strategy aims to identify 
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cardiovascular side effects during discovery and identify and mitigate the occurrence of 
undesirable cardiovascular toxicities in oncology drug development.   
Furthermore, in addition to measurement of drug-induced proarrhythmia induced during and 
directly after initiation of oncology treatment, these drugs are now known to also cause latter 
chronic forms of toxicity including pathological cardiac changes.29,221 Moreover, since chronic 
progressive cardiomyopathies are now a major concern for clinical use of cancer drugs, there is 
a need to build upon our improved understanding of mechanisms of drug-induced cardiotoxicity 
to explore and predict long-term effects of many anticancer therapeutics.83 
In light of the inherent cardiac risks of treatment with cancer therapeutics and the increasingly 
sensitive patient population, as with other drug classes, improved screening paradigms are also 
required for the development of oncology drugs.  
 
3.1.3 Improved in vitro models for evaluation of drug-induced cardiac 
 effects 
Historically, there has been a lack of in vitro cardiac models that were both clinically and 
physiologically relevant i.e. human derived cells that exhibit a cardiac phenotype and possess 
contractile ability. Such models are essential for detection of drug effects upon cardiac cells, 
including both structural and functional changes. Several studies have addressed the use of 
primary human cardiomyocytes for this purpose, and methodologies have been developed for 
their maintenance in culture which allow spontaneous beating in a synchronised manner for 
brief periods. However, barriers to supply and the existence of a narrow window by which to 
monitor cardiomyocyte contraction limits their applicability for routine screening.194 
Consequently, new cellular models are required with the ability to monitor drug effects in a 
cardiac and physiological relevant manner, and with capability for longer-term assessment. 
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3.1.3.1  The AC10 human ventricular cardiomyocyte cell line 
AC10 cardiomyocytes (AC10-CMs) are a recently developed cell line derived by fusing human 
ventricular cardiomyocytes with fibroblasts transformed with SV40 virus and devoid of 
mitochondrial DNA.188 Although other cell lines with capability for long-term in vitro culture 
exist, such as the HL-1 mouse atrial cardiomyocyte cell line,187 and the H9c2 rat cardiomyoblast 
cell line,183 these cells being non-human have limited use in examining effects of ventricular 
cardiomyopathies in humans. Conversely, the AC10-CM cell line, despite being in a pre-
contractile state, express many cardiac specific transcription factors, contractile proteins and 
possess functional gap junctions.188 As an immortalised cell line, AC10-CMs may be applicable 
for use in high-throughput screening assays for detection of structural toxicity, however current 
data remains limited. The cells have been used for toxicity studies focussed on the effects of 
methylmercury on mitochondrial bioenergetics and cell viability222 and also to investigate 
pathways relating to cellular hypertrophy of cardiomyocytes.223   The major limitation in the use 
of this cell line is its lack of contractility, meaning that it may have applicability for structural but 
not functional contractile studies.    
 
3.1.3.2  Human induced pluripotent stem cell derived cardiomyocytes  
The recent development of hiPSC-derived cardiomyocytes (hiPSC-CMs) provides a resolution to 
assessment of drug-induced functional changes in cardiomyocytes, as they are functionally 
active and spontaneously contract in vitro, and importantly are easily obtainable as they are 
created from human pluripotent stem cells.191,190 These cells address the concerns related to the 
simplistic nature of the hERG channel screen, as they are more representative of the complex 
nature of cardiomyocyte electrophysiology and cardiac cell function and therefore have the 
potential to detect both structural and functional cardiotoxicity.    
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Although hiPSC-CMs possess many favourable features, It is has been frequently noted that 
many current available models resemble embryonic cardiomyocytes and are described as having 
an immature phenotype. Robertson et al. reviewed this subject in depth and discussed the 
differences between embryonic and adult cardiomyocytes192 which are outlined in section 
1.8.2.1. Despite the immature phenotype of hiPSC-CMs, they are still considered more clinically 
relevant than other in vitro cardiac cell models, such as the rodent cell lines H9c2 and HL-1, and 
the non-contractile human AC10 or AC16 cell lines, which have been utilised in preliminary 
cardiac studies in vitro.182 
The hiPSC-CM model represents a physiologically relevant source of human adult 
cardiomyocytes that can be cultured easily for long periods of time and are readily available for 
routine drug testing - A feature absent from other human derived in vitro models.194 Therefore 
hiPSC-CMs and their inherent contractile activity have become applicable to many in vitro 
cardiotoxicity assays, and have shown considerable promise to accurately detect cardiac 
liabilities in drugs with known cardiac effects on a number of platforms.201,203 The success of this 
cell model will have significant potential for a further exciting advancement, the development 
of patient-specific hiPSC-CMs which can be used to study personalised and precision medicines 
in the context of a particular risk factor or disease.195 
The increased use of hiPSC-CMs within cardiac safety assessment studies has caused a surge in 
the development of new high-throughput assays that allow the functional activity of 
cardiomyocytes to be assessed, such as video microscopy, microelectrode arrays and 
impedance-based assays. These assays measure the electrophysiological changes that precede 
contraction or quantify the contraction itself. Impedance-based cellular analysis is an innovative 
method of assessing the contractility of hiPSC-CMs and has emerged as an exceptional platform 
for monitoring cardiomyocyte beating and viability.  
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3.1.4 In vitro technologies for determination of cardiac cell contraction 
Traditionally, monitoring electrophysiological fluctuations of excitable cells was carried out 
using patch clamping. Although this technique allows for the activity of single ion channels to be 
assessed, it is labour intensive, limited to isolated cardiomyocytes, and evaluates cell effects at 
a snapshot in time, making this technique unsuitable for high-throughput screening.199 
Microelectrode arrays (MEAs) are plate based assays whereby hiPSC-CMs are seeded into the 
wells of specialised plates that have a series of electrodes on the bottom of the wells. Once the 
cells form a cohesive monolayer and begin to spontaneously contract, their electrophysiological 
profile is captured by the electrodes in real-time allowing parameters such as beat rate, field 
potential duration, amplitude and conduction velocity to be assessed.200 In contrast to the 
traditional patch-clamp approach, MEAs measure the total extracellular change of ions and 
therefore assess changes in all major ion channels implicated in the action potential. 
 Cellular impedance-based assays measure the contraction of hiPSC-CMs, and therefore also 
assess changes in the activity of all ion channels in addition to the monitoring of other factors 
that may affect contractility.206 
 
3.1.4.1  Cellular impedance technology  
Cellular impedance technology allows for real-time, label free monitoring of cardiomyocyte 
viability and beating over sustained periods (As described previously in section 1.8.3.4). Minute 
cardiomyocyte movements that occur during contraction cause transient changes in impedance; 
these small morphological changes to cardiomyocytes are detected by electrodes which creates 
a surrogate pattern based on the contractility of the cells. These features allow for sensitive and 
robust monitoring of the effects of compounds on cardiomyocyte function and health in a high-
throughput approach that is reflective of clinical exposures.205 
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As cardiomyocyte contraction is downstream of the cardiac action potential and calcium flux in 
cardiac excitation-contraction coupling, the surrogate measurement of contractility generated 
by cellular impedance technology has the potential to detect drug induced disturbances to the 
action potential, calcium flux and mechanical contraction (Figure 3.3). Whereas patch clamping 
and MEA technologies would be applicable to detection of electrophysiological cellular changes, 
these technologies are unable to detect alterations in intracellular signalling leading to 
modulation in cardiomyocyte contractility. For example, the reduced contraction strength 
caused by the myosin II inhibitor blebbistatin can be demonstrated using impedance technology, 
however effects of the drug are absent using both microelectrode arrays (MEAs) and calcium 
fluctuation assays which measure endpoints higher in the cascade.207 As a result, impedance 
technology has the potential to detect both functional and structural drug-induced 
cardiotoxicity, which could lead to both earlier cardiovascular hazard identification in the drug 
development process and robust assessment of mechanisms of drug interactions. 
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Figure 3.3 The relationship between action potential (AP), [Ca2+]i and cellular
  contraction 
 
A recent study by Doherty et al. assessed if a multi-parameter in vitro screen could detect 
cardiotoxicity across multiple drug classes with known clinical cardiac risks. A range of studies 
were carried out, however the most sensitive test was the impedance based xCELLigence cardio 
system which detected 16/18 known cardiotoxicants as cardiotoxic.208 The results from this 
study support the development of the new cardio safety paradigm Comprehensive in vitro 
Proarrhythmia Assay (CiPA) which is currently being developed (see section 1.9.1). The overall 
goal of CiPA is to develop a new screening strategy that places greater emphasis on the accurate 
prediction of cardiotoxicity using various in vitro high-throughput hiPSC-CM assays combined 
with patch clamp assays and in silico simulations. If successfully implemented CiPA could avoid 
the unwarranted attrition of useful drugs, accelerate the development of safe drugs and reduce 
development costs.180,181  
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3.1.5 Aims and objectives 
The aim of this chapter is to characterise the suitability of the AC10 cardiomyocyte  
cell line (AC10-CMs) and hiPSC-derived cardiomyocytes (hiPSC-CMs) for detection of structural 
and functional cardiotoxicity, in order to qualify their use for in vitro screening paradigms. 
 
Specifically: 
i) Characterisation of the cardiac phenotype of AC10-CMs. The expression of cardiac specific 
proteins and markers of cellular proliferation will be determined followed by examination of 
their growth kinetics and optimisation of cytotoxicity protocols. 
ii) Optimisation of AC10-CMs for detection of structural cardiotoxicants. In AC10-CMs, viability 
and morphology of cells exposed to the hypertrophic mediator angiotensin II and the structural 
and functional cardiotoxicant sunitinib will be determined using the xCELLigence RTCA and the 
MTT assay.   
iii) Optimisation of the hiPSC-CM model for detection of structural and functional 
cardiotoxicants in vitro. The initial growth and contractility of these cells will be monitored on 
the impedance based xCELLigence cardio instrument, followed by assessment of their 
responsiveness to drugs with known cardiac effect once stable beating is detected. The 
established methodology will then be qualified using the hypertrophic mediator angiotensin II 
and the structural and functional cardiotoxicant sunitinib, with survival, contractility and cellular 
morphology monitored using the xCELLigence cardio system.   
Similar to the optimisation and qualification of hiPSC-CMs described within this chapter, an 
additional study was conducted using Axol hiPSC-CMs which was later published in Nature 
Methods Application Notes in November 2016 (Appendix 2).  
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3.2 Materials and methods 
3.2.1 Immunostaining 
AC10 cardiomyocytes (AC10-CMs) were immunostained to verify the expression of a variety of 
cardiac specific proteins including contractile proteins and transcription factors. The 
immunostaining protocol detailed below was developed by Dr Gavin Richardson (Newcastle 
University) who kindly provided reagents, antibodies and assistance with this technique.  
A suspension of AC10-CMs was created and cell number determined using a haemocytometer. 
The cell number was adjusted and cells were seeded in chamber cell culture slides (NUNC, USA) 
at a density of 1x105 cells per chamber. The cells were left overnight to adhere to the slide 
surface.  
Cells were washed with PBS and then incubated with 1ml 4% paraformaldehyde (PFA) at room 
temperature for 20 minutes. Following this the cells were washed once with PBS and incubated 
in PBS at 4°C until commencing staining. Slides were then incubated in 0.4% triton-X-100 for 20 
minutes and then blocked with 20% FBS for 30 minutes. Following addition of primary antibody 
(1:200 dilution in PBS) or no antibody control (PBS alone) the slides were incubated overnight at 
4°C. Slides were washed (3 x 5 minutes) in PBS and then incubated at room temperature for one 
hour with the relevant secondary antibody (1:500 dilution in PBS, see table 3.1 below for 
antibody details) and the nuclear stain 4',6-diamidino-2-phenylindole (DAPI; 1:500 dilution in 
PBS). For no secondary antibody control chambers, PBS and DAPI were used. Slides were then 
washed in PBS (3x 5 minutes), and antifade solution and the coverslips added. Slides were 
subsequently visualised on a Nikon Eclipse Ti confocal fluorescence microscope and images 
captured using NIS elements software V4.2. 
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Primary  
antibody 
Antibody 
type 
Secondary 
antibody* 
Fluorescent 
tag 
Colour 
emitted 
Troponin I Goat 
polyclonal 
Anti-goat Alexa 594 red 
Troponin C Goat 
polyclonal 
Anti-goat Alexa 488 green 
Tropomyosin Rabbit 
polyclonal 
Anti-Rabbit Alexa 488 green 
Alpha actinin Rabbit 
polyclonal 
Anti-Rabbit Alexa 488 green 
NKX2.5 Rabbit 
polyclonal 
Anti-Rabbit Alexa 488 green 
BMP-2 Goat 
polyclonal 
Anti-goat Alexa 488 green 
PCM1 Rabbit 
polyclonal 
Anti-Rabbit Alexa 488 green 
Ki-67 Murine 
monoclonal 
Anti-mouse Alexa 594 red 
Vimentin Chicken 
monoclonal 
Anti-chicken Alexa 594 red 
α-smooth 
muscle actin 
Rabbit 
polyclonal 
Anti-Rabbit Alexa 488 green 
*All secondary antibodies sourced from Invitrogen  
 
Table 3.1 Antibodies used for immunostaining evaluation of cardiac phenotype 
  of AC10 cardiomyocytes 
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3.2.2 Validation of the MTT assay    
Cell suspensions of AC10-CMs were created containing 4x104 and 3x104 cells/ml. These were 
serial diluted in 2-fold increments to obtain a range of 9 concentrations (4x104, 3x104, 2x104, 
1.5x104, 1x104, 7.5x103, 5x103, 3.55x103 and 2.5x103 cells/ml) which were added to 8 wells of a 
96-well plate in 100µl volumes equating to plating densities of 4,000, 3,000, 2,000, 1,500, 1,000, 
750, 500, 375 and 250 cells/well. The following day 1:10 MTT was added and absorbance 
readings were obtained and analysed as described in section 2.2. 
 
3.2.2.1  Growth curve analysis determined by the MTT assay 
Cell suspensions of AC10-CMs were created containing 1x104, 2x104, 1x105 and 2x105 cells/ml; 
each density was seeded in to 6 wells of five 96-well plates at 100µl volume equating to plating 
densities of 1,000, 2,000, 10,000 and 20,000 cells/well. MTT solution was added to one plate 
every day for the next 5 days and absorbance readings obtained and analysed as described in 
section 2.2. From the growth curve analysis a plating density of 2,000 cells/well was chosen for 
experiments using AC10-CMs in the exponential growth phase.     
 
3.2.2.2  Determination of cell number required for confluence within 24 hours 
A suspension of AC10-CMs was created containing 6x105 cells/ml, this was diluted accordingly 
to obtain suspensions at an additional 10 densities, reducing by 50,000 cells each time. Seeded 
at 100µl per well in 8 wells of a 96-well plate, this equated to plating densities of 60,000, 55,000, 
50,000, 45,000, 40,000, 35,000, 30,000, 25,000, 20,000, 15,000 and 10,000 cells/well. The 
following day the wells were observed under a microscope to check for gaps in the monolayers 
and attainment of confluence, MTT solution was then added and absorbance readings were 
obtained and analysed as described in section 2.2. Based on the results a plating density of 35-
40,000 cells/well was chosen for experiments using AC10-CMs in the plateau growth phase. 
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3.2.3 Analysis of growth kinetics of AC10 cardiomyocytes using the 
 xCELLigence RTCA system 
The growth kinetics of AC10-CMs were analysed using the xCELLigence real-time cell analyser 
(RTCA) to identify the optimum seeding density of AC10-CMs for future experiments. The 
protocol was carried out as described in section 2.3 except a serial dilution of cells was created 
starting with 2x105 cells/ml which was then serial diluted in 2 fold dilution increments five times 
to obtain a total range of six cell concentrations (2x105, 1x105, 5x104, 2.5x104, 1.25x104 and 
6.25x103 /ml), 100µl of each was added in duplicate to a 16 well E-plate. Following cell seeding 
a 1:2 medium change was performed every 48 hours until termination of the experiment by 
removing 100µl of medium from the wells and adding 100µl of fresh medium. A seeding density 
of 5000 cells/well (5x104cells/ml) was chosen as the optimum seeding density for cells in the 
exponential phase of growth. For experiments requiring cells to be in the plateau phase of 
growth, cells were plated at of 10,000 cells/well (10x105cells/ml) and left for approximately 72 
hours for the cells to reach confluence. 
 
3.2.4 Determination of cellular viability of AC10-CM following exposure 
 to angiotensin II 
AC10-CMs were seeded into 96-well plates as previously described in section 2.2 for exponential 
phase studies. Concentrations of angiotensin II were prepared ranging from 600-200pM which 
were applied to AC10-CMs the following day. The experiment was terminated following 96 hours 
exposure to angiotensin II by addition of MTT solution, absorbance readings were obtained and 
analysed as described in section 2.2. 
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3.2.5 Determination of cellular viability of AC10-CM following exposure 
 to sunitinib 
AC10-CMs were seeded into 96-well plates as previously described in section 2.2 for exponential 
and plateau phase studies. After 24 hrs, sunitinib was added to cells by performing a 1:2 serial 
dilution across the wells, resulting in final concentrations ranging from 20µM to 0.078µM. The 
experiment was terminated after 96 hours exposure to sunitinib by addition of MTT solution, 
absorbance readings were obtained and analysed as described in section 2.2 and IC50 values 
were determined by implementing curve fitting by non-linear regression on GraphPad Prism 
(Version 7.04, GraphPad Software, Inc.).   
 
3.2.6 Determination of morphological changes induced by angiotensin II 
 and sunitinib in AC10-CM using the xCELLigence RTCA    
Experiments were set up as described in section 2.3. For studies in exponential growth phase, 
Angiotensin II or sunitinib addition commenced at 24 hours and continued at 24 hour intervals 
until the experiment was complete (96 hours exposure for angiotensin II and 72 hours exposure 
for sunitinib). For studies in plateau growth phase, sunitinib addition commenced once the cell 
index demonstrated confluence (approximately 72 hours) and continued at 24 hour intervals 
until a total of 72 hours exposure. All experiments were performed in triplicate and statistical 
analysis on normalised cell index values was conducted using a One way analysis of variance 
(ANOVA) test, and a post-hoc Dunnett’s test when required using GraphPad Prism (Version 7.04, 
GraphPad Software, Inc.). 
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3.2.6.1  Evaluation of viability of AC10-CMs following exposure to angiotensin II 
  and sunitinib at specific time points, determined using the MTT assay 
Cellular viability was also determined following exposure to angiotensin II and sunitinib at 
specific time points to complement data obtained using the xCELLigence RTCA. For these 
studies, cells were plated for exponential phase studies as previously described and 200pM and 
300pM angiotensin II was added to cells every 24 hours for 4 consecutive days. Experiments 
were terminated at 96 hour exposure, and absorbance readings were obtained and analysed as 
described in section 2.2. 
For determination of cell viability of sunitinib exposed AC10-CMs, cells were plated for 
exponential phase and plateau phase studies as previously described and 50nM, 250nM and 
500nM sunitinib was added to cells the following day. Experiments were terminated following 
24 hour exposure to sunitinib, and absorbance readings were obtained and analysed as 
described in section 2.2. 
 
3.2.7 Imaging of AC10-CMs treated with angiotensin II and sunitinib 
For studies involving angiotensin II, AC10-CMs were seeded into T25 flasks at a density of 2.5 x 
104 cells. After 24hrs, 300pM angiotensin II was added every 24 hours for 4 consecutive days. At 
96 hours exposure the cells were fixed using 4% PFA as previously described (see section 3.2.1). 
For studies involving sunitinib AC10-CMs were plated at a density of 5x104 cells/well in 6 well 
plates. The following day 500nM sunitinib was added to 2 wells and following 24 hours exposure 
cells were fixed using 4% PFA (detailed in section 3.2.1). All experiments included a time 
matched vehicle control. Cellular images were collected using a Leica DIC DMI6000B inverted 
microscope and analysed using the Leica application suite. All studies were repeated in triplicate.  
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3.2.8 Evaluation of drug-induced cardiotoxicity in hiPSC-CM using the 
 xCELLigence Cardio system  
The xCELLigence cardio system was used to analyse the initial growth and contractility of Cor.4U 
hiPSC-derived cardiomyocytes (hiPSC-CMs). Briefly, this involved set up of the experiment on 
the RTCA cardio software as per manufacturer’s guidelines, fibronectin coating of the e-plate 
and seeding of hiPSC-CMs at a density of 30,000 cells/well. The day after cell seeding a full 
medium exchange was performed twice and then once daily thereafter. Full experimental 
details are described in section 2.4. Once stable beating was detected investigation of the effects 
of the β-adrenergic agonist isoproterenol and the hERG potassium channel blocker E-4031 on 
contractility was determined. Changes in morphology and contractility were also evaluated 
following addition of sunitinib and angiotensin II, which were added at 24 hour intervals over 72 
hours. For the first addition of a compound, half the media (90µl) was removed from each well 
and replaced with media containing twice the required drug concentration. For all subsequent 
compound additions, half the drug solution (90µl) was removed from each well and replaced 
with media containing required drug concentration.  The protocol followed for use of the 
xCELLigence cardio system can be found in section 2.4. 
 Statistical analysis on normalised cell index, normalised beat rate and normalised beat 
amplitude were conducted using a one way analysis of variance (ANOVA) test, and a post-hoc 
Dunnett’s test when required. Where only two data groups were compared a paired T-test was 
used. Statistical analysis was performed using GraphPad Prism (Version 7.04, GraphPad 
Software, Inc.). 
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3.3 Results      
The purpose of this phase of the project was to determine the suitability of the AC10 
cardiomyocyte cell line (AC10-CMs) and human hiPSC-derived cardiomyocytes (hiPSC-CMs) for 
detection of structural and functional cardiotoxicity. Following characterisation of growth 
kinetics in both cell types, cytotoxicity protocols were optimised for AC10-CMs and the response 
of hiPSC-CMs to drugs with known cardiac effects was determined. The established 
methodology was then qualified using the hypertrophic mediator angiotensin II and the 
structural and functional cardiotoxicant sunitinib. 
 
3.3.1 Confirmation of the cardiac phenotype of the AC10 cardiomyocyte 
 cell line 
The AC10-CMs are a proliferative cell line created by fusion of healthy human ventricular 
cardiomyocytes with SV40 transformed fibroblasts devoid of mitochondrial DNA.188 
Immunocytochemical analyses were used to determine the expression of cardiac proteins 
(Figure 3.4), markers of cellular proliferation, mesenchymal specific proteins and vascular 
proteins (Figure 3.5). 
Expression of the contractile proteins troponin I, troponin C, tropomyosin and α-actinin were 
detected in addition to the cardiac specific transcription factor NKX2.5 and bone morphogenetic 
protein 2 (BMP-2) which is involved in cardiac cell differentiation (Figure 3.4).  The cellular 
proliferation markers pericentriolar material 1 (PCM1) and Ki-67 were also present, as was the 
mesenchymal protein vimentin. Negative expression was obtained for alpha smooth muscle 
actin, which is the predominate form of actin found in vascular muscle cells. (Figure 3.5).  
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Figure 3.4 Immunostaining of AC10 cardiomyocytes for cardiac proteins 
Positive staining for troponin I, troponin C, tropomyosin, α-actinin, NKX2.5 and BMP-2. Proteins 
of interest are stained red or green, nuclei are stained blue with DAPI. Images shown are at 
either high (x40) or low (x10) magnification with 50µM scale bar shown on images.  
Troponin I Troponin C 
Tropomyosin α-actinin 
NKX2.5 BMP-2 
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Figure 3.5 Immunostaining of AC10 cardiomyocytes for other proteins of interest 
Positive staining for the proliferative markers PCM1 and Ki-67 and the mesenchymal marker 
vimentin. Negative staining was obtained for alpha smooth muscle actin. Proteins of interest are 
stained red or green, nuclei are stained blue with DAPI. Images shown are at either high (x40) or 
low (x10) magnification with 50µM scale bar shown on images. 
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3.3.2 Optimisation of cell viability assays using AC10 cardiomyocytes 
 The MTT assay as a methodology for quantifying cell number was validated by investigating the 
relationship between cell number, determined manually, and MTT conversion via quantification 
of absorbance at 550nm. Figure 3.6 shows a linear relationship between cell number of AC10-
CMs and absorbance, exemplified by the R2 value of 0.9944.  
 
 
Figure 3.6 Validation of the MTT assay in AC10 cardiomyocytes 
Cell number vs absorbance at 550nm of various densities of AC10-CMs 24 hours after cell 
seeding. Data points show average values ± SD, R2 = 0.9944. 
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3.3.2.1  Measurement of growth kinetics of AC10 cardiomyocytes using the MTT 
  assay 
Cells were seeded at various densities (1000, 2000, 10,000 and 20,000 cells/well) and the 
absorbance quantified for the MTT assay on five consecutive days (Figure 3.7). Cells seeded at 
1,000 cells/well shows little proliferation over 5 days, whereas seeding densities of 10,000 and 
20,000 cells/well showed immediate exponential growth and lack of a lag phase of cell growth, 
with cells approaching confluence after 72 hours. Cells seeded at an initial density of 2,000 
cells/well showed a relatively short lag phase, with exponential growth beginning after 1 day 
and lasting the duration of the experiment. Subsequently, a seeding density of 2000 cells/well 
was chosen for MTT studies of cells in the exponential growth phase. 
In order to identify the optimal seeding density to obtain plateau cellular growth within 24 
hours, AC10-CMs were seeded at densities between 10,000 and 60,000 cells/well. Analysis of 
absorbance using MTT assay revealed the absorbance to be relatively stable at cell densities 
above 30,000 cells (figure 3.8), therefore a density of 35-40,000 cells was chosen as the seeding 
density for MTT studies in the plateau growth phase. 
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Figure 3.7 Growth curves of AC10 cardiomyocytes generated using MTT assay 
Absorbance at 550nm of AC10-CMs seeded at 1,000, 2,000, 10,000 and 20,000 cells/well over a 
time course of 5 days. Data points show average values ± SD. 
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Figure 3.8 Optimisation of seeding density for MTT studies in plateau growth 
  phase 
Cell number vs absorbance at 550nm for various densities of AC10-CMs 24 hours after cell 
seeding. Data points show average values ± SD. 
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3.3.2.2  Measurement of growth kinetics of AC10 cardiomyocytes using  
  xCELLigence real time cell analyser 
The xCELLigence RTCA was used to assess the proliferation of AC10-CMs in real-time. The growth 
of cells plated at high density (20,000, 10,000 and 5,000 cells/well) and low density (2,500, 1,250 
and 625 cells/well) are shown in Figures 3.9A and 3.9B, respectively. Cells plated at higher 
densities reached the plateau phase of growth sooner than cells plated at lower density and 
showed a much shorter lag phase. The longer lag phase observed with cells plated at low density 
resulted in a delay in exponential growth that was not seen in cells plated at higher densities. 
Based on these findings a seeding density of 5,000 cells was chosen for exponential growth 
phase studies, as this cell number exhibited a short lag phase and long exponential phase (until 
100 hours), maintaining cells in exponential growth for the duration of experiments. When cells 
were required to be confluent (plateau growth phase), cells were plated at a density of 10,000 
cells and left to proliferate for approximately 72 hours before beginning experimental protocols.  
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3.9A 
3.9B 
 
Figure 3.9 Growth kinetics of AC10 cardiomyocytes 
xCELLigence traces showing time (hours) vs cell index for A. AC10-CMs plated at high density 
(20,000, 10,000 and 5,000 cells/well) and B. AC10-CMs plated at low density (2,500, 1,250 and 
625 cells/well) Data is representative of n=2, data points show average values ± SD. 
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3.3.3 Optimisation and characterisation of hiPSC-derived 
 cardiomyocytes for the xCELLigence Cardio RTCA system 
The hiPSC-derived cardiomyocytes (hiPSC-CMs) used in this study were the Cor.4U cells 
(Axiogenesis, Germany). These cardiomyocytes have been well characterised and express critical 
contractile proteins, possess functional ion channels, form functional syncytia and contract in 
vitro. The cardiac phenotype of these cells is shown by positive expression of the sarcomeric 
protein α-actinin (Figure 3.10).  
 
 
Figure 3.10 Immunostaining of Cor4u hiPSC-derived cardiomyocytes for cardiac 
  proteins 
Positive staining for α-actinin (green) with nuclei stained blue with DAPI. Image courtesy of 
Axiogenesis, Germany. 
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3.3.3.1  Establishment of contractile syncytium and measurement of cellular 
  contraction of hiPSC-derived cardiomyocytes using the xCELLigence 
  Cardio RTCA system 
Cor.4U hiPSC-CM cells were seeded at 30,000 cells/well, as per standardised protocol produced 
by Axiogenesis.212  Figure 3.11 shows the growth of the cells gradually increases over time, with 
cells fully confluent at approximately 75 hours. The arrows on the figure indicate the points of 
medium exchange. 
Throughout the initial growth period the contractility of the cells was monitored at regular 
intervals. Figure 3.12 shows example traces taken from a representative well at 12, 24, 36, 48, 
and 72 hours. Primitive beating is seen at 36 hours, with stable beating observed in the  
hiPSC-CMs at 72 hours 
 
 
Figure 3.11 Initial growth hiPSC-derived cardiomyocytes 
xCELLigence cardio trace showing time vs. cell index for Cor.4U hiPSC-CMs plated at 30,000 
cells/well. Arrows indicate points of medium exchange, data points show average values of 4 
representative wells ± SD. 
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Figure 3.12 Assessment of initial contractility of hiPSC-derived cardiomyocytes 
xCELLigence cardio traces showing contractility of Cor.4U hiPSC-CMs over a time course of 12, 
24, 36, 48 and 72 hours. Data was obtained from one representative well. 
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3.3.3.2  Confirmation of drug-induced perturbation of hiPSC-derived 
  cardiomyocytes 
hiPSC-CMs as a contractile confluent monolayer were exposed to the β-adrenergic agonist 
isoproterenol and the hERG potassium channel blocker E-4031. Traces showing stable baseline 
beating and beating 2 hours after compound addition are shown in figures 3.13A and 3.13B 
respectively. No visible changes were observed between the two control traces, however 
addition of isoproterenol caused the beat rate to increase and E-4031 caused both beat 
amplitude and beat rate to decrease. These effects are summarised in figures 3.14A and 3.14B. 
 
Figure 3.13 Effect of isoproterenol and E-4031 on contractility of hiPSC-derived 
  cardiomyocytes 
A. Traces of stable baseline beating before compound addition, B. Traces of beating 2 hours 
after compound addition 
3.13A 
3.13B 
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Figure 3.14 Analysis of the effect of isoproterenol and E-4031 on contractility of  
  hiPSC-derived cardiomyocytes 
 A. Bar graph showing beating rate/minute before compound addition and 2 hours after 
compound addition. B. Bar graph showing beat amplitude before compound addition and 2 
hours after compound addition.  Data obtained from one representative well for each treatment 
group, ■ control, ■ isoproterenol, ■ E-4031. 
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3.3.4 Qualification of ability of cardiomyocyte cell models to detect 
 structural changes, determined following exposure to Angiotensin  II 
Angiotensin II has pleiotropic roles within the cardiovascular system and causes 
vasoconstriction, increases in heart rate and cardiac remodelling.76 As a well known mediator of 
cardiac hypertrophy, it was used to qualify the in vitro models used in this study for detection of 
structural cardiotoxicity. 
Prior to investigating morphological effects, the effect of angiotensin II on viability of ACI0-CMs 
was ascertained using the MTT assay. Figure 3.15 shows that exposure to clinically relevant 
concentrations of angiotensin II for 96 hours caused no significant change to cellular viability of 
AC10-CMs. For future experiments concentrations of 200pM and 300pM angiotensin II were 
used. 
 
Figure 3.15 Effect of angiotensin II on viability of AC10 cardiomyocytes 
Dose response curve showing the effect of 600pM – 200pM angiotensin II on cell viability 
following 96 hour exposure, expressed as % cell survival relative to vehicle control. Data is 
representative of n=3 ± SE. 
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3.3.4.1  Angiotensin II induces morphological changes in AC10 cardiomyocytes 
The xCELLigence RTCA was used to assess the effect of angiotensin II on the morphology of AC10-
CMs. As shown in figure 3.16A, when normalised to the point of first angiotensin II addition, cell 
index gradually increased higher than the level of control in cells exposed to angiotensin II, with 
the greatest difference in cell index following 96 hours exposure (figure 3.16B). To ascertain if 
this increase in cell index was due to increased cellular proliferation or a change to cellular 
morphology, an MTT assay was carried out – AC10-CMs exposed to angiotensin II in an identical 
manner showed no difference in viability (figure 3.16C), indicating that the increase in cell index 
observed using xCELLigence was likely due to a change in morphology (figure 3.16D). 
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Figure 3.16 Angiotensin II causes hypertrophy of AC10 cardiomyocytes 
A. xCELLigence trace showing time (hours) vs normalised cell index of AC10-CMs exposed to 
angiotensin II with points of angiotensin II (arrows) and exposure time indicated, data 
representative of n=3, data points shown are average ± SD. B. Normalised cell index following 
96h exposure to angiotensin II, data is n=3 ± SE. C. Relative cell number following 96h exposure 
to angiotensin II measured by MTT assay, data is n=3 ± SE and D. Images of untreated and 
angiotensin II treated AC10-CMs showing a change in morphology. Images were taken at 40x 
magnification following 96h exposure angiotensin II.        
■ control, ■ 200pM Angiotensin II, ■ 300pM Angiotensin II. 
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3.3.4.2  Angiotensin II induces morphological changes and functional 
  disturbances in hiPSC-derived cardiomyocytes  
Stably beating Cor.4U cells were exposed to angiotensin II every 24 hours for a total of 72 hours, 
and the effects on cell behaviour were monitored in real-time. As shown in figure 3.17A, when 
normalised to the point of first angiotensin II addition, cell index increased higher than the level 
of control in cells exposed to 200pM angiotensin II, with the greatest difference in cell index 
approximately 72 hours after angiotensin II was initially added (figure 3.17B), indicating that 
angiotensin II induced a morphology change to the cells. 
Assessment of the effect of angiotensin II on contractility of hiPSC-CMs was carried out after 72 
hours exposure to angiotensin II, as the cells showed the greatest degree of hypertrophy at this 
time-point. The representative traces of contractility shown for control and angiotensin II 
treated cells in figure 3.18A show no visible changes in contractility with angiotensin II addition. 
Detailed analysis of beat rate and amplitude is shown in figures 3.18B and 3.18C respectively. 
Assessment of the effect of angiotensin II on contractility of hiPSC-CMs was also carried out 
immediately after the first addition of angiotensin II.  The representative traces of contractility 
shown for control and angiotensin II treated cells in figure 3.19A show visible changes to 
increases to beat rate and decreases to beat amplitude immediately after angiotensin II 
addition. Detailed analysis of beat rate and amplitude is shown in figures 3.19B and 3.19C 
respectively. 
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Figure 3.17 Effect of angiotensin II on morphology of hiPSC-derived cardiomyocytes 
A. xCELLigence trace showing time (hours) vs normalised cell index of hiPSC-CMs exposed to 
angiotensin II with points of angiotensin II addition (arrows) and exposure time indicated, data 
representative of n=2, data points shown are average ± SD. B. Normalised cell index at 170 hours 
following 72 hours exposure to angiotensin II. Data points show average of 3 wells ± SE. 
* p< 0.05, ■ control, ■ 200pM Angiotensin II. 
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Figure 3.18 Effect of 72 hours angiotensin II exposure on contractility of hiPSC-
  derived cardiomyocytes 
A. Representative traces showing contractility of control cells and cells following exposure to 
200pM angiotensin II for 72 hours, B. Beating rate/min following 72 hours exposure to 
angiotensin II, data points show average of 3 wells ± SE and C. Beating amplitude following 72 
hours exposure angiotensin II. Data points show average of 3 wells ± SE.    
■ control, ■ 200pM Angiotensin II. 
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Figure 3.19 Immediate effect of angiotensin II exposure on contractility of hiPSC-
  derived cardiomyocytes 
A. Representative traces showing contractility of control cells and cells immediately after 
angiotensin II addition, B. Beating rate/min immediately after angiotensin II addition, data 
points show average of 3 wells ± SE and C. Beating amplitude immediately after angiotensin II 
addition. Data points show average of 3 wells ± SE, * p< 0.05.   
■ control, ■ 200pM Angiotensin II. 
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3.3.5 Sunitinib to qualify in vitro models for detection of functional 
 cardiotoxicity 
Sunitinib is a cancer therapy that targets multiple tyrosine kinases including the vascular 
endothelial growth factor receptor (VEGF-R) which is its primary target. As such, it is mainly 
indicated for the treatment of highly vascularised malignancies such as renal cancer; although 
successful at inhibiting angiogenesis and halting tumour growth its use is associated with 
numerous cardiotoxicities including development of arrhythmias, hypertension and 
impairments to ventricular function.96 As a well-known functional cardiotoxicant and mediator 
of cardiac hypertrophy, it will be used to qualify the in vitro models used in this study for 
detection of functional and structural cardiotoxicity.       
 
3.3.5.1  Effect of sunitinib on viability of AC10 cardiomyocytes  
Prior to investigating morphological effects, the toxicity profile of sunitinib in ACI0-CMs was 
determined in both the exponential and plateau growth phases. Figure 3.20 shows the 
sensitivity of AC10-CMs exposed to a range of sunitinib concentrations (20μM - 0.078μM) 
continuously for 96 hours, with the CMax indicated by the dashed line.  At concentrations below 
the CMax little cell death occurred in both growth phases, however above the CMax varying degrees 
of response to the sunitinib were seen, with cells in exponential growth showing increased 
sensitivity. The IC50 values obtained for both growth phases are shown in table 3.2, the value 
calculated for exponential growth phase was 10.7 ± 1.5μM, this value at least doubled for cells 
in the plateau phase to greater than 20μM.  
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Figure 3.20 Chemosensitivity studies with sunitinib in AC10 cardiomyocytes 
Dose response curves showing the effect of sunitinib on cell viability expressed as % cell survival 
relative to vehicle control for cells in exponential and plateau growth phases. The dashed line 
represents the C
Max
 of sunitinib (253nM)224, data is representative of n=3 ± SE. 
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3.3.5.2  Qualification of ability of cardiomyocyte cell models to detect functional 
  changes following exposure to sunitinib 
Cells in exponential and plateau growth phase were exposed to varying concentrations of 
sunitinib, and the effects on cell behaviour were monitored in real-time. As shown in figure 
3.21A and summarised in figure 3.21B following 24 hours sunitinib exposure, when normalised 
to the point of first sunitinib addition, cells in exponential growth phase exposed to 500nM and 
250nM sunitinib exhibited an immediate increase in cell index that was maintained throughout 
the experiment, whereas the cell index of cells exposed to 50nM was unaffected. To ascertain if 
this increase in cell index was due to increased cellular proliferation or a change to cellular 
morphology an MTT assay was carried out – AC10-CMs exposed to sunitinib for 24 hours showed 
no major differences in viability (figure 3.21C), indicating that the increase in cell index observed 
using xCELLigence was due to a change in morphology (figure 3.21D). A parallel study conducted 
in cells in the plateau phase of growth showed similar findings, the results of which are shown 
in figure 3.22A-C.  An additional finding in the plateau growth phase studies was that the cells 
exposed to 50nM sunitinib also showed immediate increases in cell index that were maintained 
throughout the experiment (figure 3.22A), with dose-dependent increases in cell index observed 
after 24 hours exposure (figure 3.22B).  
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Figure 3.21 Effect of sunitinib on morphology of AC10 cardiomyocytes in  
  exponential growth phase 
A. xCELLigence trace showing time (hours) vs normalised cell index of AC10-CMs in exponential 
growth phase exposed to sunitinib with points of sunitinib addition (arrows) and exposure time 
indicated, data representative of n=3, data points shown are average ± SD. B. Normalised cell 
index following 24 hours exposure to sunitinib, data is n=3 ± SE. C. Relative cell number following 
24 hours exposure to sunitinib measured by MTT assay, data is n=3 ± SE and D. Images of 
untreated and sunitinib treated AC10 cardiomyocytes showing a change in morphology. Images 
were taken at 40x magnification following 24 hours exposure to sunitinib. * p< 0.05, ** p< 0.001 
(treatment groups compared to control). ■ control, ■ 50nM sunitinib, ■ 250nM sunitinib,  
■ 500nM sunitinib. 
0
1
2
3
4
N
o
rm
al
is
ed
 c
el
l i
n
d
ex
 f
o
llo
w
in
g 
 2
4
 
h
o
u
rs
 e
xp
o
su
re
 t
o
 s
u
n
it
in
ib
0
0.2
0.4
0.6
0.8
1
1.2
R
el
at
iv
e 
ce
ll 
n
u
m
b
er
 f
o
llo
w
in
g 
 2
4
 
h
o
u
rs
 e
xp
o
su
re
 t
o
 s
u
n
it
in
ib
[Sunitinib] [Sunitinib] 
3.21A 
3.21B 3.21C 3.21D 
Control 
500nM sunitinib 
* 
** 
121 
 
 
 
      
 
Figure 3.22 Effect of sunitinib on morphology of AC10 cardiomyocytes in plateau 
  growth phase 
A. xCELLigence trace showing time (hours) vs normalised cell index of AC10-CMs in plateau 
growth phase exposed to sunitinib with points of sunitinib addition (allows) and exposure time 
indicated, data representative of n=3, data points shown are average ± SD. B. Normalised cell 
index following 24 hours exposure to sunitinib, data is n=3 ± SE. and C. Relative cell number 
following 24 hours exposure to sunitinib measured by MTT assay, data is n=3 ± SE. * p< 0.05,  
** p< 0.005 (treatment groups compared to control), ■ control,  ■ 50nM sunitinib,  
■ 250nM sunitinib,  ■ 500nM sunitinib. 
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3.3.5.3  Sunitinib induces morphological changes and functional disturbances in 
  hiPSC-derived cardiomyocytes  
The xCELLigence cardio system was used to assess the effect of sunitinib on the morphology and 
contractility of hiPSC-CMs. As shown in figure 3.23A, when normalised to the point of first 
sunitinib addition, cell index immediately increased higher than the level of control in cells 
exposed to 50nM, 250nM and 500nM sunitinib in a dose-dependent manner, with the greatest 
difference in cell index approximately 72 hours after sunitinib was initially added (figure 3.23B), 
indicating that sunitinib induced a morphology change to the cells. 
Assessment of the effect of sunitinib on contractility of hiPSC-CMs was carried out after 72 hours 
exposure to sunitinib as the cells showed the greatest degree of hypertrophy at this time-point. 
The representative traces of contractility shown for control and sunitinib treated cells in figure 
3.24A show visible changes in contractility, with beat number decreasing with increasing 
concentrations of sunitinib and increased amplitude with 500nM sunitinib. Detailed analysis of 
beat rate and amplitude is shown in figures 3.24B and 3.24C respectively.  
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Figure 3.23 Effect of sunitinib on morphology of hiPSC-derived cardiomyocytes 
A. xCELLigence trace showing time (hours) vs normalised cell index of hiPSC-CMs exposed to 
sunitinib with points of addition (arrows) and exposure time indicated, data points shown are 
average ± SD. B. Normalised cell index following 72 hours exposure to sunitinib, data points 
show average of 3 wells ± SE. * p< 0.0001 (treatment groups compared to control).  
■ control, ■ 50nM sunitinib, ■ 250nM sunitinib, ■ 500nM sunitinib. 
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Figure 3.24 Effect of 72 hours sunitinib exposure on contractility of hiPSC-derived 
  cardiomyocytes 
A. Representative traces showing contractility of control cells and cells exposed to sunitinib for 
72 hours, B. Normalised beating rate/minute following 72 hours exposure to sunitinib, data 
points show average of 3 wells ± SE and C. Normalised beat amplitude following 72 hours 
exposure to sunitinib, data points show average of 3 wells ± SE.  * p< 0.001 (treatment groups 
compared to control). ■ control, ■ 50nM sunitinib, ■ 250nM sunitinib, ■ 500nM sunitinib. 
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3.4 Discussion     
Cardiotoxicity is a leading cause of drug withdrawal, and its occurrence related to the use of 
cancer therapies is a considerable problem;179,225 suggesting that the current in vitro methods 
for identification of cardiotoxicity are inadequate. The purpose of this phase of the project was 
to determine the suitability of the AC10 cardiomyocyte cell line (AC10-CMs) and hiPSC-derived 
cardiomyocytes (hiPSC-CMs) for detection of structural and functional cardiotoxicity.  
 
3.4.1 Suitability of the AC10 cardiomyocyte cell line    
AC10 cardiomyocytes (AC10-CMs) are a recently developed cell line created by Davison et al., 
whereby human ventricular cardiomyocytes were fused with fibroblasts transformed with SV40 
virus and devoid of mitochondrial DNA. The cells were well characterised by Davison et al. and 
although they are in a pre-contractile state, they express many contractile proteins.188 In 
agreement with Davison et al., positive expression of troponin I and α-actinin was detected in 
AC10-CMs in this current study in addition to the contractile proteins troponin C and 
tropomyosin. The pattern of immunostaining observed is distinct from what would be expected 
in mature cardiomyocytes, there is minimal indication of filamentous protein structure and no 
evidence of sarcomeres. Due to the lack of organised contractile machinery and functional ionic 
currents, the AC10-CMs are unable to spontaneously contract and are described as being in a 
pre-contractile state. 
The cardiac specific transcription factors GATA4, MYCD and NFATc4 that are involved in cardiac 
development and function were identified using real-time polymerase chain reaction (qRT-PCR) 
by Davison et al., in this study the transcription factor NKX2.5 was also found to be expressed in 
AC10-CMs by immunostaining. NKX2.5 is involved in cardiogenesis in early cardiac development 
and has been shown to interact with GATA4, the presence of cardiac specific transcription 
factors in the cells are useful markers of cardiac myogenesis and provide further evidence that 
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AC10-CMs are committed to a cardiac-like phenotype.    
In contrast to Davison et al. who found bone morphogenetic protein 2 (BMP-2) only upon 
silencing of the SV40 gene, BMP-2 was detected in AC10-CMs in this study without SV40 
silencing. Due to the involvement of BMP-2 in cardiomyocyte differentiation, its presence 
suggests that the AC10-CMs may be further into the process of cardiomyocyte differentiation 
and exist at an intermediate stage of development. 
In accordance with their proliferative potential, the cellular proliferation markers pericentriolar 
material 1 (PCM1) and Ki-67 were also present, as was the mesenchymal protein vimentin.  
Vimentin is found in mesenchymal cells such as fibroblasts and would not be found in primary 
cardiomyocytes, indeed the study by Davison et al. reported that vimentin was not present in 
the AC10-CMs. However as the cells are a fusion cell line of cardiomyocytes and fibroblasts, this 
may explain why positive expression of vimentin was found in this study. As discussed in section 
1.4.3 although cardiomyocytes form the bulk of the myocardium, they are outnumbered by 
support cells of the myocardium which make up 70% of the cells in the heart; 15% of which are 
fibroblasts.53 Fibroblasts are responsible for a plethora of events in the myocardium including 
cardiac remodelling and maintenance of the ECM,54 therefore the presence of vimentin within 
the AC10-CMs may favour studies investigating morphological changes induced by 
cardiotoxicants. An additional positive feature of these cells is their ability to form functional 
gap junctions, although not investigated within this study, Davison et al. reported the presence 
of functional gap junctions exemplified by expression of Cx-40, Cx-43 and dye coupling 
studies.188  
Despite the cells inability to spontaneously contract, their expression of contractile proteins, 
cardiac specific transcription factors and the presence of functional gap junctions demonstrate 
that the AC10-CMs are committed to the cardiac lineage and therefore suitable for studies into 
structural cardiotoxicity and viability following exposure to cardiotoxicants.  
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As cardiomyocytes in the heart are terminally differentiated and possess limited capacity for 
regeneration, studies throughout this research were conducted, where necessary, in both the 
exponential and plateau phases of growth in an attempt to recapitulate the adult human heart 
and investigate if different responses are obtained in each growth phase. For MTT studies this 
equated to seeding densities of 2,000 cells/well for exponential growth phase studies and 35-
40,000cells/well for studies in the plateau growth phase. Analysis of the proliferation of AC10-
CMs using the xCELLigence RTCA showed that the cells were able to adhere to the plates and 
their proliferation rate was monitored in real time. The growth kinetics analysis allowed 
identification of 5,000 cells/well and 10,000/cells as appropriate seeding densities for 
conducting studies in the exponential and plateau phases of growth respectively, where 
exponential studies would begin 24 hours after seeding and plateau studies would commence 
once the cells reach the plateau phase of growth (at approximately 72 hours).  
As the xCELLigence RTCA uses impedance to monitor the behaviour of cells, it is a suitable 
platform for evaluation of structural cardiotoxicity and viability following exposure to 
cardiotoxicants, as decreases to cell index may represent cytotoxicity or reduction in cell size, 
whereas increases to cell index may represent increased proliferation or increases in cell size. 
The use of complimentary MTT studies and imaging would provide a comprehensive assessment 
of cellular status at a specific time-point and therefore allow for identification of structural 
cardiotoxicity.  
 
3.4.2 Suitability of hiPSC-derived cardiomyocytes 
The growth and contractility of Cor.4U hiPSC-CMs (axiogenesis) was monitored using the 
impedance based xCELLigence cardio system, once cells were fully confluent and stable beating 
was observed hiPSC-CMs were exposed to the β-adrenergic agonist isoproterenol and the hERG 
potassium channel blocker E-4031.  
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Isoproterenol exhibits both positive inotropy and chronotropy, meaning that clinically it causes 
an increase in both the force and rate of contraction. Analysis of contractility 2 hours after the 
addition isoproterenol showed an increased rate of contraction, however the amplitude of the 
beats (an indication of the strength of contraction) was slightly less, meaning that positive 
inotropy was not observed. Similar results were reported by Pointon et al. who found that the 
positive inotropes digoxin and isoproterenol altered contraction strength measured by IonOptix, 
however the direction was reversed with negative inotropy rather than positive inotropy being 
detected.203  
These discrepancies may be due to the immature phenotype of hiPSC-CMs. As discussed in 
section 1.9.2.1 there are many differences between adult and embryonic cardiomyocytes, 
including smaller sarcomeres, reduced numbers of mitochondria, lack of an extensive T-tubule 
network and reduced SERCA and RyR expression. Consequently, the dynamics of calcium 
handling are different in embryonic cardiomyocytes, which results in calcium entry primarily 
through the sarcolemma rather than released from the sarcoplasmic reticulum and slower 
cardiac excitation-contraction coupling.192 The reduced contractile capacity of hiPSC-CMs 
compared to adult cardiomyocytes may render them unable to increase their contractile 
strength in response to positive inotropes such as isoproterenol.  
Efforts to develop maturity in these cells, perhaps by co-culture with support cells, may help to 
detect positive inotropy in hiPSC-CMs.  Work in this area has been conducted by ACEA 
biosciences who demonstrated that electrical pacing of hiPSC-CMs for three weeks prior to 
exposure to positive inotropes reverses the negative-force frequency relationship of hiPSC-CMs 
and increases in beat amplitude are observed. Although further characterisation of the paced 
cells is required, improved sarcomeric structure and better localisation of RyRs may be 
responsible for the observed improvements to contractility.226    
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E-4031 blocks the rapid delayed rectifier outward potassium current (IKR) and thereby delays 
ventricular repolarisation, which increases the duration of the myocardial contraction.  Analysis 
of contractility 2 hours after the addition of E-4031 showed the expected result of decreases to 
both beat number and amplitude. As therapeutic inhibition of the hERG channel is associated 
with arrhythmogenesis and fatal disorders such as Torsades de pointes (TdP),214,215 accurate 
detection of the contractile deficits caused by these inhibitors pre-clinically is of great 
importance, and demonstrates the utility of these cells in future screening for cardiac liabilities.  
This study has demonstrated that hiPSC-CMs monitored on the xCELLigence cardio system are 
able to spontaneously contract after approximately 72 hours, and irrespective of their immature 
phenotype are responsive to positive chronotropy (isoproterenol) and negative chronotropy 
and inotropy (E-4031), and is therefore a suitable platform for the assessment of changes in 
cardiomyocyte contractility. Changes in viability and morphology will also be possible using 
hiPSC-CMs grown on the xCELLigence cardio system. Similar to the xCELLigence RTCA, increases 
in cell index may represent increases to cell size, and decreases to the cell index may be due to 
cytotoxicity or decreases in cell size. 
 
3.4.3 Qualification studies with angiotensin II  
As a well-known mediator of cardiac hypertrophy angiotensin II was used to qualify the in vitro 
models developed for detection of structural cardiotoxicity. A hypertrophic response was 
detected in AC10-CMs using the xCELLigence RTCA following repeated addition of clinically 
relevant doses of angiotensin II, which was confirmed using cellular viability studies and imaging. 
A similar response was observed in hiPSC-CMs using the xCELLigence cardio system, with 
immediate increases in cell index occurring following addition of 200pM angiotensin II. Many 
groups have reported cardiomyocyte hypertrophy upon angiotensin II addition in vivo and in 
vitro and have attempted to identify other contributory factors to angiotensin II induced 
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hypertrophy. Studies using isolated neonatal rat cardiomyocytes have detected angiotensin II 
induced hypertrophy and assessed the impact of TAK-1 and Smad2/3,227 whilst studies using 
isolated adult rat cardiomyocytes compared the hypertrophic response of cardiomyocytes from 
normal and post-infarcted rats when cultured in angiotensin II.228 The potential of fibroblasts to 
augment angiotensin II induced hypertrophy was also investigated by Gray et al., who isolated 
neonatal rat cardiomyocytes and fibroblasts and conducted co-culture experiments. The results 
showed that co-culture of cardiomyocytes with fibroblasts enhanced cardiomyocyte 
hypertrophy due to paracrine signalling,229 thus illustrating the crucial role of support cells such 
as fibroblasts within the myocardium. 
This study is the first to show that angiotensin II induced hypertrophy can be detected using 
impedance based systems in vitro using the human derived models AC10-CMs and hiPSC-CMs. 
This has significant implications in terms of 3R’s benefits, as it demonstrates that the human 
derived in vitro models used are able to respond as expected to the hypertrophic mediator and 
therefore may replace or reduce the use of primary cardiomyocytes from animal sources for 
these purposes which require difficult culture techniques and animal sacrifice.218  
The use of these in vitro models for detection of hypertrophy also extends towards improved 
pre-clinical testing of pharmaceuticals as a means for early identification of structural 
cardiotoxicity. As previously mentioned, the current method of pre-clinical testing for cardiac 
liabilities focusses narrowly on the ability of compounds to block the hERG potassium channel 
in vitro, followed by evaluation of the ability to prolong ventricular repolarisation and therefore 
prolong the QT-interval in vivo.177 This screening strategy overlooks the development of 
structural changes, which are associated with a number of cancer therapeutics with the 
potential to cause cardiovascular liabilities.144 Structural changes can have a huge impact on the 
pumping ability of the heart, therefore early identification of the problem is of crucial 
importance.     
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 The initiation of hypertrophy in response to angiotensin II suggests both the presence of the 
ATR1 on AC10-CMs and hiPSC-CMs and functional signalling cascades that upon receptor 
activation cause cellular hypertrophy. Angiotensin signalling via the ATR1 receptor has been 
outlined in section 1.4.5.2 and figure 1.3. 
 In hiPSC-CMs, further analysis to contractility found that hypertrophy induced by 72 hours 
exposure to angiotensin II did not affect contractility of the cells in terms of amplitude and beat 
number, however immediately after angiotensin II addition increases in beat number and 
decreases to beat amplitude were detected. Positive chronotropy and negative inotropy has 
been previously detected in isolated rat cardiomyocyte cultures, in addition to increases in 
calcium flux into the cells following a few minutes exposure to angiotensin II.230 The lack of 
contractile changes reported in this study following long-term exposure may be due to the short 
half-life of angiotensin II, in circulation the half-life of angiotensin II can be as short as 30 seconds 
which can increase to 30 minutes in tissues.231 It is difficult to determine in the presented studies 
how long angiotensin II remained active in vitro, but it is likely that effects on contractility will 
only occur up 30 minutes following addition so only acute responses can be observed. It is worth 
noting that although changes to contractility were detected immediately after angiotensin II 
addition, hiPSC-CMs are particularly sensitive to changes in temperature, so following return of 
the cells to the incubator transient reductions in beat number are seen on the whole. For this 
reason changes in contractility are usually assessed 2 hours after drug addition at the earliest.  
 
3.4.4 Qualification of cellular models to detect drug-induced functional 
 changes in cardiomyocyte contractility 
Sunitinib is an angiogenesis inhibitor used in the treatment of highly vascularised malignancies 
such as renal cancer. Although successful at halting tumour growth its clinical use is associated 
with numerous cardiotoxicities including development of arrhythmias, hypertension and 
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impairments to ventricular function.96 As a well-known functional cardiotoxicant and mediator 
of cardiac hypertrophy, it was used to qualify the in vitro models used in this study for detection 
of functional and structural cardiotoxicity. 
The toxicity profile of sunitinib was determined in both the exponential and plateau phases of 
growth in AC10-CMs following 96 hours exposure to varying concentrations of sunitinib. Cells in 
both growth phases showed no toxicity at the CMax of sunitinib, (250nM).  Interestingly, at 
concentrations higher than the CMax cells in exponential growth exhibited increased sensitivity 
to sunitinib with an IC50 of 10.7 ± 1.5μM, this value at least doubled for cells in the plateau phase 
to greater than 20μM. This could be due to the mechanism of action of sunitinib. As a tyrosine 
kinase inhibitor, sunitinib has the ability to suppress the growth of rapidly proliferating cells such 
as cancer cells by inhibiting growth factor signalling. This results in decreases to cell growth, 
proliferation and angiogenesis in tumours and may explain the increased sensitivity of AC10-
CMs in the exponential growth phase, as it is possible that these cells express higher levels of 
sunitinib’s targets than the non-proliferating cells in plateau phase.  
Analysis of morphological changes to AC10-CMs using the impedance based xCELLigence RTCA 
showed induction of dose-dependent hypertrophy in both the exponential and plateau phases 
of growth following repeated addition of sunitinib. Clinically relevant concentrations of sunitinib 
(500nM = 2x CMax, 250nM = CMax and 50nM = 0.2 CMax) were used, with all except 50nM causing 
hypertrophy in the exponential growth phase and all three concentrations causing hypertrophy 
in the plateau phase of growth. Occurrence of hypertrophy was verified using cellular viability 
studies and imaging following 24 hours exposure to sunitinib. A similar pattern of hypertrophy 
was observed in hiPSC-CMs with all three concentrations of sunitinib causing an immediate 
increase in cell index that was sustained throughout repeated addition of sunitinib.  
Other groups have also reported hypertrophy as a result of sunitinib treatment in vivo and in 
vitro. For example, Chu et al. found evidence of hypertrophy in myocardial biopsies taken from 
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the myocardium of patients who had developed chronic heart failure post-sunitinib treatment.98 
In hiPSC-CMs, addition of 3µM sunitinib for 48 hours caused an enlarged, hypertrophic like cell 
shape.232 Investigations in the rat H9c2 cell line, concluded that application of 1, 2.5 and 5µM 
sunitinib induced cellular hypertrophy.184 The mechanism of sunitinib induced hypertrophy to 
cardiomyocytes is currently unclear but it is thought to be at least partially due to inhibition of 
PDGFR by sunitinib (see section 1.6.1.1). Evidence from the H9c2 cell line also implicates 
involvement of the aryl hydrocarbon receptor, as antagonism of this receptor was found to 
reduce sunitinib induced hypertrophy.184    
This study is the first to demonstrate sunitinib induced hypertrophy using impedance based 
systems in vitro with the human derived models AC10-CMs and hiPSC-CMs. In contrast to 
previous studies, where hypertrophy was detected at higher sunitinib concentrations, this study 
identified sunitinib hypertrophy at lower clinically relevant doses over prolonged periods that 
are more reflective of clinical exposures. This illustrates the utility of the xCELLigence systems to 
detect morphology changes to AC10-CMs and hiPSC-CMs in a manner that is translational to the 
clinical setting.  
Analysis of contractility in the hiPSC-CMs revealed that sunitinib caused dose-dependent 
decreases in beat number and increased beat amplitude with sunitinib following 72 hour 
exposure. Other groups have reported changes to contractility following sunitinib exposure 
using the xCELLigence cardio system. For example, Doherty et al. also found dose-dependent 
reductions in beat rate following 2 hours and 24 hours exposure to 625nM, 2.5µM and 10µM 
sunitinib. Although beat amplitude was not measured by Doherty et al., the effects of sunitinib 
on ionic currents was assessed by patch clamping, where sunitinib was found to inhibit the hERG 
channel with an IC50 of 500nM, and inhibit specific sodium (Nav1.5) and calcium (Cav1.2) 
currents at higher concentrations.232 It is possible that the increase in beat amplitude observed 
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in this current study with sunitinib is due to inhibition of one or a mixture of these ion channels.  
      
3.4.5 Conclusion 
The aim of this phase of the study was to determine the suitability of the AC10 cardiomyocyte 
cell line (AC10-CMs) and hiPSC-derived cardiomyocytes (hiPSC-CMs) for detection of structural 
and functional cardiotoxicity. The Induction of hypertrophy that was observed in AC10-CMs and 
hiPSC-CMs following exposure to angiotensin II and sunitinib qualifies the use of these cell 
models for detection of structural cardiotoxicity and supports the use of these cells on an 
impedance-based platform in screening assays for detection of structural toxicity. The 
contractility assessments of hiPSC-CMs exposed to isoproterenol, E-4031, angiotensin II and 
sunitinib support the use of the impedance-based xCELLigence cardio system to detect changes 
in cardiomyocyte contractility by assessment of transient changes to impedance. 
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Chapter 4: In Vitro Evaluation of 
Anthracycline-induced Cardiotoxicity 
 
4.1 Introduction 
An integral component of multiple chemotherapy regimes since their introduction in the 1960’s; 
their widespread use makes anthracyclines (e.g. doxorubicin, daunorubicin and epirubicin) one 
of the most successful drug categories. Anthracyclines are potent cytotoxic drugs whose broad 
spectrum activity makes them suitable for use as single agents or alongside other drugs where 
they are used in a curative, adjuvant or palliative manner.15 Their anti-proliferative effects are 
exerted on cancer cells by intercalating between DNA base pairs, generating damaging oxygen 
free radicals and inhibiting the DNA replicative enzyme topoisomerase IIα. (TopIIα) thereby 
causing DNA double strand breaks. This culminates in an array of cellular injury including damage 
to cellular components and disruption of DNA synthesis and replication.111 Despite the 
oncological success of anthracyclines in treating a wide range of adult and paediatric 
malignancies, their use is hampered by the occurrence of acute, chronic and delayed 
cardiotoxicity which considerably limits their clinical usefulness.16 
Strategies employed in an effort to reduce the cardiotoxicity of anthracyclines include 
development of less toxic analogues, modification to dosing schedules, creation of new delivery 
and nano-formulations, enzymatic pro-drug conjugates to restrict anthracycline location to the 
tumour site, concurrent administration of cardioprotective therapies and improved imaging 
modalities and approaches to assess cardiac function.28,151,233 These modifications and strategies 
all fall under the umbrella of cardio-oncology, a new multi-disciplinary approach that aims to 
effectively treat a patients’ cancer whilst minimising the collateral damage to the cardiovascular 
system.41,153,234   
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4.1.1 Cardiotoxicity of the anthracycline doxorubicin 
Doxorubicin is the most well studied of the anthracyclines, exhibiting broad spectrum activity 
against many different tumour types, and thus is considered the standard anthracycline to which 
all of the other family members may be compared (Figure 4.1).15 The cardiotoxic effects of 
anthracyclines were first reported by Lefrak et al. in 1973, who observed heart failure in patients 
following doxorubicin treatment.112 Although doxorubicin-induced cardiotoxicity has been 
classified as the most noted chemotherapy-induced cardiotoxicity to date,114 it is still unclear as 
to how anthracyclines such as doxorubicin cause irreversible damage to cardiomyocytes. 
Collective evidence suggests that the adverse cardiac effects initiated by doxorubicin is 
progressive and multi-factorial. From a tissue and cellular level, doxorubicin is reported to cause 
significant cytotoxicity of post-mitotic differentiated cardiomyocytes (and supporting cells, such 
as fibroblasts) and subsequent loss of cellular mass.144 Tissue changes to the myocardium 
include widespread areas of myocardial interstitial fibrosis, fibroblast proliferation, increased 
macrophage infiltration and scattered vacuolated cardiomyocytes with a loss of regular 
shape.235 At the subcellular level doxorubicin causes cytoplasmic vacuoles, mitochondrial 
membrane disruption and disorder of myofibril arrangement.116 From a molecular perspective, 
mechanisms of doxorubicin-induced cardiomyopathy include impaired calcium handling, altered 
gene and protein expression of key pathways involved in cardiomyocyte survival and function, 
DNA breakage via inhibition of cellular topoisomerase IIβ (TopIIβ), intracellular collation of iron, 
inhibition of mitochondrial topoisomerase I (TopImt) and consequent function, and the 
formation of oxygen free radicals that damage the mitochondria of the cells.16,34,118,124,127 These 
mechanisms of doxorubicin-induced cardiotoxicity are discussed in detail in section 1.7.1.1. 
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4.1.1.1  Clinical manifestation of doxorubicin-induced acute cardiotoxicity 
Acute cardiotoxicity can occur within weeks of treatment, although this is fairly rare and usually 
self-limiting and reversible.16 The incidence of acute cardiotoxicity has been estimated at 
approximately 11% and presents as drug-induced pericarditis and perturbations in cardiac 
contractility causing cardiac dysrhythmias.142,235 Doxorubicin-induced electrophysiological 
disturbances are centred around non-specific ST-T changes and decreased amplitude of the QRS 
complex.  A case study by Steinberg et al. evaluated the cardiac function of 29 patients post-
doxorubicin treatment and concluded that arrhythmias in the first hour after doxorubicin 
treatment are very uncommon, however occur more commonly over the next 23 hours, usually 
in the form of ventricular premature beats and non-sustained ventricular tachycardia.141 In 
addition, the mechanism of acute cardiotoxicity is thought to involve an inflammatory response, 
shown by Pecoraro et al. who observed increased levels of pro-inflammatory cytokines with a 
concomitant reduction of the anti-inflammatory cytokine IL-10 in a 24 hour mouse study of 
acute doxorubicin cardiotoxicity.236 
Despite in many cases these early toxicities not posing an immediate threat or necessitation of 
treatment interruption, they may ‘prime’ the heart to subsequent remodelling and occurrence 
of the move severe forms of delayed toxicity. Acute cardiotoxicity as a consequence of 
doxorubicin treatment is discussed in section 1.7.1.2.2.  
 
4.1.1.2  Clinical manifestation of doxorubicin-induced delayed and chronic 
  cardiotoxicity 
The cardiotoxicity demonstrated by anthracyclines, including doxorubicin, is largely irreversible 
and related to the total cumulative dose that patients have been exposed to. The importance of 
cumulative dose as a determinant for development of heart failure was identified by Von Hoff 
et al. who conducted a retrospective analysis of over 4000 patients treated with anthracyclines. 
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Although this study has been critiqued due to sole utilisation of clinician identified symptoms of 
heart failure, a sudden rise in the prevalence of heart failure occurred at a cumulative dose of 
550mg/m2,113 which is slightly higher than the current maximum recommended cumulative 
lifetime dose of 450mg/m2.15 A retrospective analysis of three clinical trials conducted by Swain 
et al. further investigated the importance of cumulative dose in relation to anthracycline-
induced cardiotoxicity (AIC), and reported the prevalence of heart failure in patients who were 
exposed to a range of cumulative doses of anthracycline. The incidence of heart failure was 
found to increase with cumulative dose, with estimated incidence of 5%, 26% and 48% with 
400mg/m2, 550mg/m2 and 700mg/m2 cumulative dose, respectively. Interestingly, this study 
also found an increased risk of cardiotoxicity with lower amounts of doxorubicin (<300 mg/m2) 
which were previously not linked with left ventricular dysfunction.17  
The notable short and long term effects of doxorubicin on the cardiac system are development 
of left ventricular dysfunction (LVD) which can lead to heart failure (HF). This progressive form 
of drug-induced cardiotoxicity usually occurs following completion of treatment, either within 
one year of treatment (chronic cardiotoxicity) or decades after chemotherapy has been 
completed (delayed cardiotoxicity).134 Chronic cardiotoxicity is the most prevalent and clinically 
relevant manifestation of anthracycline-induced cardiotoxicity. Symptoms usually present 
approximately one year following treatment as dilated cardiomyopathy a prerequisite for heart 
failure.135      
Delayed cardiotoxicity is particularly relevant in adult survivors of childhood cancer, whereby 
cardiotoxicity arises decades after exposure to doxorubicin after a long asymptomatic period.136 
Due to their younger age at the time of treatment, childhood survivors are in a developmental 
stage that makes them more vulnerable to adverse health effects from potentially toxic 
therapies, which become clinically apparent years later. In these survivors, cardiovascular 
related disease has been identified as the leading cause of morbidity and mortality after 
development of cancer recurrence.31 
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4.1.2 Cardiotoxicity of the anthracycline epirubicin 
Epirubicin is a derivative of doxorubicin (Figure 4.1), used in the treatment of many tumour types 
including haematological malignancies and cancers of the breast, lung, ovary and bladder.131 Its 
use has been evaluated mainly in breast cancer patients where it is preferred over doxorubicin 
due to its more favourable toxicity profile. These ‘safer drug’ benefits of epirubicin compared to 
doxorubicin include reduced neutropenia and nausea, making this drug more tolerable for 
patients which may allow for greater dose escalation and combination with other potentially 
cardiotoxic therapies.237 However, although disease free and overall survival was improved for 
patients who received 5-flurouracil/epirubicin/cyclophosphamide (FEC) compared to those who 
received methotrexate instead of epirubicin, the rate of heart failure increased from 0.3% to 
1.4% in epirubicin treated patients.238 A retrospective analysis conducted by Ryberg et al. in 1998 
evaluated the influence of cumulative dose, dose intensity and schedule on the development of 
heart failure in 469 breast cancer patients treated with epirubicin.239  The study found, similar 
to doxorubicin, that the risk of developing heart failure is linked to cumulative lifetime exposure, 
with 7.2% patients developing heart failure after a median follow-up of 75 months, with toxicity 
risks increasing alongside higher cumulative doses. The risk was 4% at 900mg/m2, increasing to 
15% at 1000mg/m2,239 therefore the maximum recommended cumulative dose for epirubicin is 
clinically recognised at 900mg/m2,131 which could be considered analogous to receiving 450 - 
550mg/m2 doxorubicin.237 Many randomised controlled trials (RCTs) have been conducted 
comparing epirubicin and doxorubicin at equimolar doses, where epirubicin was found to 
possess similar oncological efficacy to doxorubicin but was less cardiotoxic.237  
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4.1.3 Cardiotoxicity of the anthracycline daunorubicin 
Daunorubicin was the first anthracycline to be identified (Figure 4.1), and was isolated from the 
Streptomyces peucetius bacteria in the 1950’s.109 Daunorubicin is used much less frequently than 
other anthracyclines, mainly in the treatment of acute leukaemia in children and leukaemia in 
adults, often as part of a combination regimen. Much like the other anthracycline agents, 
cardiotoxicity is a major limitation of daunorubicin use and clinically the maximum cumulative 
dose is 550mg/m2 in adults or 300mg/m2 in children.132 The first clinical trial to assess the 
cardiotoxic potential of daunorubicin was conducted by Halazun et al. in 1974 who compared 
schedules consisting of methotrexate, vincristine, mercaptopurine, prednisolone +/- 
daunorubicin in children with acute lymphocytic leukaemia. The study found that heart failure 
occurred suddenly in patients treated with daunorubicin, where the incidence was 9.9%. A wide 
range of doses were used throughout the study (360 – 1260mg/m2), all of which caused 
cardiotoxicity – however in general incidence increased with increasing doses of 
daunorubicin.240 Studies comparing daunorubicin to doxorubicin are not as plentiful as 
daunorubicin is used far less frequently than other anthracyclines, however analogous to 
epirubicin, daunorubicin is believed to be less cardiotoxic than doxorubicin. A study conducted 
using data pooled from various studies analysed 15,815 survivors of childhood cancer and found 
that heart failure was less prevalent in daunorubicin treated patients than those treated with 
doxorubicin.241 This has potential implications because if the two anthracyclines are equally 
efficient at killing cancer cells in a patient population, then daunorubicin may represent a better 
option in terms of preservation of cardiac function in paediatric cancer cases.  
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4.1.4 Risk factors for anthracycline-induced cardiotoxicity 
Whilst the notion of total lifetime cumulative dose exists to protect patients from developing 
anthracycline induced cardiotoxicity, it has become evident that some patients develop 
cardiotoxicity following exposure to lower cumulative doses, whereas others are able to 
withstand much higher amounts of drug without developing cardiac abnormalities. Several risk 
factors have been reported to increase susceptibility to developing AIC including extremes of 
age, concurrent treatment with the molecular-targeted agent trastuzumab or radiation therapy 
and pre-existing cardiac disease.16,105,144,145 Risk factors for AIC are discussed in section 1.7.1.3.  
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Figure 4.1 Structures of the anthracyclines doxorubicin, epirubicin and  
  daunorubicin 
143 
 
4.1.5 Aims and objectives 
The occurrence of cardiac liabilities following anthracycline treatment is well established 
clinically, particularly doxorubicin induced cardiotoxicity. The aim of this phase of the study is to 
use the in vitro models and methods that were qualified in chapter 3 to determine if the 
structural and functional acute cardiotoxicity induced by anthracyclines in the clinic can be 
detected using these in vitro cardiomyocyte models.  
Specifically: 
i) Determination of the sensitivity of AC10 cardiomyocytes (AC10-CMs) to doxorubicin, with 
clinically relevant doses of the drug used to assess structural changes to cells using the 
xCELLigence RTCA system. Parallel studies will be conducted using human induced pluripotent 
stem cell derived cardiomyocytes (hiPSC-CMs) where functionality and morphology following 
exposure to doxorubicin will be monitored using the xCELLigence cardio system.  
ii) Studies will be conducted in AC10-CMs to investigate the differential effects of an 
anthracycline panel comprised of doxorubicin, daunorubicin and epirubicin. Investigations will 
be conducted in both the exponential and plateau phases of growth for 24 hours and 96 hours 
exposure times to assess the sensitivity of the cells to the anthracycline panel and elucidate the 
effects of proliferative capacity and exposure time on cell sensitivity to the drugs.  
iii) Structural changes following addition of clinically relevant doses of the anthracycline panel 
will be assessed using the xCELLigence RTCA on AC10-CMs in both the exponential and plateau 
phases of growth. Parallel studies will be conducted using hiPSC-CMs where functionality and 
morphology following exposure to the anthracycline panel will be monitored using the 
xCELLigence cardio system. 
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4.2 Materials and methods 
4.2.1 Evaluation of viability of AC10-CMs following anthracycline 
 treatment determined using the MTT assay    
AC10-CMs were seeded into 96-well plates as previously described in section 2.2 for exponential 
and plateau phase studies. After 24 hours the anthracyclines doxorubicin, daunorubicin and 
epirubicin were added to cells in separate plates, with a 1:5 serial dilution performed across the 
wells, resulting in final concentrations ranging from 5µM to 128pM, 2µM to 25nM or 1µM to 
2nM, respectively. Following 24 hours exposure, drugs were removed and media replaced with 
fresh medium. For 96 hour exposure studies, cells were exposed to the drugs for the duration 
of the experiment. After 96 hours post drug addition, cell viability was assessed using the MTT 
assay (see section 2.2). All studies were repeated a minimum of three times and IC50 values 
determined by implementing curve fitting by non-linear regression on GraphPad Prism (Version 
7.04, GraphPad Software, Inc.). 
 
4.2.2 Investigations of morphological changes to AC10-CMs induced by 
 anthracyclines using the xCELLigence real-time cell analyser 
Experiments were set up as described in section 2.3. For continuous exposure studies in 
exponential growth phase, doxorubicin was added at 24 hours and cells were exposed to 50nM, 
100nM, 250nM and 500nM doxorubicin for 96 hours. For studies analysing 24 hours exposure 
in exponential growth phase, anthracyclines (doxorubicin, daunorubicin and epirubicin; 50nM 
and 500nM) were added at 24 hours and replaced with fresh medium following 24 hours 
exposure. For studies in plateau growth phase, anthracyclines (doxorubicin, daunorubicin and 
epirubicin; 50nM and 500nM) were added once the cell index demonstrated confluence 
(approximately 72 hours) and replaced with fresh medium following 24 hours exposure. All 
experiments were performed in triplicate and statistical analysis on normalised cell index values 
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was conducted using a one way analysis of variance (ANOVA) test, and a post-hoc Dunnett’s test 
when required using GraphPad Prism (Version 7.04, GraphPad Software, Inc.). 
 
4.2.2.1  Evaluation of viability of AC10-CMs following anthracycline treatment 
  at specific time points determined using the MTT assay 
In parallel, cellular viability was determined to complement data obtained using the xCELLigence 
real-time cell analyser (RTCA). AC10-CMs were seeded into 96-well plates as previously 
described in section 2.2 for exponential and plateau phase studies. For continuous exposure in 
exponential growth phase, doxorubicin (50nM, 100nM, 250nM and 500nM) was added 24 hours 
after cell seeding and experiments terminated following 48 hours exposure. For studies 
analysing 24 hours exposure in both exponential and plateau growth phase, anthracyclines 
(doxorubicin, daunorubicin and epirubicin; 50nM and 500nM) were added 24 hours after cell 
seeding and experiments terminated after 24 hours exposure. Absorbance readings were 
obtained and analysed as described in section 2.2. All experiments were performed in triplicate. 
 
4.2.3 Imaging of AC10-CMs treated with doxorubicin 
AC10-CMs were plated at a density of 5x104 cells/well in 6 well plates. The following day 50nM 
doxorubicin was added to 2 wells and following 48 hours exposure the cells were fixed using 4% 
PFA (see section 3.2.1). All experiments included a time matched vehicle control. Cellular images 
were collected using a Leica DIC DMI6000B inverted microscope and analysed using the Leica 
application suite. All studies were repeated in triplicate. 
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4.2.4 Evaluation of anthracycline-induced cardiotoxicity in hiPSC-CMs 
 using the xCELLigence cardio system 
hiPSC-CMs were plated into a cardio E-plate at a density of 30,000cells/well, in wells pre-coated 
with fibronectin (Cell plating and maintenance described in section 2.4). Once stable beating 
was detected, half the media (90µl) was removed from each well and replaced with media 
containing twice the required drug concentration. Doxorubicin was added to a final 
concentration of 50nM, 100nM and 250nM, whereas epirubicin and daunorubicin were added 
at 50nM only. Changes to the cell index and contractility following drug addition were analysed 
at various points throughout 24 hours exposure to the drugs, as per standard xCELLigence assay. 
Following 24 hours exposure to anthracyclines the drugs were washed out using the four step 
medium change method (see section 2.4.2) and cells were re-challenged with the same 
anthracycline 96 hours later.   
Statistical analysis on normalised cell index, normalised beat rate and normalised beat 
amplitude were conducted using a one way analysis of variance (ANOVA) test, and a post-hoc 
Dunnett’s test when required. Statistical analysis was performed using GraphPad Prism (Version 
7.04, GraphPad Software, Inc.). 
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4.3 Results 
The purpose of this phase of the study was to apply the methodologies previously established 
to investigate the structural and functional cardiotoxicity related to anthracyclines. Initially the 
sensitivity of AC10 cardiomyocytes (AC10-CMs) to doxorubicin was evaluated, followed by 
investigations into morphological changes to these cells and changes to the morphology and 
contractility of hiPSC-derived cardiomyocytes (hiPSC-CMs) after exposure to doxorubicin. 
Comparative studies using the anthracyclines doxorubicin, daunorubicin and epirubicin were 
then convened using the same methodology to investigate if the observed responses were 
specific to doxorubicin or are a ubiquitous effect related to the anthracycline class.  
 
4.3.1 Cardiomyocyte cell types are differentially sensitive to doxorubicin 
Prior to investigating morphological effects, the effect of doxorubicin on viability of AC10-CMs 
in the exponential growth phase was ascertained using the MTT assay. Figure 4.2 shows that 
exposure to concentrations of doxorubicin ranging from 5µM to 12.8pM for 96 hours caused a 
dose-dependent decrease in the cellular viability of AC10-CMs, with an IC50 of 14.66 ± 3.31nM. 
The CMax of doxorubicin is 1.1µM (indicated on the graph), for future experiments investigating 
the morphological changes to cells, concentrations of 0.5, 0.25, 0.1 and 0.05 CMax were used, 
which equates to concentrations of 500nM, 250nM, 100nM and 50nM doxorubicin.  
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Figure 4.2 Effect of doxorubicin on viability of AC10 cardiomyocytes 
Dose response curve showing the effect of doxorubicin on cell viability following 96 hours 
exposure expressed as % cell survival relative to vehicle control for cells in exponential growth 
phase. The dashed line represents the C
Max
 of doxorubicin (1.1µM), data is representative of n=3 
± SE. 
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4.3.1.1  Doxorubicin induces morphological changes in AC10 cardiomyocytes  
The xCELLigence RTCA was used to assess the effect of doxorubicin on the morphology of  
AC10-CMs. As shown in figure 4.3A and 4.3B, when normalised to the point of doxorubicin 
addition, cell index initially increased higher than the level of control in cells exposed to 
doxorubicin. The cell index of cells treated with 250nM and 500nM doxorubicin then declined 
(figure 4.3B), whereas the cell index of cells treated with 50nM and 100nM doxorubicin 
continued to increase, with the highest cell index observed at 48 hours exposure to 50nM 
doxorubicin (figure 4.3A). This data is summarised in figure 4.3C.  To ascertain if the increases in 
cell index was due to increased cellular proliferation or a change to cellular morphology an MTT 
assay was carried out. With respect to AC10-CMs treated with 50nM and 100nM doxorubicin, if 
cell index were based purely on cell number then treatment with 50nM doxorubicin would 
increase cell number, and treatment with 100nM doxorubicin would not impact cell number 
significantly. However, AC10-CMs exposed to 50nM and 100nM doxorubicin in an identical 
manner showed dose-dependent decreases in cell viability (figure 4.3D), indicating that the 
increase in cell index observed using xCELLigence was due to a change in morphology (figure 
4.3E). 
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Figure 4.3 Doxorubicin induces morphological changes in AC10 cardiomyocytes (1) 
A/B. xCELLigence traces showing time (hours) vs normalised cell index of AC10-CMs in 
exponential growth phase exposed to doxorubicin with point of doxorubicin addition (arrow) 
and exposure time indicated, data representative of n=3, data points shown are average ± SD 
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Figure 4.2 Doxorubicin induces morphological changes in AC10 cardiomyocytes (2) 
C. Normalised cell index following 48 hours exposure to doxorubicin, data is n=3 ± SE. D. Relative 
cell number following 48 hours exposure to doxorubicin measured by MTT assay, data is n=3 ± 
SE and E. Images of untreated and doxorubicin treated AC10 cardiomyocytes showing a change 
in morphology. Images were taken at 10x magnification following 48 hours exposure to 
doxorubicin. ■ control, ■ 50nM doxorubicin, ■ 100nM doxorubicin, ■ 250nM doxorubicin,  
■ 500nM doxorubicin. 
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4.3.1.2  Doxorubicin induces morphological changes and functional  
  disturbances in hiPSC-derived cardiomyocytes 
Stably beating Cor.4U cells were exposed to doxorubicin for 24 hours and the effects on cell 
morphology and contractility were monitored in real-time. As shown in figure 4.4A, when 
normalised to the point of doxorubicin addition, cell index immediately increased higher than 
the level of control in cells exposed to 50nM, 100nM and 250nM doxorubicin, with the greatest 
difference in cell index approximately 6 hours after doxorubicin was initially added (figure 4.4B), 
indicating that doxorubicin induced a morphology change to the cells. 
Assessment of the effect of doxorubicin on contractility of hiPSC-CMs was carried out after 6 
and 24 hours exposure, as these time points represent the greatest degree of hypertrophy and 
maximum exposure to the drug respectively. The representative traces of contractility shown 
for control and doxorubicin treated cells in figure 4.5A show no visible changes in contractility 
following 6 hours exposure, however visible changes to both beat rate and amplitude are 
evident following 24 hours exposure. Detailed analysis of beat rate and amplitude is shown in 
figures 4.5B and 4.5C respectively.  
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Figure 4.4 Doxorubicin induces morphological changes in hiPSC-derived  
  cardiomyocytes 
A. xCELLigence trace showing time (hours) vs normalised cell index of hiPSC-CMs exposed to 
doxorubicin with point of doxorubicin addition (arrow) and exposure time indicated, data 
representative of n=2, data points shown are average ± SD. B. Normalised cell index following 6 
hours exposure to doxorubicin, data points show average of 4 wells ± SE. * p< 0.0001 (treatment 
groups compared to control). ■ control, ■ 50nM doxorubicin, ■ 100nM doxorubicin, ■ 250nM 
doxorubicin. 
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Figure 4.5 Doxorubicin induced changes to contractility of hiPSC-derived  
  cardiomyocytes are greater following 24 hours exposure 
A. Representative traces showing contractility of control cells and cells exposed to doxorubicin 
(DOX) for 6 and 24 hours. B. Normalised beating rate following 6 and 24 hours exposure to 
doxorubicin, data points show average of 3 wells ± SE. C. Normalised beat amplitude 
following 6 and 24 hours exposure to doxorubicin, data points show average of 3 wells ± SE. 
* p< 0.001, ** p< 0.0001 (treatment groups compared to control). ■ control, ■ 50nM 
doxorubicin, ■ 100nM doxorubicin, ■ 250nM doxorubicin. 
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4.3.2 Anthracyclines exhibit similar toxicity profiles in cardiomyocyte cell 
 models 
Prior to investigating morphological changes, the effect of doxorubicin, daunorubicin and 
epirubicin on viability of ACI0-CMs was investigated in the exponential and plateau phases of 
growth for both 96 hours continuous exposure and 24 hours exposure plus a 72 hours recovery 
period. Figure 4.6 shows the viability of AC10-CMs following 24 hours exposure (plus recovery 
period) to the anthracyclines in both the exponential and plateau phases of growth. In general, 
similar chemosensitivity profiles were obtained in both growth phases, with cells in the 
exponential growth phase being slightly more sensitive to all of the anthracyclines, as evidenced 
by the IC50 values (table 4.1). In contrast, following 96 hour exposure to anthracyclines, AC10-
CMs in the exponential phase of growth were more sensitive compared to cells exposed to 24 
hours anthracyclines only (Figure 4.7). The increased exposure time did not affect the sensitivity 
of cells in the plateau growth phase, with similar IC50 values obtained for 24 and 96 hours 
exposure times (table 4.1 and 4.2). For future experiments investigating the morphological 
changes to cells, exposure times of 24 hours were chosen as the current studies suggest that the 
majority of anthracycline induced damage occurs within this timeframe.  
As the data presented in table 4.1 includes a 72 hour recovery period following 24 hours 
anthracycline exposure the IC50 values presented are not true IC50 values. 
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Figure 4.6 Anthracyclines exhibit similar toxicity profiles in AC10 cardiomyocytes 
  following 24 hours exposure and a 72 hour recovery period 
Dose response curves showing cell viability expressed as % cell survival relative to vehicle control 
for cells in exponential and plateau growth phases exposed for 24 hours to A. Doxorubicin,  
B. Daunorubicin and C. Epirubicin. The dashed line represents the C
Max
 of the drug (daunorubicin 
= 430nM,242 doxorubicin = 1.1µM,243 epirubicin = 766nM244). Data is n=3 ± SE, IC50 values shown 
inset in table 4.1.  
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Figure 4.7 AC10 cardiomyocytes in the exponential growth phase are more  
  sensitive than those in plateau growth phase to anthracyclines  
  following 96 hours exposure 
Dose response curves showing cell viability expressed as % cell survival relative to vehicle control 
for cells in exponential and plateau growth phases exposed for 96 hours to A. Doxorubicin,  
B. Daunorubicin and C. Epirubicin. The dashed line represents the C
Max
 of the drug (daunorubicin 
= 430nM,242 doxorubicin = 1.1µM,243 epirubicin = 766nM244). Data is n=3 ± SE, IC50 values shown 
inset in table 4.2. 
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4.3.2.1  Anthracyclines induce morphological changes in AC10 cardiomyocytes 
Cells in exponential and plateau growth phase were exposed to 50nM (~0.05 CMax) and 500nM 
(~0.5 CMax) anthracyclines for 24 hours, and the effects on cell behaviour were monitored in real-
time. As shown in figure 4.8A/B following 24 hours anthracycline exposure, when normalised to 
the point of anthracycline addition, cells in exponential growth phase exposed to 50nM and 
500nM anthracyclines exhibited an immediate increase in cell index. The cell index continued to 
increase following 24 hours exposure to 50nM anthracyclines whereas with exposure to 500nM 
anthracyclines the cell index began to decrease at approximately 18 hours exposure. The 
normalised cell index following 24 hours exposure to anthracyclines is summarised in figure 
4.8C. To ascertain if the increases in cell index were due to increased cellular proliferation or a 
change to cellular morphology an MTT assay was carried out - AC10-CMs exposed to 50nM and 
500nM anthracyclines for 24 hours showed dose-dependent decreases in viability (figure 4.8D), 
indicating that the increases in cell index observed using xCELLigence was due to a change in 
morphology. A parallel study conducted in cells in the plateau phase of growth showed similar 
findings, however in this growth phase 500nM anthracyclines resulted in a higher cell index than 
50nM anthracyclines following 24 hours exposure. The cell index began to decrease after 24 
hours exposure to 500nM anthracyclines, whereas with 50nM anthracyclines the cell index 
remained steady after this time point (Figure 4.9A/B).  The results of this study are shown in 
figure 4.9A-D. 
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Figure 4.8 Anthracyclines induce morphological changes of AC10 cardiomyocytes in
  exponential growth phase 
A/B. xCELLigence traces showing time (hours) vs normalised cell index of AC10-CMs in exponential growth 
phase exposed to A. 50nM and B. 500nM anthracyclines with point of anthracycline addition (arrow), 
anthracycline removal (round-headed arrow) and exposure time indicated, data representative of n=3, data 
points shown are average ± SD. C. Normalised cell index following 24 hours anthracycline exposure, data is n=3 
± SE and D. Relative cell number following 24 hours anthracycline exposure measured by MTT assay, data is 
n=3 ± SE. * p< 0.05 (treatment groups compared to control). ■ control, ■ 50nM doxorubicin, ■ 50nM 
daunorubicin, ■ 50nM epirubicin. 
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Figure 4.9 Anthracyclines induce morphological changes of AC10 cardiomyocytes 
  in plateau growth phase 
A/B. xCELLigence traces showing time (hours) vs normalised cell index of AC10-CMs in plateau growth phase 
exposed to A. 50nM and B. 500nM anthracyclines with point of anthracycline addition (arrow), anthracycline 
removal (round-headed arrow) and exposure time indicated, data representative of n=3, data points shown are 
average ± SD. C. Normalised cell index following 24 hours anthracycline exposure, data is n=3 ± SE and D. 
Relative cell number following 24 hours anthracycline exposure measured by MTT assay, data is n=3 ± SE.  
* p< 0.05, * p< 0.01  (treatment groups compared to control).  ■ control, ■ 50nM doxorubicin, ■ 50nM 
daunorubicin, ■ 50nM epirubicin. 
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4.3.2.2  Anthracyclines induce similar morphological changes and functional 
  disturbances in hiPSC-derived cardiomyocytes 
Stably beating Cor.4U cells were exposed to 50nM anthracyclines for 24 hours and the effects 
on cell morphology and contractility were monitored in real-time. As shown in figure 4.10A, 
when normalised to the point of anthracycline addition, cell index immediately increased higher 
than the level of control in cells exposed to all of the anthracyclines, with the greatest difference 
in cell index approximately 6 hours after the anthracyclines were added (figure 4.10B), indicating 
that all of the anthracyclines induced a morphology change to the cells. 
Assessment of the effect of the anthracyclines on contractility of hiPSC-CMs was carried out 
after 6 and 24 hours exposure to anthracyclines, as these time points represent the greatest 
degree of hypertrophy and maximum exposure to the drug respectively. The representative 
traces of contractility shown for control and anthracycline treated cells in figure 4.11A show no 
visible changes in contractility following 6 hours exposure, however visible changes to both beat 
rate and amplitude are evident following 24 hours exposure. Detailed analysis of beat rate and 
amplitude is shown in figures 4.11B and 4.11C respectively. 
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Figure 4.10 Anthracyclines induce morphological changes in hiPSC-derived  
  cardiomyocytes 
A. xCELLigence trace showing time (hours) vs normalised cell index of hiPSC-CMs exposed to 
anthracyclines with point of addition (arrow) and exposure time indicated, data points shown 
are average ± SD. B. Normalised cell index following 6 hours exposure to anthracyclines, data 
points show average of 4 wells ± SE. * p< 0.0001 (treatment groups compared to control). 
 ■ control, ■ 50nM doxorubicin, ■ 50nM daunorubicin, ■ 50nM epirubicin. 
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Figure 4.11 Anthracycline induced changes to contractility of hiPSC-derived  
  cardiomyocytes are greater following 24 hours exposure 
A. Representative traces showing contractility of control cells and cells exposed to 
anthracyclines (DOX = doxorubicin, DAUN = daunorubicin and EPI = epirubicin) for 6 and 24 
hours. B. Normalised beating rate following 6 and 24 hours exposure to anthracyclines, data 
points show average of 3 wells ± SE and C. Normalised beat amplitude following 6 and 24 hours 
exposure to anthracyclines, data points show average of 3 wells ± SE. * p< 0.05 (treatment groups 
compared to control). ■ control, ■ 50nM doxorubicin, ■ 50nM daunorubicin, ■ 50nM epirubicin. 
0.8
0.9
1
1.1
N
o
rm
al
is
ed
 b
ea
ti
n
g 
ra
te
 f
o
llo
w
in
g 
6
 a
n
d
 2
4
 h
o
u
rs
 a
n
th
ra
cy
cl
in
e 
ex
p
o
su
re
 
0.6
0.7
0.8
0.9
N
o
rm
al
is
ed
 b
ea
t 
am
p
lit
u
d
ee
 f
o
llo
w
in
g 
6
 a
n
d
  2
4
 h
o
u
rs
 a
n
th
ra
cy
cl
in
e 
ex
p
o
su
re
 
4.11A 
6h 
exposure 
24h 
exposure 
6h 
exposure 
24h 
exposure 
4.11B BEATING RATE 4.11C BEAT AMPLITUDE 
* 
* 
164 
 
4.4 Discussion 
The occurrence of cardiac liabilities following anthracycline treatment is well established 
clinically, particularly doxorubicin induced cardiotoxicity. The challenge addressed in this phase 
of the study was to utilise the previously characterised in vitro models to determine if the 
structural and functional cardiotoxicity induced by anthracyclines in the clinic can be detected 
using in vitro cardiomyocyte models. 
 
4.4.1 In vitro assessment of doxorubicin-induced cardiotoxicity 
Doxorubicin is the most frequently used anthracycline and is notoriously associated with 
cardiotoxicity;16 hence is considered the archetypal anthracycline for comparison of other 
anthracyclines. Following 96 hours exposure, the IC50 value of doxorubicin in AC10 
cardiomyocytes (AC10-CMs) in the exponential growth phase was 14.66 ± 3.31nM. This is 
considerably less than the CMax of doxorubicin in humans (1.1µM), however is clinically relevant 
as following administration doxorubicin is quickly cleared from the blood, metabolised by the 
liver and distributed into tissues, therefore the concentration of active drug that contacts the 
myocardium will be lower than the CMax.15 In a study using five cancer cell lines originating from 
different tissues, the IC50 values of doxorubicin ranged from 20 – 420nM,245 and in the rat H9c2 
cardiomyoblast cell line, Chularojmontri et al. reported an IC50 value of 142nM following 48 
hours exposure of the cells to doxorubicin.246 
Exposure to four clinically relevant concentrations (50nM, 100nM, 250nM and 500nM) of 
doxorubicin initiated a hypertrophic response in AC10-CMs, which was confirmed using cellular 
viability studies and imaging. At 48 hours exposure a dose-dependent response was observed in 
cell index, with 50nM doxorubicin showing the highest cell index and 500nM showing the lowest 
cell index, this paired with the viability studies conducted at this time point illustrate that the 
cell index values depict a balance between cell death and hypertrophy. Studies in hiPSC-CMs 
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using the xCELLigence cardio system showed a similar response to doxorubicin, with immediate 
increases in cell index occurring following addition of 50nM, 100nM and 250nM doxorubicin, 
indicating that doxorubicin had also induced hypertrophy in this cell type. 
Many groups have reported cardiomyocyte hypertrophy upon doxorubicin addition in vivo and 
in vitro. Myocardial biopsies performed in human hearts after doxorubicin treatment revealed 
an increase in both the size of the cells and the sarcoplasmic reticulum and T-tubules following 
24 hours exposure.247 Studies using the rat H9c2 myoblast cell line also reported doxorubicin 
induced hypertrophy248 and morphological alterations, including alterations to fibrous structural 
proteins, mitochondrial damage and membrane blebbing with associated with changes to 
cellular shape.185 The results in this study progress these preliminary findings and have now 
confirmed this morphological and phenotypic change, in a clinically applicable manner and using 
novel methodologies permissive of real-time and physiologically relevant analyses.  
Despite the activity of hiPSC-CMs being investigated following doxorubicin treatment previously, 
the main focus was primarily on identifying changes to beat parameters using higher doses of 
doxorubicin, thus lacking clinical significance. For example, a recent study by Koci et al. used a 
range of doxorubicin concentrations from 0.3µM - 100µM and monitored contractility over 72 
hours. Changes in contractility were seen with all concentrations of doxorubicin used by 72 
hours, however cell death occurred quickly with all concentrations so hypertrophy would be 
difficult to ascertain.249 The use of high doses of doxorubicin caused a rapid loss of 
cardiomyocytes in the study by Koci et al., demonstrated by sharp declines in cell index. The 
majority of the concentrations of doxorubicin used in the aforementioned study are much higher 
than the level exposed to the body and lack relevance as the acute cardiotoxicity response to 
doxorubicin is associated with inflammation rather than a loss of tissue mass. In contrast, the 
current study used much lower clinically relevant concentrations and found initiation of 
morphological changes and altered contractility with all doses of doxorubicin applied within 24 
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hours. At the point when cells showed the greatest degree of hypertrophy (6 hours exposure) 
following exposure to doxorubicin at 50nM and 100nM no changes in contractility were 
observed, however in cells treated with 250nM doxorubicin (close to the lowest dose used by 
Koci et al.) a reduction in beat frequency was observed. This illustrates that it is possible to 
detect changes in the contractility of hiPSC-CMs with low clinically relevant doses of doxorubicin 
following a much shorter exposure time of 6 hours.  
In the same cells following 24 hours exposure to doxorubicin, hiPSC-CMs treated with all doses 
used in this study exhibited alterations to their contractility. Treatment with 50nM doxorubicin 
caused decreases in beat frequency and amplitude which were further decreased in cells 
challenged with 100nM doxorubicin. Interestingly, treatment with 250nM doxorubicin caused a 
large decrease in beat amplitude paired with a large increase in beat frequency relative to 
control. As the highest dose used in the study, 250nM doxorubicin was toxic to cells as shown 
by the decrease in cell index and hence decrease in beat amplitude following 24 hours exposure. 
The beat frequency of the cells would also be anticipated to decrease (as was the case with the 
lower doses used), however it increased. This may be due to the toxicity of the drug causing cell 
death resulting in gaps in the syncytium. A fully formed syncytium is essential for efficient 
monitoring of contractility using xCELLigence technology, and any disturbances could cause the 
system to detect ‘flutters’ of the disrupted syncytium rather than organised cellular contraction.   
Nevertheless, the results of the current work have shown that it is possible to detect both 
hypertrophy and contractile disturbances in human derived cell types using in vitro impedance 
based systems, with cellular changes occurring in response to clinically relevant concentrations 
of doxorubicin in as little as 6 hours. These changes potentially relate to the acute cardiotoxicity 
of doxorubicin, which in humans manifests as transient arrhythmias and inflammation141,142 
which may be involved in increasing susceptibility to the more severe chronic form of 
doxorubicin-induced cardiotoxicity.    
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4.4.2 Comparative studies using the anthracyclines doxorubicin, 
 daunorubicin and epirubicin 
The studies indicative of induction of doxorubicin-induced hypertrophy in AC10-CMs and hiPSC-
CMs, led to comparative studies using the anthracyclines doxorubicin, daunorubicin and 
epirubicin to investigate if this response is specific to doxorubicin or is a ubiquitous effect related 
to the anthracycline class. 
Viability studies conducted using AC10-CMs in the exponential and plateau phases of growth for 
both 24 and 96 hours continuous exposure showed comparable levels of toxicity. In general, 
similar chemosensitivity profiles were obtained in both growth phases, with cells in the 
exponential growth phase being slightly more sensitive to all of the anthracyclines, and 
increased sensitivity following 96 hours exposure compared to 24 hours exposure only - as 
evidenced by the IC50 values. Owing to the mechanism of action of anthracyclines in cancer cells, 
which cause disruption of DNA synthesis and replication in proliferating cells, increased toxicity 
would be expected in cells in the exponential growth phase as the anthracyclines would be able 
to interfere more readily with DNA replication and topoisomerase II than in cells in the plateau 
growth phase, as these cells would be in a more quiescent state and therefore have reduced 
levels of proliferation. Increased duration of exposure would also be expected to increase 
toxicity as the drugs have more time to induce cellular damage, as was the case with the current 
study. 
As the effects on viability were detectable within 24 hours exposure to anthracyclines, 
subsequent studies investigating the morphological changes to cells were focused on this 
timeframe, which also reflects the plasma half-life of the anthracyclines. Taking doxorubicin as 
an example, the drug undergoes rapid metabolism by the liver and undergoes triphasic 
elimination with a terminal half-life of approximately 30 hours.15 This means that its takes 
approximately 30 hours for 50% of doxorubicin to be eliminated from the body, and a total of 6 
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half-lives (approximately one week) for one intravenous administration of doxorubicin to be 
completely eliminated from the body. In this study AC10-CMs were exposed to high (500nM) 
and low (50nM) clinically relevant concentrations of anthracyclines for 24 hours, as this 
represents the different stages following clinical administration of anthracyclines, specifically 
soon after administration and a few days into the elimination process.  
Exposure of AC10-CMs to all of the anthracyclines used showed hypertrophy in both the 
exponential and plateau growth phase which was confirmed using cellular viability studies. 
These results demonstrate the interplay that exists between cell death and hypertrophy in 
response to anthracyclines in the exponential growth phase and the influence of proliferative 
capacity in the plateau growth phase. In the plateau phase of growth addition of 500nM 
anthracyclines resulted in a higher cell index than 50nM anthracyclines following 24 hours 
exposure, whereas in exponential growth phase the cells exposed to 500nM anthracyclines had 
already began to die by this time point, thus demonstrating that cells in the plateau growth 
phase are less sensitive to anthracycline toxicity in terms of occurrence of cellular death due to 
their quiescent state, but perhaps are more affected by the damaging effects of the drugs in 
terms of changes to cellular structure. This illustrates that this growth phase may more 
accurately model the cardiomyocytes of the human heart.  
A similar response was observed in hiPSC-CMs using the xCELLigence cardio system, with 
immediate and sustained increases in cell index occurring following addition of 50nM of all 
anthracyclines used, indicating that the anthracyclines also induced hypertrophy in this cell type. 
As previously discussed, cardiomyocyte hypertrophy in response to doxorubicin has been 
described using different in vitro cardiomyocyte models, however studies using other 
anthracyclines are scarcer. Until now, the only studies into this area have used animal derived 
cell lines such as the H9c2 rat cardiomyoblast cell line, where its use identified morphological 
changes following treatment with daunorubicin.250 Although effects on morphology were not 
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assessed, an interesting study by Toldo et al. compared the effects of doxorubicin and epirubicin 
in the HL-1 mouse atrial cell line with respect to reactive oxygen species (ROS) generation, DNA 
damage and apoptosis. The study found that both anthracyclines exhibited similar toxicity 
profiles, however reduced toxicity was observed with a liposomal formulation of doxorubicin.251 
The results in this study build on these findings and have now confirmed that morphological 
changes occur in both doxorubicin and epirubicin treated human derived cardiomyocyte cells at 
comparable levels using novel methodologies permissive of real-time and physiologically 
relevant analyses. 
As previously discussed, the majority of studies undertaken to date using hiPSC-CMs have 
utilised higher doses of anthracyclines and focussed on changes to beat parameters. For 
example, Doherty et al. reported that 5µM daunorubicin caused 20% decreases to beat rate and 
amplitude of hiPSC-CMs which were preceded by increases to ROS, suggesting that the 
generation of ROS contributes to the early cardiotoxicity of daunorubicin.208 Studies in isolated 
rat cardiomyocytes conducted by Chan et al. compared contractility following 20 minutes 
exposure to 10µM doxorubicin and epirubicin and found that all indices of contractility were 
decreased in equal amounts, and that the antioxidant enzymes superoxide dismutase and 
catalase afforded protection against these changes to contractility.252 The exposure time of 20 
minutes used in the aforementioned study does not accurately reflect clinical exposure times, 
therefore the current study has used an increased exposure time of 24 hours and much lower 
doses to provide a more clinically relevant analysis of the effects of anthracyclines on 
contractility.  
Upon addition of 50nM of the anthracyclines to hiPSC-CMs minimal changes to contractility 
were seen following 6 hours exposure (when the cells showed the greatest degree of 
hypertrophy). However following 24 hours exposure, hiPSC-CMs treated with all anthracyclines 
used in this study exhibited alterations to their contractility. Treatment with 50nM doxorubicin 
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caused decreases in beat frequency and amplitude which were decreased slightly more in cells 
challenged with epirubicin and daunorubicin.  
 
4.4.3 Translatability of in vitro comparative anthracycline studies 
The studies by Toldo et al. and Chan et al. both compared doxorubicin and epirubicin using in 
vitro cardiomyocyte models and reported no differences between the two anthracyclines with 
their ability to structurally damage cells and induce contractility changes.251,252 The work 
presented herein has confirmed anthracycline induced hypertrophy in AC10-CMs and hiPSC-
CMs, both human relevant models, at clinically relevant concentrations and in an in vitro model 
system. However, there was a lack of substantial differences between the degree of hypertrophy 
observed with any of the anthracyclines, as was also the case with the IC50 values that were 
determined using chemosensitivity studies.  
These results are not in line with the current clinical view that epirubicin is less cardiotoxic then 
doxorubicin.237 Randomised controlled clinical trials conducted in breast cancer patients 
comparing epirubicin and doxorubicin at equimolar doses found epirubicin possesses similar 
oncological efficacy to doxorubicin but is significantly less cardiotoxic as fewer patients 
developed heart failure on the epirubicin arm of the trials compared to the doxorubicin treated 
patients.  Therefore epirubicin is preferred over doxorubicin as it is currently perceived to 
possess a more favourable toxicity profile including reduced risk of cardiotoxicity and 
neutropenia and a lower incidence of nausea and vomiting. The effects of anthracyclines on 
cardiac function in humans is dependent on many factors in addition to induction of damage to 
cardiomyocytes, which may explain why little differences have been observed between 
anthracyclines using in vitro cardiomyocyte models. For example, epirubicin has a different 
pharmacokinetic profile to doxorubicin characterised by altered drug metabolism, a higher 
clearance rate and a shorter half-life, all of which may contribute to the reduced toxicity of the 
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drug clinically.131,237 An in vitro study by Ramanathan et al. investigated the interaction of 
doxorubicin and epirubicin with blood components and assessed their binding to erythrocytes, 
haemoglobin and plasma proteins and found that epirubicin was more able to bind to 
haemoglobin and therefore sits inside erythrocytes, whereas doxorubicin was less able to bind 
to haemoglobin and remained on the surface of the erythrocytes. These differences may 
influence the disposition of the drugs in the bloodstream and affect their cardiotoxic profiles in 
patients.253 
Finally, whilst cardiomyocytes are the classic target for anthracycline-induced cardiotoxicity, 
damage can also occur to the support cells of the myocardium, which is not assessed using in 
vitro cardiomyocyte models such as those utilised in this study. Fibroblasts, constitute 15% of 
the myocardium, and are crucial for cardiac remodelling and maintenance of the ECM.53 Kania 
et al. exposed human fibroblast cell lines to the anthracyclines aclarubicin, daunorubicin and 
idarubicin and reported morphological changes, increases to intracellular calcium levels and 
activation of caspase-3 which is related to apoptosis.254 Studies in cardiomyocytes, endothelial 
cells and fibroblasts isolated from neonatal rat hearts found that fibroblasts and endothelial cells 
were more sensitive to doxorubicin-induced cardiotoxicity than cardiomyocytes, thus 
illustrating that adverse effects following anthracycline exposure also in occur in support cells 
such as fibroblasts and endothelial cells.255 Due to the crucial role of cardiac endothelial cells, 
any drug-induced damage would adversely affect cardiac function as the supply of oxygen, 
nutrients and cellular signalling factors to cardiomyocytes would be compromised. Likewise, 
fibroblasts have the ability to influence the phenotype of cardiomyocytes, receive and respond 
to distress signals from neighbouring cardiomyocytes following tissue damage, and therefore 
potentially play a role in the development of anthracycline induced cardiotoxicity. 
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4.4.4 Conclusion  
In summary, the Induction of hypertrophy that was observed in AC10-CMs and hiPSC-CMs 
following exposure to anthracyclines demonstrates the detection of structural cardiotoxicity and 
provides additional data to support the use of these cells on an impedance-based platform in 
screening assays for detection of structural toxicity. The contractility assessments of hiPSC-CMs 
suggest that the hypertrophy induced by low-dose (50nM) anthracyclines does not affect the 
contractility of the cells following 6 hours exposure, however changes became evident following 
24 hours exposure, which were more pronounced with higher doses of doxorubicin. These 
changes potentially relate to the acute cardiotoxicity of doxorubicin, which in humans manifests 
as transient arrhythmias and inflammation which may be involved in increasing susceptibility to 
the more severe chronic form of doxorubicin-induced cardiotoxicity. The lack of 
distinguishability between the severity of toxicity induced by the anthracyclines does not 
correspond with the toxicity profile displayed in the clinic, however there are many factors that 
influence the development of anthracycline-induced cardiotoxicity in patients that are not 
accounted for using in vitro cardiomyocyte models.  
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Chapter 5: In Vitro Evaluation of Angiotensin 
Blockade as a Strategy to Minimise 
Anthracycline-Induced Cardiotoxicity  
 
5.1 Introduction 
Anthracycline-induced cardiotoxicity (AIC) has been classified as the most noted chemotherapy-
induced cardiotoxicity to date, and many strategies have been explored for reducing the 
associated cardiotoxicity such as modification of dosing schedules, the use of liposomal 
formulations and concurrent administration of cardioprotective therapies.16,28 The formation of 
damaging free radicals and oxidative stress are implicated as central mechanisms underlying the 
cardiotoxic nature of doxorubicin.91,118 In this context, many experimental drug treatments have 
been evaluated to ameliorate the toxicity focussed on the use of anti-oxidants and iron chelators 
such as dexrazoxane.154,155 Unfortunately due to controversial clinical trial data, the use of 
dexrazoxane has been contraindicated in paediatric patients,156 and barriers to the use of anti-
oxidants include difficulty achieving constant plasma concentrations coupled with poor uptake 
by the myocardium in humans.256 
 
5.1.1 Clinical studies investigating cardiotherapeutic drugs to mitigate 
 anthracycline-induced cardiotoxicity 
The use of clinically-utilised therapeutics focused on the cardiac system have also been 
evaluated in terms of AIC, such as statins and β-blockers.152 
Statins, which are used clinically to inhibit cholesterol synthesis and treat ischaemic heart 
disease possess both anti-inflammatory and anti-oxidative properties. Thought to interfere with 
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the generation of ROS and inhibition of Topoisomerase IIβ (TopIIβ) associated with AIC, a small 
randomised controlled trial (RCT) found prophylactic atorvastatin protected patients from 
declines in LVEF,157 and a larger RCT called ‘Preventing anthracycline cardiovascular toxicity with 
statins (PREVENT)’ is currently underway.158 
With regards to β-blockers, their negative chronotropic and inotropic properties induce declines 
in the myocardial consumption of oxygen and nutrients, thus reducing the workload of the heart 
in patients with cardiovascular diseases. Carvedilol is unique amongst β-blockers as it possess 
additional vasodilatory and anti-oxidant properties.74,159 With respect to reduction of AIC, the 
anti-oxidant properties of carvedilol may be beneficial. Studies comparing the efficacy of 
carvedilol and atenolol at protecting cultured rat cardiomyocytes from AIC in vitro showed that 
carvedilol was able to decrease the production of damaging free radicals and prevent apoptosis 
of cardiomyocytes, whereas atenolol was not.160 This suggests that carvedilol may possess the 
ability to protect the heart from AIC and as such it has been employed in a number of small 
studies where its prophylactic effects on AIC have been investigated with encouraging results.152 
The first such study was conducted by Kalay et al. who concluded that carvedilol may protect 
both systolic and diastolic functions of the left ventricle in patients undergoing anthracycline 
therapy.161 
 
5.1.1.1  Clinical studies investigating angiotensin blockade for cardioprotection 
  against anthracycline-induced cardiotoxicity 
There is a growing body of evidence that administration of angiotensin converting enzyme 
inhibitors (ACEi) or angiotensin receptor blockers (ARB) can protect the heart from the damaging 
effects of anthracyclines.28,152 ACEi and ARB are routinely used in the management of congestive 
heart failure (CHF) and hypertension.162,163 Both prevent the physiological activity of angiotensin 
II; ACEi prevent the formation of angiotensin II and therefore decrease circulating levels, 
whereas ARB stop angiotensin II binding to the angiotensin type I receptor (ATR1). Angiotensin 
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II is the principal effector of the renin–angiotensin system (RAS), which plays a crucial role in the 
pathogenesis of several cardiovascular events including vasoconstriction, cardiac hypertrophy 
and cardiac remodelling.75,76 The mechanism and clinical use of these agents is addressed in 
section 1.4.5.2.  
As previously described, AIC manifests primarily as heart failure and cardiac remodelling (section 
1.7.1.2.1), factors which also show a physiological relationship to activity of the angiotensin 
signalling pathway. Consequently, it was hypothesised that perturbation of this pathway may 
be a viable strategy for treatment of AIC. Several studies have now been conducted to evaluate 
this potential therapeutic intervention. Prophylactic use of the ACEi enalapril has been shown in 
several studies to produce positive results against mitigation of AIC, mainly in the area of 
preventing declines in left ventricular function.150,164,165 Similarly, studies investigating the use of 
ARB such as valsartan, telmisartan and candesartan have also yielded similar positive results, 
including alleviations to decline of left ventricular function, prevention of acute transient rhythm 
abnormalities and decreases in the levels of damaging ROS.166–168  The outcomes of these studies 
are summarised in section 1.7.2.1 (table 1.2).   
Although findings of these studies was primarily positive overall, they are not without limitations 
which include short follow up time of patients (ranging from 1 week – 1 year) and the low 
number of patients enrolled. Larger phase II and phase III clinical studies are currently underway 
that aim to assess the cardioprotective potential of ACEi/β-blocker combinations (SAFE clinical 
trial)170 and ACEi alone (PROACT Trial – Newcastle University)171 in breast cancer patients 
receiving anthracycline treatment. These clinical trials will hopefully support the findings of the 
smaller studies and provide additional information regarding the optimal cardioprotective 
strategies and monitoring schedules for detection of sub-clinical damage.  
In addition to prophylactic or preventative use of ACEi and ARB against AIC, the potential for 
reversal of established AIC using ACEi has also been investigated in long-term survivors of 
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childhood cancer, where only transient benefits were reported.172 This exemplifies the 
permanent nature of damage caused by anthracyclines and supports the current view that 
concomitant angiotensin blockade alongside anthracycline treatment is the most effective way 
to use these agents as cardioprotectors.   
 
5.1.2 Pre-clinical in vivo studies investigating angiotensin blockade for 
 cardioprotection 
Further to the encouraging results clinically with ACEi and ARB against AIC, a considerable 
number of studies have also been investigated with these agents against AIC in vivo have also 
been undertaken, to ascertain optimal therapeutic strategies and provide mechanistic 
information. In mice, the ARB candesartan showed a cardioprotective effect against 
daunorubicin, reversing deteriorations to left ventricular function and myocardial pathological 
changes.257 A study investigating telmisartan against doxorubicin-induced cardiotoxicity in rats 
showed histological disruption of cardiac tissues in the doxorubicin treated group which was 
reduced with telmisartan treatment.258 Furthermore, telmisartan treatment decreased lipid 
peroxidation in cardiac tissue and elicited a significant decrease in the activities of the 
antioxidant enzyme catalase in comparison with the doxorubicin treated group.258 However, 
some of these effects are likely to be a consequence of telmisartan also being a partial 
peroxisome proliferator activated receptor-γ (PPARγ) agonist, as such telmisartan possesses 
additional anti-inflammatory and antioxidant properties.259 More recently, a study involving the 
novel ARB fimasartan also reported similar positive cardioprotection against AIC, and 
additionally made a distinction between high and low dose fimasartan which improved survival 
rates accordingly with 100% and 75% survival rates respectively, compared to 50% survival in 
rats treated with doxorubicin only.260 Echocardiography showed preserved left ventricular 
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function in the high fimasartan group and that cardiac remodelling was attenuated in both the 
low and high fimasartan groups compared to the doxorubicin only treated rats.260 
Similar to studies with ARB, treatment using ACEi have also generated positive results in pre-
clinical studies. For example, treatment with the ACEi captopril and enalapril before doxorubicin 
administration was found to decrease the level of lipid peroxidation compared to the 
doxorubicin only treatment group, and also prevented decreases in superoxide dismutase 2 
(SOD2) that occurred in the doxorubicin only treated rats.261 A more recent study evaluated the 
mitochondrial function of rats treated with enalapril and doxorubicin, in addition to changes in 
cardiac contractility and generation of ROS. In this study, rats pre-treated with enalapril were 
protected from losses in left ventricular contractility and increases in ROS formation compared 
to rats treated with doxorubicin only, and were also protected from decreases in mitochondrial 
function associated with doxorubicin treatment.262 
A comparison between the ability of the ACEi captopril and the ARB telmisartan to improve 
cardiac outcomes in doxorubicin treated rats showed co-administration of telmisartan and 
captopril equally ameliorated the cardiotoxic effects of doxorubicin on all parameters measured, 
suggesting that both drug types provide equivalent protection against doxorubicin induced 
cardiotoxicity, thus implying that angiotensin II signalling plays a role in the development of 
doxorubicin induced cardiotoxicity.263 
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5.1.3 Aims and objectives  
Despite mitigation of anthracycline-induced cardiotoxicity being demonstrated by ACEi and ARB 
both pre-clinically in vivo and clinically, the direct effects upon, and involvement of the cardiac 
system, as well as the molecular mechanism involved have yet to be resolved. The aim of this 
stage of the project is to address these issues and determine if the previously discussed 
structural and functional cardiotoxicity induced by anthracyclines can be mitigated by the 
addition of ACEi and ARB using in vitro cardiomyocyte models.  
Specifically:  
 
i) The mitigation of AIC with therapeutics that limit angiotensin signalling suggests a role for the 
angiotensin signalling pathway in mediating this toxicity; therefore initially the sensitivity of 
AC10 cardiomyocytes (AC10-CMs) to doxorubicin alone and in the presence of angiotensin II will 
be evaluated, followed by investigations into morphological changes to these cells and changes 
to the morphology and contractility of hiPSC-derived cardiomyocytes (hiPSC-CMs) following 
simultaneous treatment with doxorubicin and angiotensin II.   
ii) This will then be expanded to investigate the differential effects on viability of AC10-CMs 
following treatment with doxorubicin alone and in combination with angiotensin targeting 
drugs. Morphological changes to AC10-CMs and changes to the morphology and contractility of 
hiPSC-CMs following simultaneous treatment with doxorubicin and ACEi/ARB will then be 
assessed to determine the impact of ACEi and ARB on mitigating the structural and functional 
changes associated with doxorubicin treatment. 
iii) Where applicable, the differential effects on viability of H460 lung cancer cells will be 
determined following treatment with doxorubicin alone and in combination with ARB and/or 
ACEi. 
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5.2 Materials and methods 
5.2.1 Determination of viability of proliferating AC10-CMs in response to 
 different drug treatment protocols using the MTT assay 
 The MTT assay (previously detailed in section 2.2) was used to determine the cytotoxic 
sensitivity of AC10-CMs to a combination of doxorubicin and angiotensin II, and also to 
investigate the effects on viability of the test drugs (enalapril, enalaprilat, telmisartan and 
losartan) alone and in combination with doxorubicin in AC10-CMs. Similar experiments involving 
doxorubicin and telmisartan/losartan were also conducted in H460 lung cancer cells. 
  
5.2.1.1  Evaluation of viability of AC10-CMs following treatment with  
  doxorubicin and angiotensin II  
Briefly, AC10-CMs were seeded into 96-well plates as previously described in section 2.2. Cells 
were dosed over three days as follows: Day 1 - Angiotensin II (150pM – 500pM) was added to 
cells; day 2 – Angiotensin II was added in addition to 50nM doxorubicin, alongside a doxorubicin 
only treatment group (absence of angiotensin II); day 3 – doxorubicin was removed and 
angiotensin II was added as per day 1 (doxorubicin only treated cells received medium only). 
Experiments were terminated following 96 hours from the point of first angiotensin II addition 
and the MTT assay conducted as described in section 2.2. All experiments were performed in 
triplicate.  
 
5.2.1.2  Investigations into viability of AC10-CMs following treatment with 
  drugs targeting the angiotensin pathway 
AC10-CMs were seeded into 96-well plates as previously described in section 2.2. The following 
day cells were exposed to the ACEi enalapril and enalaprilat or the ARBs telmisartan and 
losartan, with a 1:2 serial dilution in drug concentration performed across the plate, resulting in 
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final concentrations ranging from 10µM to 78nM. Drug exposures were repeated on a daily basis 
and cell viability ascertained at 96 hours by MTT assay, as described in section 2.2. All 
experiments were performed in triplicate.  
 
5.2.1.3  Investigations into viability of AC10-CMs following combination  
  treatment with angiotensin targeting drugs and doxorubicin 
AC10-CMs were seeded into 96-well plates as previously described in section 2.2. The following 
day cells were exposed to enalapril (1µM/10µM), enalaprilat (1µM/10µM), telmisartan 
(1µM/5µM) and losartan (1µM/5µM) - One plate per drug, half plate for each concentration, 
one plate containing medium only. Following 24 hours exposure, a 1:5 serial dilution of 
doxorubicin was applied to all plates resulting in final concentrations of 5µM – 0.32nM. The cells 
un-exposed to test drugs were exposed to doxorubicin only, whereas the test drugs were added 
to the previously pre-treated cells. Following 24 hours exposure to doxorubicin, drug dilutions 
were removed and replaced with either medium (doxorubicin only treated cells), or appropriate 
test drugs. Cell viability was determined at 96 hours exposure from the first test drug addition 
as described in section 2.2. All experiments were performed in triplicate and IC50 values were 
determined by implementing curve fitting by non-linear regression on GraphPad Prism (Version 
7.04, GraphPad Software, Inc.). Statistical analysis of IC50 values was conducted using a one way 
analysis of variance (ANOVA) test, and a post-hoc Dunnett’s test when required using GraphPad 
Prism (Version 7.04, GraphPad Software, Inc.). 
 
5.2.1.4  Investigations into viability of H460 lung cancer cells following  
  combination treatment with telmisartan/losartan and doxorubicin 
H460 lung cancer cells were seeded into 96-well plates as previously described in section 2.2. 
The following day cells were exposed to telmisartan (1µM/5µM) and losartan (1µM/5µM) - One 
plate per drug, half plate for each concentration, and one plate containing medium only. 
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Following 24 hours exposure, a 1:5 serial dilution of doxorubicin was applied to all plates 
resulting in final concentrations of 5µM – 0.32nM. The cells un-exposed to test drugs were 
exposed to doxorubicin only, whereas the test drugs were added to the previously pre-treated 
cells. Following 24 hours exposure to doxorubicin, drug dilutions were removed and replaced 
with either medium (doxorubicin only treated cells) or appropriate test drugs. Cell viability was 
determined at 96 hours exposure from the first test drug addition as described in section 2.2. 
All experiments were performed in triplicate, and IC50 values were determined by implementing 
curve fitting by non-linear regression on GraphPad Prism (Version 7.04, GraphPad Software, 
Inc.). Statistical analysis of IC50 values was conducted using a one way analysis of variance 
(ANOVA) test, and a post-hoc Dunnett’s test when required using GraphPad Prism (Version 7.04, 
GraphPad Software, Inc.). 
 
5.2.2 Determination of morphological changes to proliferating AC10-CMs 
 in response to different drug treatment protocols using the 
 xCELLigence real-time cell analyser 
The xCELLigence real-time cell analyser (RTCA) was used to investigate the effects a combination 
of doxorubicin and angiotensin II on the morphology of AC10-CMs, and also to assess the effects 
of telmisartan and losartan alone and in combination with doxorubicin on the morphology of 
AC10-CMs. The protocol followed for use of the xCELLigence RTCA is detailed in section 2.3. 
 
5.2.2.1  Investigations into morphology of AC10-CMs following combination 
  treatment with doxorubicin and angiotensin II 
Experiments were set up as described in section 2.3. Cells were dosed over three days as follows: 
Day 1 – 200pM angiotensin II/50nM doxorubicin and 50nM doxorubicin alone was added to 
cells; day 2 and day 3 –200pM angiotensin II was added to the cells previously treated with 
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doxorubicin/angiotensin II and medium added to the cells treated with doxorubicin only. All 
experiments were performed in triplicate and statistical analysis on normalised cell index values 
was performed between treatment groups using a paired T-test on GraphPad Prism (Version 
7.04, GraphPad Software, Inc.). 
 
5.2.2.1.1 Evaluation of viability of AC10-CMs following treatment with  
  doxorubicin and angiotensin II at specific time points determined using 
  the MTT assay  
Separate experiments were performed to complement data obtained from the xCELLigence 
RTCA at both 24 hours and 48 hours exposure times. Cells were plated for exponential studies 
and dosed as follows: For 24 hours exposure – 200pM angiotensin/50nM doxorubicin and 50nM 
doxorubicin alone was added to cells and viability determined following 24 hours exposure; for 
48 hours exposure – angiotensin II and doxorubicin were added as above, following 24 hours 
exposure 200pM angiotensin II was added to the doxorubicin/angiotensin II treated cells and 
medium was added to the cells exposed to doxorubicin only. Following 48 hours exposure, cell 
viability was determined as described in section 2.2. All experiments were performed in 
triplicate. 
 
5.2.2.2  Investigations into morphology of AC10-CMs following treatment with 
  telmisartan and losartan 
Experiments were set up as described in section 2.3. Cells were exposed to telmisartan 
(1µM/5µM) and losartan (1µM/5µM) the following day which was repeatedly added every 24 
hours until termination of the experiment. All experiments were performed in triplicate.  
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5.2.2.3  Investigations into morphology of AC10-CMs following combination 
  treatment with telmisartan/losartan and doxorubicin  
Experiments were set up as described in section 2.3. Cells were dosed over three days as follows: 
Day 1 – Cells were exposed to telmisartan (1µM/5µM) or losartan (1µM/5µM); day 2 – 50nM 
doxorubicin was added to the pre-treated cells and to previously untreated cells, telmisartan 
(1µM/5µM) or losartan (1µM/5µM) was added to the previously pre-treated cells; day 3 –
Telmisartan (1µM/5µM) or losartan (1µM/5µM) was added to the previously pre-treated cells 
and medium added to the cells treated with doxorubicin only. All experiments were performed 
in triplicate and statistical analysis on normalised cell index values was performed using a one 
way analysis of variance (ANOVA) test, and a post-hoc Dunnett’s test when required using 
GraphPad Prism (Version 7.04, GraphPad Software, Inc.). 
 
5.2.3 Evaluation of contractility and morphology of hiPSC-CMs following 
 exposure to different treatment protocols using the xCELLigence 
 cardio system  
The xCELLigence cardio system was used to analyse changes in morphology and contractility of 
hiPSC-derived cardiomyocytes (hiPSC-CMs) following addition of a combination of 50nM 
doxorubicin and 200pM angiotensin II, and to assess the effects of telmisartan and losartan 
alone and in combination with 50nM doxorubicin on the morphology and contractility of hiPSC-
CMs. hiPSC-CM cells were plated into a cardio e-plate at a density of 30,000cells/well, in wells 
pre-coated with fibronectin (described in section 2.4). Once stable beating was detected, half 
the media (90µl) was removed from each well and replaced with media containing twice the 
required drug concentration. Final concentrations are as follows: doxorubicin - 50nM; 
telmisartan - 1µM; losartan - 1µM and angiotensin II – 200pM.  The treatment protocol included 
24 hours pre-treatment with losartan, telmisartan and angiotensin II, followed by 24 hours 
exposure to the same pre-treatment compound plus 50nM doxorubicin. Changes to the cell 
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index and contractility following drug addition were analysed at various points throughout 24 
hours exposure to the doxorubicin. Following the treatment protocols drugs were washed out 
using the four step medium change method (see section 2.4.2) and cells were re-challenged with 
the same treatment protocol 96 hours later.  The protocol followed for use of the xCELLigence 
RTCA can be found in section 2.4.  
Statistical analysis on normalised cell index, normalised beat rate and normalised beat 
amplitude were conducted between treatment groups using a paired T-test. When more than 
two groups were compared a one way analysis of variance (ANOVA) test was performed, 
followed by a post-hoc Dunnett’s test when required. Statistical analysis was performed using 
GraphPad Prism (Version 7.04, GraphPad Software, Inc.). 
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5.3 Results  
The objective of this stage of the project was to utilise the previously reported in vitro 
cardiomyocyte models to determine if the structural and functional cardiotoxicity induced by 
anthracyclines can be mitigated by the addition of angiotensin converting enzyme inhibitors 
(ACEi) and angiotensin receptor blockers (ARB), and evaluate the direct involvement of 
cardiomyocytes, and subsequently elucidate the direct relationship between the angiotensin 
signalling pathway and mitigation of anthracycline-induced cardiotoxicity (AIC).  
 
5.3.1 Angiotensin II does not alter the sensitivity of AC10 cardiomyocytes 
 to doxorubicin 
Initially the sensitivity of AC10 cardiomyocytes (AC10-CMs) to doxorubicin alone and in the 
presence of angiotensin II was evaluated using MTT assay. This study has shown previously that 
angiotensin II had no effect on the viability of AC10-CMs at clinically relevant concentrations 
(Section 3.3.4); here a range of concentrations of angiotensin II were added to a subclinical dose 
(50nM) of doxorubicin to assess if angiotensin II alters the sensitivity of the cells to doxorubicin. 
Figure 5.1 shows that simultaneous exposure of 150pM – 500pM angiotensin II with 50nM 
doxorubicin did not affect the sensitivity of cells as compared to cells treated with doxorubicin 
only. 
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Figure 5.1 Angiotensin II does not alter the sensitivity of AC10 cardiomyocytes to 
  doxorubicin 
Dose response curve showing the effect of a combination of 150pM – 500pM angiotensin II and 
50nM doxorubicin on cell viability following 96 hour exposure, expressed as % cell survival 
relative to vehicle control. The dashed line represents the % cell survival of AC10-CMs treated 
with 50nM doxorubicin only, data is representative of n=3 ± SE. 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
100 200 300 400 500
%
 C
e
ll 
su
rv
iv
al
 r
e
la
ti
ve
 t
o
 v
e
h
ic
le
 c
o
n
tr
o
l 
Concentration of Angiotensin II (pM) + 50nM doxorubicin
% Cell survival of cells treated  
with 50nM doxorubicin only 
187 
 
5.3.2 Angiotensin II does not affect the morphology of AC10 
 cardiomyocytes exposed to doxorubicin 
Previous studies have confirmed the ability of the AC10 in vitro model to detect angiotensin II 
induced hypertrophy (section 3.3.4.1) and the induction of cellular hypertrophy as a response 
to doxorubicin exposure (section 4.3.1.1). The effect of combination of angiotensin II and 
doxorubicin upon cellular morphology and behaviour were thereby monitored in real-time using 
the xCELLigence RTCA. Cells in exponential growth phase were exposed to angiotensin II for a 
total of 72 hours, within which cells were exposed to doxorubicin for 24 hours. Figure 5.2A shows 
that when normalised to the point of doxorubicin addition, cell index increased higher than the 
level of control in cells in both treatment groups, with very little difference observed in the cell 
index of both treatment groups throughout the experiment (Figure 5.2B). To ascertain if the 
changes to cell index were accompanied by changes to cell number, MTT assays were 
simultaneously performed – AC10-CMs exposed to doxorubicin only and doxorubicin plus 
angiotensin II in an identical manner, showed no difference in viability following 24 hours and 
48 hours exposure (figure 5.2C), indicating that the addition of angiotensin II to doxorubicin 
treated cells did not induce further morphological changes or effects upon cellular viability.  
Although not shown below in figure 5.2, previous studies have confirmed the ability of the AC10 
in vitro model to detect Angiotensin II induced hypertrophy (section 3.3.4.1). 
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Figure 5.2 Angiotensin II does not affect the morphology of AC10 cardiomyocytes 
  exposed to doxorubicin 
A. xCELLigence trace showing time (hours) vs normalised cell index of AC10-CMs exposed to 
doxorubicin and angiotensin II with points of angiotensin II addition (grey arrows), doxorubicin 
addition (black arrow), doxorubicin removal (round headed arrow) and exposure time 
indicated, data representative of n=3, data points shown are average ± SD. B. Normalised cell 
index following 24h and 48h exposure, data is n=3 ± SE. C. Relative cell number following 24h 
and 48h exposure measured by MTT assay, data is n=3 ± SE. ■ control,  ■ 50nM doxorubicin,  
■ 50nM doxorubicin + angiotensin II. 
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5.3.3 Effect of a combination of angiotensin II and doxorubicin on 
 morphology and contractility of hiPSC-derived cardiomyocytes  
The previous studies had shown angiotensin II and doxorubicin both individually induced 
morphological and contractile changes of hiPSC-CMs (section 3.3.4.2 and 4.3.1.2). The 
xCELLigence cardio system was therefore used to assess whether combination of these two 
agents would result in further effects upon morphology and contractility of hiPSC-CMs.  
Stably beating Cor.4U cells were exposed to angiotensin II and doxorubicin for 24 hours and the 
effects on cell behaviour were monitored in real-time. As shown in figure 5.3A, when normalised 
to the point of doxorubicin addition, cell index increased higher than the level of control in cells 
exposed to 50nM doxorubicin alone and in combination with 200pM angiotensin II, with cells 
treated with doxorubicin only showing a greater increase in cell index. The greatest difference 
in cell index was approximately 6 hours after angiotensin II and doxorubicin were added (figure 
5.3B), indicating  induction of morphology changes to the cells, however the cells were not 
imaged as E-plates have a metal base which does not allow for visualisation of the monolayer.  
Assessment of the effect of angiotensin II and doxorubicin on contractility of hiPSC-CMs was 
evaluated after 6 hours and 24 hours exposure to these agents, as these time-points represent 
the highest degree of hypertrophy observed and maximum exposure time. The representative 
traces of contractility shown for control and cells treated with doxorubicin +/- angiotensin II in 
figure 5.4A show no visible changes in contractility between the two treatment groups following 
6 hours exposure, however following 24 hours exposure, decreases in beat amplitude can be 
seen with angiotensin II addition. Detailed analysis of beat rate and amplitude is shown in figures 
5.4B and 5.4C respectively. 
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Figure 5.3 Effect of doxorubicin and angiotensin II on morphology of hiPSC- 
  derived cardiomyocytes 
A. xCELLigence trace showing time (hours) vs normalised cell index of hiPSC-CMs exposed to 
doxorubicin +/- angiotensin II with point of addition (arrow) and exposure time indicated, data 
points shown are average ± SD. B. Normalised cell index following 6 hours exposure to 
doxorubicin +/- angiotensin II, data points show average of 3 wells ± SE.  * p< 0.05 (comparison 
between treatment groups). ■ control, ■ 50nM doxorubicin, ■ 50nM doxorubicin + angiotensin II. 
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Figure 5.4 Effect of a combination of doxorubicin and angiotensin II exposure on 
  contractility of hiPSC-derived cardiomyocytes 
A. Representative traces showing contractility of control cells and cells exposed to doxorubicin 
(DOX) +/- 200pM angiotensin II (ANGII) for 6 and 24 hours, B. Normalised beating rate following 
6 and 24 hours exposure to doxorubicin +/- 200pM angiotensin II, data points show average of 
3 wells ± SE and C. Normalised beat amplitude following 6 and 24 hours exposure to doxorubicin 
+/- 200pM angiotensin II, data points show average of 3 wells ± SE. * p< 0.001 (comparison 
between treatment groups). ■ control, ■ 50nM doxorubicin, ■ 50nM doxorubicin + angiotensin II. 
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5.3.4 Cytotoxicity of angiotensin receptor blockers and angiotensin 
 converting enzyme inhibitors against AC10 cardiomyocytes 
The sensitivity of AC10-CMs in the exponential growth phase to both ARB (telmisartan and 
losartan) and the ACEi enalapril and its active form enalaprilat were evaluated using MTT assay. 
Figure 5.5 shows that exposure to concentrations of the test drugs ranging from 10µM to 78nM 
for 96 hours did not significantly affect viability of AC10-CMs, with the exception of the highest 
dose used of the ARB telmisartan and losartan. The CMax values of the test drugs are 
approximately 265nM, 86nM, 330nM and 685nM for enalapril, enalaprilat, telmisartan and 
losartan respectively264 (indicated on the figure). For future experiments investigating the 
effects of the test drugs on viability of AC10-CMs exposed to doxorubicin, concentrations of 
1µM/10µM were used for enalapril and enalaprilat and concentrations of 1µM/5µM were used 
for telmisartan and losartan as these concentrations are greater than the CMax and therefore 
should allow complete blockade of the targets whilst not causing toxicity to the cells. 
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Figure 5.5 Cytotoxicity of angiotensin receptor blockers and angiotensin  
  converting enzyme inhibitors against AC10 cardiomyocytes 
Dose response curves showing the effects on cell viability following 96 hour exposure to  
10µM – 78nM of A. Enalapril, B. Enalaprilat, C. Telmisartan and D. Losartan.  Results are 
expressed as % cell survival relative to vehicle control. The dashed line represents the C
Max
 of 
the drugs, data is representative of n=3 ± SE. 
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5.3.5 Angiotensin receptor blockade increases the viability of AC10 
 cardiomyocytes treated with doxorubicin 
The MTT assay was used to investigate the effect of the angiotensin targeting drugs on viability 
of AC10-CMs in the exponential growth phase treated with a serial dilution of doxorubicin for 
96 hours. Figure 5.6 shows that exposure to both enalapril and enalaprilat at 1µM and 10µM did 
not affect the sensitivity of the cells to doxorubicin (5.6A and B), whereas exposure to the ARBs 
telmisartan and losartan at 1µM and 5µM did affect the sensitivity of the cells to doxorubicin, 
as the dose response curves for these treatment groups were shifted to the right of the 
doxorubicin only curve. This is shown by the higher IC50 values compared to doxorubicin only 
treated cells in table 5.1 
 
5.3.6 Angiotensin receptor blockade does not decrease the therapeutic 
 efficacy of doxorubicin in H460 lung cancer cells 
As the ARBs telmisartan and losartan were found to increase the viability of AC10-CMs treated 
with doxorubicin, a parallel experiment was conducted to assess the effect of these drug 
combinations on H460 non-small cell lung cancer cells to ensure that concomitant ARB 
treatment would not reduce the therapeutic efficiency of doxorubicin. Figure 5.7 shows that 
exposure to both telmisartan and losartan at 1µM and 5µM did not decrease the therapeutic 
efficacy of doxorubicin in H460 cells, and treatment with 1µM and 5µM telmisartan increased 
the sensitivity of the cells to doxorubicin. The IC50 values for all treatment groups are shown in 
table 5.1. 
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Figure 5.6 The effect of a combination of angiotensin targeting drugs and  
  doxorubicin on viability of AC10 cardiomyocytes 
Dose response curves showing the effect on cell viability following 96 hour exposure to  
5µM – 32pM doxorubicin alone and in combination with A. Enalapril, B. Enalaprilat,  
C. Telmisartan and D. Losartan.  Results are expressed as % cell survival relative to vehicle 
control, data is representative of n=3 ± SE.  
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Figure 5.7 Angiotensin receptor blockade does not decrease the therapeutic 
  efficacy of doxorubicin in H460 lung cancer cells 
Dose response curves showing H460 cell viability following 96 hour exposure to 5µM – 0.32nM 
doxorubicin alone and in combination with A. Telmisartan and B. Losartan.  Results are 
expressed as % cell survival relative to vehicle control, data is representative of n=3 ± SE. 
 
  
  
IC50 (nM) 
AC10 Cardiomyocytes  
H460 Lung 
cancer cell line 
Doxorubicin  14.66 ± 3.31 21.33 ± 1.78 
Doxorubicin  + 1μM Losartan 65.67 ± 18.92 15.66 ± 1.78 
Doxorubicin  + 5μM Losartan 71.33 ± 27.44  19 ± 1.69 
Doxorubicin 14.66 ± 3.31 40.66 ± 13.81 
Doxorubicin + 1μM Telmisartan 96.67 ± 27.32 23 ± 4.96 
Doxorubicin + 5μM Telmisartan 90 ± 30.03  10.66 ± 2.76 
 
Table 5.1 IC50 values of AC10 cardiomyocytes and H460 lung cancer cells treated 
  with doxorubicin alone and in combination with 1µM/5µM telmisartan 
  and losartan for 96 hours, data is representative of n=3 ± SE. 
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5.3.7 Angiotensin receptor blockade reduces morphology changes 
 induced by doxorubicin in AC10 cardiomyocytes 
Following the viability studies that showed angiotensin blockade increased the survival of AC10-
CMs treated with doxorubicin, but did not affect the therapeutic efficacy of doxorubicin in lung 
cancer cells, doxorubicin and the ARB telmisartan were combined and the effects on 
morphology and behaviour of AC10-CMs were monitored in real-time using the xCELLigence 
RTCA. Cells in exponential growth phase were exposed to telmisartan for a total of 96 hours, 
within which cells were exposed to doxorubicin for 24 hours. Figure 5.8A shows that when 
normalised to the point of doxorubicin addition, cell index increased higher than the level of 
control in cells in both treatment groups, however cells treated with doxorubicin and 
telmisartan showed reduced cell index compared to doxorubicin alone from 48 to 96 hours 
(Figure 5.8B). Paired with the dose response curves shown above in figure 5.6C where AC10-
CMs treated in an identical manner had improved viability with concurrent angiotensin blockade 
(summarised in figure 5.8C), this suggests that angiotensin blockade concurrent to doxorubicin 
treatment improves viability of AC10-CMs and reduces hypertrophy. Telmisartan alone was also 
added to AC10-CMs for 72 hours and had no effect on the cell index when normalised to the 
point of first telmisartan addition, as the readings obtained were similar to that of control (inset 
- figure 5.8A). 
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Figure 5.8 Angiotensin receptor blockade reduces morphology changes induced 
  by doxorubicin in AC10 cardiomyocytes 
A. xCELLigence trace showing time (hours) vs normalised cell index of AC10-CMs exposed to doxorubicin 
and telmisartan with points of telmisartan addition (grey arrows), doxorubicin addition (black arrow), 
doxorubicin removal (round headed arrow) and exposure time indicated, data points shown are average 
± SD. A (inset) xCELLigence trace showing time (hours) vs normalised cell index of AC10-CMs exposed to 
telmisartan with points of addition (grey arrows) and exposure time indicated, data representative of n=3, 
data points shown are average ± SD. B. Normalised cell index following 96h exposure to 50nM doxorubicin 
+/- telmisartan, data is n=2 ± SE and C. % AC10-CM cell survival relative to vehicle control following 96h 
exposure to 40nM doxorubicin +/- telmisartan measured by MTT assay, data is n=3 ± SE. * p< 0.05 
(Doxorubicin treatment group compared to doxorubicin/telmisartan treatment groups)   ■ control, ■ 
50nM doxorubicin, ■ 50nM doxorubicin + 1µM telmisartan, ■ 50nM doxorubicin + 5µM telmisartan. 
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5.3.8 Angiotensin receptor blockade reduces doxorubicin-induced 
 changes to morphology but does not affect contractility of hiPSC-
 derived cardiomyocytes  
In chapter 4, doxorubicin was found to induce morphology and contractility changes to hiPSC-
CMs when used alone. Using the xCELLigence cardio system the effect of a combination of 
doxorubicin plus ARB on the morphology and contractility of hiPSC-CMs was evaluated.  
Stably beating Cor.4U cells were exposed to doxorubicin +/-telmisartan/losartan for 24 hours 
and the effects on cell behaviour were monitored in real-time. As shown in figure 5.9A, when 
normalised to the point of doxorubicin addition, cell index increased higher than the level of 
control in all three treatment groups, however the addition of telmisartan/losartan to 50nM 
doxorubicin resulted in less of an increase to cell index compared to 50nM doxorubicin alone.  
The greatest difference in cell index was approximately 6 hours after doxorubicin +/- 
losartan/telmisartan were added (figure 5.9B), indicating that the addition of the ARB 
telmisartan and losartan may have reduced the hypertrophy induced by doxorubicin.  
Telmisartan and losartan alone were also added to hiPSC-CMs and had no effect on the cell index 
when normalised to the point of drug addition, as the readings obtained were similar to that of 
control (inset - figure 5.9A). 
Assessment of the effect of doxorubicin +/- telmisartan/ losartan on contractility of hiPSC-CMs 
was carried out after 6 hours and 24 hours, as these time-points represent the highest degree 
of hypertrophy observed and maximum exposure time. The representative traces of contractility 
shown for control and cells treated with doxorubicin +/- telmisartan/losartan in figure 5.10A 
show no visible changes in contractility following 6 hours exposure, however following 24 hours 
exposure, decreases in beat number and amplitude can be seen. Detailed analysis of beat rate 
and amplitude is shown in figures 5.10B and 5.10C respectively where there were no changes 
between doxorubicin +/- ARB treated cells. 
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Figure 5.9 Angiotensin receptor blockade reduces doxorubicin-induced changes to 
  morphology of hiPSC-derived cardiomyocytes 
A. xCELLigence trace showing time (hours) vs normalised cell index of hiPSC-CMs exposed to 
doxorubicin +/- the ARBs telmisartan and losartan with point of addition (arrow) and exposure 
time indicated, data points shown are average ± SD. A (inset) xCELLigence trace showing time 
(hours) vs normalised cell index of hiPSC-CMs exposed to telmisartan and losartan with point of 
addition (arrow) and exposure time indicated, data points shown are average ± SD.    
B. Normalised cell index following 6 hours exposure to doxorubicin +/- the ARBs telmisartan and 
losartan, data points show average of 3 wells ± SE. * p< 0.0001 (Doxorubicin treatment group 
compared to Doxorubicin/telmisartan treatment groups) ■ control, ■ 50nM doxorubicin,  
■ 50nM doxorubicin + 1µM telmisartan, ■ 50nM doxorubicin + 1µM losartan. 
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Figure 5.10 Angiotensin receptor blockade does not affect contractility of hiPSC- 
  derived cardiomyocytes exposed to doxorubicin 
A. Representative traces showing contractility of control cells and cells exposed to doxorubicin 
(DOX) +/- the ARB telmisartan (TEL) and losartan (LOS) for 6 and 24 hours. B. Normalised beating 
rate following 6 and 24 hours exposure to doxorubicin +/- the ARB telmisartan and losartan, 
data points show average of 3 wells ± SE and C. Normalised beat amplitude following 6 and 24 
hours exposure to doxorubicin +/- the ARB telmisartan and losartan, data points show average 
of 3 wells ± SE.  ■ control, ■ 50nM doxorubicin, ■ 50nM doxorubicin + 1µM telmisartan,  
■ 50nM doxorubicin + 1µM losartan. 
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5.4 Discussion 
The occurrence of cardiac liabilities following anthracycline treatment is well established 
clinically, particularly doxorubicin induced cardiotoxicity.16 The mitigation of these toxicities 
using drugs that perturb angiotensin signalling has been investigated in both clinical studies and 
pre-clinically in vivo with encouraging results,152 however the number of in vitro studies in this 
area remains limited. In addition, the direct effects upon and involvement of the cardiac system, 
as well as the molecular mechanism of cardioprotection have yet to be resolved.  The aim of this 
stage of the project is to address these issues and determine if the previously discussed 
structural and functional cardiotoxicity induced by anthracyclines can be mitigated by the 
addition of ACEi and ARB using in vitro cardiomyocyte models. 
 
5.4.1 Synergistic effects of angiotensin II and doxorubicin treatment 
Accumulating evidence supports the role of the renin-angiotensin system as a modulator of 
cardiovascular remodelling; via interaction with the angiotensin type I receptor (ATR1), 
angiotensin II is a mediator of both cardiomyocyte growth and left ventricular hypertrophy.75,231 
The mitigation of anthracycline-induced cardiotoxicity (AIC) with therapeutics that limit 
angiotensin signalling suggests a role for the angiotensin signalling pathway in also mediating 
this toxicity; therefore initially the synergistic effects of angiotensin II and doxorubicin treatment 
were assessed in AC10 cardiomyocytes (AC10-CMs) and hiPSC-derived cardiomyocytes (hiPSC-
CMs) following simultaneous treatment with doxorubicin and angiotensin II.   
A relationship between angiotensin signalling and doxorubicin induced cardiomyopathy has 
previously been established by Toko et al. using ATR1 knockout mice (AT1KO).265 In this elegant 
12 week study, doxorubicin administered to wild type (WT) mice was found to impair cardiac 
function and cause histopathological abnormalities such as myofibrillar loss, increased numbers 
of apoptotic cells and cytoplasmic vacuolisation, however these changes were absent in the 
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AT1KO mice group and WT mice treated with an ATR1 antagonist. The protection afforded to 
the AT1KO mice and the mice treated with an ATR1 antagonist suggests that there is interplay 
between the angiotensin signalling pathway and doxorubicin-induced cardiomyopathy.265  
As the aforementioned study by Toko et al. was conducted in mice, it is more challenging to 
ascertain the mechanism of cardioprotection in the mice with ablated angiotensin signalling. In 
addition to the effects of angiotensin signalling on remodelling activities in the heart, 
angiotensin II also has systemic effects in other organs such as the kidneys and blood vessels 
where it is involved in the absorbance of water and salt, and vasoconstriction respectively.266 
These activities have the overall effect of increasing blood pressure which could partially 
contribute to the improved cardiac function of the AT1KO mice treated with doxorubicin.  In 
contrast, the current study focussed on isolated cardiomyocytes found that addition of a 
physiologically relevant dose of angiotensin II, previously found to induce hypertrophy of AC10-
CMs, did not alter the toxicity profile of doxorubicin or augment the doxorubicin-induced 
hypertrophy of AC10-CMs when co-administered with doxorubicin. This may be due to the use 
of shorter exposure times that did not allow for the accumulation of further structural damage, 
or the use of a more simplistic in vitro model that does not fully represent the complexity of the 
cardiovascular system and human body.  
Similar findings were observed in hiPSC-CMs exposed to a combination of angiotensin II and 
doxorubicin with respect to hypertrophy, however some changes were observed in the beat 
characteristics of the cells.  Assessment of the effect of angiotensin II and doxorubicin on 
contractility of hiPSC-CMs was carried out after 6 hours and 24 hours, with 24 hours exposure 
resulting in a decrease in beat amplitude of the cells compared to cells treated with doxorubicin 
only. As a decrease in beat amplitude relates to negative inotropy (reduced force of muscle 
contraction), the reduction observed in beat amplitude observed following 24 hours exposure 
to doxorubicin and angiotensin II may be due to increased impairment to the contractile 
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machinery of the cells and myofibrillar loss. This would be in alignment with the findings from 
the study by Toko et al., where AT1KO mice were protected from myofibrillar loss and 
cytoplasmic vacuolisation induced by doxorubicin treatment, as determined by electron 
microscopic analysis; thus supporting the notion that angiotensin signalling plays a role in AIC.265 
The results from the current study illustrate the advantages of hiPSC-CMs as an in vitro model 
that is capable of determining changes in contractility in a clinically relevant manner.   
        
5.4.2 Synergistic effects of doxorubicin with concurrent angiotensin 
 converting  enzyme inhibitor and angiotensin receptor blocker 
 treatment 
Promising results from both clinical and in vivo studies utilising angiotensin receptor blockers 
(ARB) and angiotensin converting enzyme inhibitors (ACEi) point towards these medicines as a 
potential route for mitigation of AIC.152 In the current study the ACEi enalapril and its active form 
enalaprilat did not augment the sensitivity of AC10-CMs to doxorubicin cytotoxicity. The lack of 
protection observed in AC10-CMs that were co-administered with enalapril and enalaprilat may 
be due to a combination of two factors: the use of an in vitro model and the mechanism of action 
of these compounds. In the human body, angiotensin converting enzyme (ACE) is required to 
convert angiotensin I to angiotensin II which has a variety of effects including vasoconstriction 
which increases blood pressure. 
As an ACEi, enalaprilat, which is the active metabolite of enalapril, reduces production of 
angiotensin II, leading to decreased vasoconstriction and decreased blood pressure.267 This 
process requires the starting peptide angiotensin I which is produced by cleavage of 
angiotensinogen by an enzyme called renin. Although these proteins are thought to primarily 
originate from the liver and kidneys respectively, more recent evidence points toward the 
existence of a local renin-angiotensin-system in the myocardium which produces all the 
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necessary elements to create angiotensin II except renin which is sequestered from the 
bloodstream.231,268 
 
 
Figure 5.11 Angiotensin II synthesis in the myocardium 
The pathway of angiotensin II production showing components expressed by the myocardium 
(green), pathway enzymes (yellow), cleavage products (grey) and therapeutic agents used to 
decrease angiotensin signalling (blue). The myocardium expresses all the necessary elements to 
produce angiotensin II except renin (red) which is sequestered from the bloodstream, therefore 
it is unlikely that in vitro cardiomyocyte cell models are able to produce angiotensin II. 
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Preliminary studies using reverse transcriptase polymerase chain reaction (RT-PCR) in the 
current study, detected gene expression of angiotensinogen and ACE in AC10-CMs, however 
expression of renin was not detected in the cells (See Appendix 5). With this is mind, it is unlikely 
that the AC10-CMs used in this study could produce angiotensin I, therefore the 
enalapril/enalaprilat added to this artificial system had no function as any ACE enzyme that was 
present would likely be inactive. The lack of direct interaction of enalapril/enalaprilat with 
cardiomyocytes is illustrated in toxicity studies where the compounds were added alone and the 
effects upon viability of AC10-CMs determined. At the highest concentration of 10µM the drugs 
exhibited negligible toxicity, with survival rates of approximately 94% for both compounds 
relative to vehicle control. In contrast, addition of the ARB telmisartan and losartan at 10µM 
yielded survival rates of 84% and 70% respectively which suggests direct interaction with the 
drugs’ target, the ATR1. Indeed, preliminary studies using RT-PCR found positive expression of 
the ATR1 in AC10-CMs (See appendix 5) and the previously described results of angiotensin II 
induced hypertrophy (Section 3.3.4.1) suggests expression of the ATR1 in the AC10-CM cell line.  
Unlike the ACEi enalapril and its active form enalaprilat, the ARB telmisartan and losartan were 
able to protect AC10-CMs from doxorubicin induced toxicity as evidenced by the increased IC50 
values when cells were co-treated with telmisartan/losartan and doxorubicin compared to cells 
treated with doxorubicin alone. In relation to this, a recent study conducted by Gergely et al. 
used high-throughput screening to identify a novel compound with ability to protect H9c2 rat 
cardiomyocytes from doxorubicin induced damage.269 Out of a library of 10,000 compounds only 
one was found to be convincingly cardioprotective – the compound is called EODB and possesses 
a benzimidazole moiety, which is also a feature of the ARB telmisartan. It is possible that the 
cardioprotection provided by EODB in this study was also related to ATR1 blockade, however 
further studies would be needed to elucidate the exact mechanism of cardioprotection. The 
authors of the study also investigated the effect that EODB had on cancer cell lines, as it is 
imperative that cardioprotectants do not compromise the anti-cancer activity of doxorubicin. 
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Encouragingly, it was found that EODB did not hamper the anti-cancer activities in cancer cell 
lines originating from the lung, bone and blood cells.269 The same consideration was made in the 
current study, where no decreases to doxorubicin’s anti-tumour efficacy was observed with 
telmisartan and losartan when added in tandem with doxorubicin to the H460 lung cancer cell 
line. In fact, 5µM telmisartan appeared to increase the sensitivity of H460 cells to doxorubicin 
as evidenced by the IC50 values which reduced from 40.66nM when cells were treated with 
doxorubicin alone, to 10.66nM when a combination of doxorubicin and 5µM telmisartan was 
added to the cells. 
Having considered the ability of telmisartan and losartan to protect AC10-CMs from doxorubicin 
induced cell death without affecting therapeutic efficacy in H460 lung cancer cells, the impact 
of angiotensin blockade on cellular morphology of doxorubicin treated AC10-CMs and hiPSC-
CMs was determined. Simultaneous to increased viability of AC10-CMs, blockade of the 
angiotensin receptor was also found to reduce the hypertrophic response induced by 
doxorubicin in both AC10-CMs and hiPSC-CMs.  
A number of clinical studies have provided strong evidence that use of ARB alone can reduce left 
ventricular hypertrophy including the Losartan Intervention for Endpoint Reduction in 
Hypertension (LIFE) study270 and the Swedish Irbesartan Left Ventricular Hypertrophy 
Investigation versus Atenolol (SILVHIA) study.271 Both of these studies compared the use of ARB 
to the β-blocker atenolol and found that the ARB achieved a significantly greater reduction in 
left ventricular hypertrophy compared to atenolol, despite similar reductions in blood pressure. 
This suggests that blockade of the ATR1 may be a more efficient approach to curb the cardiac 
remodeling that occurs due to pressure overload and further supports the role of angiotensin II 
in development of pathogenic hypertrophy.  In line with the symptoms of ordinary heart failure, 
the chronic and delayed forms of doxorubicin-induced cardiotoxicity are also associated with 
impairments to left ventricular function and changes to cardiomyocyte structure.144 This links 
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with the findings from the current study which have shown using in vitro cardiomyocyte models 
that mitigation of the cardiomyocyte hypertrophy induced by doxorubicin is possible through 
blockade of the ATR1 by ARB.  
Unlike the LIFE and SILVHIA clinical studies mentioned above, the current study was conducted 
in vitro and therefore is focussed on direct evaluation of cardiomyocyte behaviour independent 
of systemic effects. The reduction in cardiomyocyte hypertrophy observed in this study 
demonstrates that perturbation of angiotensin signalling in the context of doxorubicin-induced 
cardiotoxicity has direct protective effects on cardiomyocytes. This may relate to a reduction in 
the acute cardiotoxicity response which potentially primes cardiomyocytes for the more severe 
forms of cardiotoxicity that involve cardiac remodelling and ventricular hypertrophy. 
A further implication of using in vitro cardiomyocyte models is that the cells used in this study 
were not exposed to circulating levels of angiotensin II that would ordinarily bind to the ATR1 
and initiate signalling cascades. Evidence suggests that biomechanical stress (such as exposure 
to doxorubicin) to cardiomyocytes in vitro can induce changes to cardiomyocytes including the 
induction of ATR1 activation independent of agonist binding,272 which may also be responsible 
for ATR1 activation in the current study. Considering this, in addition to exposure of a patient’s 
myocardium to doxorubicin causing hypertrophy (biomechanical stress) and subsequent ATR1 
activation independent of angiotensin II, patients also have their own circulating angiotensin II 
which regrettably may increase further due to the oxidative stress caused by exposure to 
doxorubicin. The doxorubicin-induced biomechanical stress and increased levels of angiotensin 
II could thereby likely further increase stimulation of ATR1 thus increasing the activity of this 
potentially cardiotoxic signalling cascade. 
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5.4.3 Conclusion 
The findings from this chapter provide further evidence to the existing in vivo and clinical studies 
that support the use of drugs that interfere with angiotensin signalling as a means to mitigate 
AIC. As this study was conducted in vitro using AC10-CMs and hiPSC-CMs, this suggests that 
direct interaction of the ARB with the ATR1 on cardiomyocytes may be at least partially 
responsible for the protection afforded by ARB against AIC. As it is unlikely that the in vitro 
models used in this study produce angiotensin II, it is possible that an alternative mechanism of 
cardioprotection may exist that is independent of angiotensin signalling. Further work into 
clarifying the involvement of the ATR1 in the cardioprotective response observed is required 
and could be obtained using siRNA techniques. In addition to facilitating improved survival and 
reduced hypertrophy of cardiomyocytes treated with doxorubicin, telmisartan and losartan did 
not reduce the therapeutic efficacy of doxorubicin in H460 lung cancer cells, which is essential 
if ARB are to be used for cardiotoxicity mitigation in cancer treatment. The protection given to 
the cardiomyocytes used in this study is likely due to direct interaction of the ARB with the ATR1 
on cardiomyocytes, however may occur via an off-target mechanism. This may relate to a 
reduction in the acute cardiotoxicity response which potentially primes cardiomyocytes for the 
more severe forms of cardiotoxicity that involve cardiac remodelling and ventricular 
hypertrophy. The interaction between angiotensin signalling and doxorubicin-induced 
cardiotoxicity will be investigated further in the following chapter.  
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Chapter 6: Molecular relationship 
between the angiotensin signalling 
pathway and anthracycline-induced 
cardiotoxicity 
 
6.1 Introduction 
In terms of heart failure, the reduction in the heart’s ability to maintain sufficient cardiac output, 
compensatory mechanisms lead to cardiac remodelling and increases in cardiac beat rate. The 
purpose of this remodelling is to increase the stroke volume and cardiac capacity in order to 
return cardiac output to the required level. However, the alteration in cardiac structure 
decreases cardiac efficiency and increases myocardial strain, further deteriorating cardiac 
output, exasperating cardiac failure, and increasing the risk of arrhythmias and cardiac 
arrest.82,273 
 
6.1.1 Angiotensin signalling pathways in the cardiac system 
An important physiological mediator of cardiac output and cardiac stroke volume is the renin-
angiotensin system. This system has an overall role in regulating blood pressure through altering 
blood volumes, via alteration of renal water retention, and perturbation of vascular resistance 
and cardiac tone.231,266 Angiotensin II, the major effector of the RAS, is an octapeptide formed 
by sequential cleavage of angiotensinogen to angiotensin I by renin, followed by cleavage of 
angiotensin I to angiotensin II by angiotensin converting enzyme (ACE). The angiotensin receptor 
signalling pathway mediates the cellular response to angiotensin II through the angiotensin 
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receptors (ATR), of which there are two subtypes – ATR1 and ATR2 receptors.274 The majority of 
the known physiological effects of angiotensin II are mediated by the ATR1 receptors.75,76 
Consequently, disruption of the RAS signalling pathway is a known pharmacological target, with 
drugs targeting this pathway used clinically for management of hypertension and heart failure 
(see section 1.4.5.2).162,163 
Although the RAS system is predominantly systemic in activity and function, culminating in 
changes in blood volume and pressure, there is substantial evidence to also support a direct 
involvement of angiotensin signalling upon cardiac tissue.231,268 The heart contains a variety of 
cell types including cardiomyocytes, fibroblasts, endothelial cells and pericytes (See section 
1.4.3). These cell types play specific roles within the heart and rely on an array of signalling 
cascades to communicate and maintain optimal cardiac function. (See section 1.4.5). The heart 
is equipped with sophisticated mechanisms to respond to extracellular stimuli such as changes 
to cardiac demand, including G-protein coupled receptors such as the ATR.69 The physiological 
importance of angiotensin II in the cardiovascular system is paramount, as it is responsible for 
regulating changes in vascular tone and blood flow to maintain cardiac output and function.  
 
6.1.2 Perturbation of the angiotensin signalling pathway as a therapeutic 
 strategy 
Interruption of angiotensin signalling is a clinically utilised strategy for management of heart 
failure and hypertension, through either reducing the amount of circulating angiotensin II or 
preventing its binding to ATR.162,163  
Inhibition of ACE is a frontline approach in this respect, preventing conversion of angiotensin I 
to II. The second strategy is through the use of angiotensin receptor blockers (ARB) which retard 
the binding of angiotensin II to ATR1, thereby disrupting angiotensin signalling. In contrast to 
ACE inhibition which has a general systemic effect and subsequent indirect effect upon cardiac 
212 
 
tissue, blockade of ATR1 is known to bind to receptors in the heart and directly curb angiotensin-
induced changes such as cardiomyocyte hypertrophy and cardiac remodelling.270,271 
Interestingly, the ARB valsartan has been shown to simultaneously block signalling of ATR1 and 
β2 adrenergic receptors in mice, suggesting further complex receptor interactions and perhaps 
more use for angiotensin signalling modulators in heart failure.78 
 
6.1.3 Inhibition of Angiotensin signalling for mitigation of anthracycline-
 induced cardiotoxicity 
This project has previously demonstrated anthracyclines, such as doxorubicin, are associated 
with severe dose-limiting cardiotoxicity (see section 1.7.1.2).16 As a result, many different 
strategies to reduce the occurrence of cardiotoxicity have been explored including iron 
chelators, liposomal formulations and co-administration of heart therapies such as those that 
augment angiotensin signalling.28,152 The use of ARB and ACEi for reducing anthracycline-induced 
cardiotoxicity (AIC) has been investigated in clinical studies which have reported positive results, 
mainly in the area of preventing declines in left ventricular function associated with 
anthracycline treatment.150,164–168 The findings of these studies are summarised in section 1.7.2.1 
and table 1.2.   
Although some of the cardioprotective properties of reducing angiotensin signalling can be 
attributed to a systemic reduction in blood pressure, it is likely that reduction of angiotensin 
signalling also affords some direct protection to cardiomyocytes. However, the mechanism by 
which anthracyclines, such as doxorubicin, induce structural and functional changes to 
cardiomyocytes has yet to be fully identified. 
Collective evidence suggests that the cardiomyopathy initiated by doxorubicin is a progressive 
and multi-factorial process. At the subcellular level, exposure to doxorubicin causes cytoplasmic 
vacuoles, mitochondrial membrane disruption and disorder of myofibril arrangement.116,144 
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From a molecular perspective, mechanisms of doxorubicin-induced cardiomyopathy include 
impaired calcium handling, altered gene and protein expression of key pathways involved in 
cardiomyocyte survival and function, DNA breakage via inhibition of cellular topoisomerase IIβ 
(TopIIβ), intracellular collation of iron, inhibition of mitochondrial topoisomerase 1 (Top1mt) 
and consequent function, and the formation of oxygen free radicals that damage the 
mitochondria of the cells.16,34,118,124,127 These mechanisms of doxorubicin-induced cardiotoxicity 
are discussed in detail in section 1.7.1.1. 
Several studies have reported that angiotensin II promotes the generation of reactive oxygen 
species (ROS) from the mitochondria, a process involving activation of NADPH oxidase and 
mitochondrial ROS-induced ROS release (RIRR), and subsequent oxidative stress within 
cardiomyocytes.275,276 In relation to anthracyclines, doxorubicin is also known to bind to the 
mitochondrial membrane protein cardiolipin, causing the accumulation of the drug within the 
cardiomyocyte, redox cycling and generation of substantial ROS.91 Subsequently, the presence 
of iron (Fe2+) fuels the process and production of further damaging reactive species, termed the 
iron and free radical hypothesis.118 
Therefore, anthracycline-induced free radical production and angiotensin-mediated signalling is 
likely to result in exacerbation of oxidative stress, providing a possible rationale for the 
mitigation of cardiotoxicity by pharmaceutical agents that reduce angiotensin signalling. Such a 
hypothesis was addressed in a murine study by Taskin et al. who administered doxorubicin in 
the presence or absence of the ACEi captopril and/or the renin inhibitor aliskiren.277 In this study 
doxorubicin decreased mitochondrial membrane potential and ATP levels in cardiomyocytes, a 
process shown to involve increased oxidative stress.278 Whereas treatment with doxorubicin in 
the presence of ACE or renin inhibition resulted in much higher ATP levels and little change in 
the mitochondrial membrane potential, by a process postulated to involve decreased oxidative 
stress and inhibition of angiotensin II production.277 
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Another suggested mechanistic basis for the cardiotoxic effects of doxorubicin and involvement 
of angiotensin signalling is provided by the induction of mechanical stretch and subsequent 
physical stress by doxorubicin treatment. This hypothesis proposes that this drug-induced 
cardiomyocyte stretch further increases circulating levels of angiotensin II, a concept 
investigated by Okumura et al. who determined ACE activity in hamsters treated with 
doxorubicin.279 Following two weeks treatment, activity of cardiac ACE increased in doxorubicin 
treated hamsters, suggesting cardiac ACE may play an important role in development of AIC, 
causing increased production of angiotensin II and exacerbated cardiac hypertrophy.279 
Increased levels of angiotensin II has the additional detrimental effect of down-regulating 
essential neuregulin signalling in cardiomyocytes.175 As previously discussed in section 1.6.2.1 
neuregulin signalling is involved in cardiac development and physiology, with studies in 
conditional gene knockout murine models demonstrating spontaneous dilated cardiomyopathy 
and increased susceptibility to stress such as pressure overload.108 In terms of cardiotoxicity of 
oncology therapeutics, trastuzumab-induced cardiotoxicity reportedly involves inhibition of the 
neuregulin signalling pathway;105 therefore it is possible that altered neuregulin signalling may 
play a role, alongside elevated angiotensin II levels and oxidative stress, in AIC. 
With regards to angiotensin signalling and AIC, increased oxidative stress, decreases in survival 
signalling pathways and cardiac remodelling are areas of clear overlap. However, it is still unclear 
as to how the angiotensin signalling pathway and anthracycline-treatment interact to facilitate 
cardiotoxicity and the underpinning molecular mechanisms. Ultimately, greater understanding 
of the temporal and spatial involvement of the angiotensin-signalling pathway in this 
cardiotoxicity, at the level of the cardiomyocyte, will assist in the understanding of this toxicity 
and its detection and management.  
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6.1.4 Aims and objectives    
This study has previously confirmed that ARB can mitigate anthracycline-induced structural 
changes in cardiomyocytes, utilising qualified in vitro models. The aim of this phase of the study 
is to interrogate the molecular mechanisms of the angiotensin-signalling pathway associated 
with anthracycline-induced cardiotoxicity, potentially indicating a molecular relationship 
between the angiotensin II signalling pathway and anthracycline-induced cardiotoxicity. 
 
Specifically: 
i) Studies will be conducted to evaluate the involvement and regulation of ATR1 in doxorubicin-
induced cardiotoxicity using the previously qualified in vitro cardiomyocyte models. 
ii) Molecular pathways perturbed by doxorubicin in cardiomyocytes at the genetic level will be 
examined and the relationship to the angiotensin-signalling pathway and cardiotoxicity will be 
addressed. 
 
 
 
 
 
 
 
 
 
216 
 
6.2 Materials and methods  
Solution and gel compositions used for western blotting are outlined in Appendix 4. 
6.2.1 Evaluation of protein expression by western blotting:  
 Cell lysate preparation of AC10 cardiomyocytes   
AC10 cardiomyocytes (AC10-CMs) were seeded in 6-well plates at a density of 300,000 cells per 
well and cultured for 24 hours in complete culture medium. Cells were then incubated with 
doxorubicin (50-500nM) for a further 24 hours. Following culture media removal and cellular 
trypsinisation, the number of cells was adjusted to 500,000 cells per sample. After centrifugation 
for 5 minutes at 1000rpm, cell pellets were lysed by addition of 50µl of lysis buffer containing 
both protease and phosphatase inhibitors. The resultant cell lysates were centrifuged at 
1000rpm and the supernatant (soluble fraction) transferred to a fresh tube, or the cell lysates 
were not centrifuged and the whole cell lysates (soluble and insoluble fraction) were stored at -
20°C. 
The amount of protein in the cell lysates was quantified using the Bradford assay.280 A series of 
protein standards (0-1µg/µl) were made using bovine serum albumin (BSA) diluted in lysis 
buffer. 10µl of the test samples and standards were added to a 96 well plate in duplicate. To 
each well, 200µl of Bradford Reagent (BioRad, UK) diluted 1:5 in deionised water was added, the 
plate incubated at room temperature for 5 minutes to allow the reaction to occur, and the 
absorbance of the samples at measured at 595nm using a spectrophotometer plate reader 
(MultiSkan GO, Thermo Scientific, USA). The concentration of test samples was then calculated 
using the standard curve. Cell lysates were stored at -20°C until required. 
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6.2.1.1  Evaluation of protein expression by western blotting:  
  Polyacrylamide gel electrophoresis and membrane transfer 
Protein samples were diluted to a final concentration of 1µg/µl by mixing the calculated volume 
of cell lysate, water and 4x sample buffer (Containing 10% β-mercaptoethanol), heated at 95°C 
for 5 minutes to denature proteins, before transfer onto wet ice. 
Protein samples (30µg) were separated through a 10% polyacrylamide SDS resolving gel and a 
5% stacking gel using a BioRad mini-gel electrophoresis rig (BioRad, UK) filled with running 
buffer. For size determination, 5µl Precision Plus protein ladder (BioRad, UK) was also loaded 
into the gel. Proteins were separated at 200V for 1 hour or until the dye front reached the end 
of the gel.  
Western blotting was conducted as per the methodology of Towbin et al.281 Briefly, gels were 
removed from the tank and the proteins transferred from the polyacrylamide gel to a 
polyvinylidene difluoride (PVDF) membrane (Amersham Hybond, GE Healthcare Life Sciences, 
UK), as follows. Prior to use the PVDF membrane was activated by soaking in methanol for 15 
seconds and then placed in transfer buffer. The western transfer cassette was assembled as 
shown in figure 6.1.  
The resultant cassette was placed in a transfer tank (BioRad, UK) containing transfer buffer, 
immersed in wet ice and the proteins transferred at 300mA for 1 hour. 
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Figure 6.1 Gel and PVDF membrane sandwich for protein transfer 
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6.2.1.2  Evaluation of protein expression by western blotting:  
  Antibody probing and protein detection 
After completion of protein transfer, PVDF membranes were incubated in a solution of 5% non-
fat dried milk in Tris-buffered saline with Tween-20 (TBS-T), for 1 hour at room temperature with 
agitation to block non-specific antibody binding.  To probe for expression of specific proteins, 
‘blocked’ membranes were then incubated overnight at 4°C with the respective primary 
antibody (table 6.1), diluted in 1% milk in TBS-T in a 50ml sample tube on a rotating mixer (Bibby 
Scientific, UK). 
 
Primary 
antibody 
Type Company Dilution 
Secondary 
antibody 
Molecular 
weight (kDa) 
ATR1 
Rabbit 
polyclonal 
Millipore 1:250 
Anti-rabbit 
(1:2000) 
43 
β-actin 
Mouse 
monoclonal 
Sigma 1:10000 
Anti-mouse 
(1:2000) 
42 
 
Table 6.1 Characteristics of antibodies used in this study 
  
After overnight antibody exposure, membranes were washed three times in TBS-T for 15 
minutes on a shaker at room temperature to remove unbound antibody. The PVDF membranes 
were then incubated in the appropriate HRP-conjugated secondary antibody diluted in 1% milk 
in TBS-T (table 6.1) for 1 hour at room temperature. Membranes were than washed for 15 
minutes on a rocker at room temperature to remove unbound secondary antibodies. 
Antibody binding was detected by chemiluminescence, using a pre-mixed enhanced 
chemiluminescence solution (ECL) and left to react in the dark for 3 minutes. Excess ECL was 
removed by dabbing membranes onto tissue paper, before placing the membrane in a small 
plastic bag and marking the location of the protein ladder. Bands were detected using a 
ChemiDoc MP System (BioRad, UK). Exposed membranes were stored at 4°C for further analysis 
of protein expression.  
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Blots were stripped and re-probed for β-actin to ensure equal loading of all samples. Briefly, the 
membranes were incubated in acid stripping buffer for two 30 minute incubations and then the 
acid was neutralized by triplicate three minute washes in PBS. The membrane was blocked for 1 
hour as previously described and then incubated in primary antibody diluted in 1% milk in TBS-
T (table 6.1) for 1 hour and binding detected as previously described. Protein expression was 
analysed semi-quantitatively using densitometry on the ImageJ image processing package 
(National institute of Health, USA), with fold change in respective protein expression relative to 
vehicle control calculated.  
Statistical tests were conducted on densitometry values using a one way analysis of variance 
(ANOVA) test. Statistical analysis was performed using GraphPad Prism (Version 7.04, GraphPad 
Software, Inc.). 
 
6.2.2 Analysis of anthracycline-induced changes to gene expression 
 relating to cardiotoxicity and angiotensin signalling 
PCR arrays were used to analyse changes in expression of a panel of pathway specific genes to 
be profiled in cells following drug treatment. The PCR arrays used for these studies were the 
Human Cardiotoxicity array (PAHS-095Z) and the Human GPCR Signalling Pathway Finder (PAHS-
071Z) (SABiosciences, Qiagen, Germany) using the previously described methodology.282 
 
6.2.2.1  Production of cDNA from AC10 cardiomyocytes 
AC10-CMs were seeded in 6-well plates at a density of 300,000 cells per well and grown for 24 
hours prior to the addition of 50nM doxorubicin or 0.1% DMSO. After drug exposure for 24 
hours, media was removed and the cells scraped in PBS and collected into a microcentrifuge 
221 
 
tube. Following centrifugation for 5 minutes at 1000rpm at 4°C (VWR, Micro Star 17R) cell pellets 
were stored at -20°C prior to RNA extraction. 
RNA was extracted from AC10-CMs using the RNeasy mini kit, following the manufacturer’s 
instructions (Qiagen, Germany).283 Briefly, cell pellets were thawed, 350µl RLT buffer added, and 
the pellet homogenized using a QIAshredder spin column. RNA was precipitated from the lysate 
by addition of 350µl 70% ethanol. The RNA was isolated from the sample using an RNeasy spin 
column and then on column DNA digestion performed using an RNase-Free DNase set, by 
washing in RW1 buffer, digestion of DNA using RDD buffer and DNase I for 15 mins, and a final 
wash in RW1 and RPE buffers to remove unwanted biomolecules and salts. RNA was eluted by 
addition of RNase free water and centrifugation of the column. RNA was stored at -80 °C. 
The quality and concentration of RNA in the samples was determined using the NanoDrop 2000c 
(Thermo Scientific, USA), analysing 1µl RNA sample relative to an RNase free water blank. The 
concentration of RNA in the samples was recorded, with a 260:280 absorbance ratio of greater 
than 1.8 confirming RNA quality. 
cDNA was synthesised using the RT2 First Strand Kit (Qiagen, Germany), according to the 
manufacturer’s instructions.284 Briefly, RNA was combined with genomic elimination (GE) and 
RNase-free water, to a total volume of 10µl, incubated at 42°C for 5 minutes, and then 
immediately placed on wet-ice ice. The reverse transcription reaction was developed by 
combination of the RNA sample (10µl) with Buffer BC3 (4µl), Control P2 (1µl), RNase-free water 
(3µl) and reverse transcriptase mix (2µl). The mixture was incubated at 42°C for 15 minutes and 
then rapidly incubated at 95°C for 5 minutes to halt the transcriptase reaction. The volume of 
reaction was then adjusted to a final amount of 111µl through addition of RNase-free water, 
and the cDNA stored at -20°C until required.  
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6.2.2.2  Pre-array verification of cDNA quality 
Before undertaking real-time PCR (qRT-PCR), the quality of the cDNA was ascertained by 
checking the expression of the GAPDH house-keeping gene using semi-quantitative reverse-
transcriptase PCR (RT-PCR). A PCR amplification mixture was created containing 10µl Taq MM 
(x2; New England Biolabs) 0.2µl GAPDH forward primer (5’-CCACCCATGGCAAATTCCATGGCA-3’), 
0.2µl GAPDH reverse primer (5’-TCTAGACGGCAGGTCAGGTCCACC-3’) (Invitrogen, UK), 2µl cDNA 
and 7.6µl RNase-free water. RT- PCR was then carried out using a thermocycler (Prime, Fischer 
Scientific, UK) on the samples using the following cycling conditions: 
 
Step            Temp (˚C)  Duration 
Initial denaturation and  
activation of polymerase 94  5minutes 
 
Denature   94  30Seconds 
Primer annealing  54  30seconds              
Extension   68  90seconds 
 
Final extension   68  5 minutes 
 
The PCR products were analysed by separation through a 1% (w/v) agarose gel, containing 0.01% 
ethidium bromide. Samples were combined with 10% loading dye (30% glycerol, 0.25% 
bromophenol blue) to allow sample visualisation and loaded into the gel alongside a DNA ladder 
(QuickLoad 100bp DNA ladder, New England Biolabs). Electrophoresis was performed in Tris-
Acetate EDTA buffer (TAE; 40mM Tris, 20mM acetic acid and 1mM EDTA) at 100V for 
approximately 1 hour. The gel was viewed using a ChemiDoc MP System (BioRad, UK) and 
30 cycles 
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ImageLab software (BioRad, UK). The expected PCR product size was 598bp, cDNA quality was 
deemed suitable if discrete bands of comparable intensity were observed.  
 
6.2.2.3  Real-time PCR of Gene expression arrays  
The qRT-PCR protocol and methodology was as per the manufacturers protocol.284 A reaction 
mixture was produced by combination of 102µl test cDNA, 1048µl RNase-free water and 1150µl 
RT2 SYBR Green ROX FAST 2x mastermix (Qiagen, Germany). To each well of the respective RT2 
Rotor-Disc 100 gene array, 20µl of the PCR mixture was added to each of the 100 wells. The 
plate was sealed, clipped into loading disc and locking ring, and inserted into the Rotor-Gene 
instrument (Qiagen, Germany). The associated RT2 Rotor-Gene template was loaded into the 
Rotor-Gene Q software (V2.0) and the programme initiated. After the qRT-PCR run, the baseline 
was automatically defined and the threshold cycle value (CT) determined for each well. Changes 
in gene expression for control and doxorubicin treated cDNA samples were analysed using the 
SABiosciences data analysis web based software. Data was normalised using automatic selection 
from the housekeeping gene panel on the qRT-PCR Array. The CT values for these genes were 
then used for the ∆∆CT calculations. This is normalized gene expression expressed as fold change 
and is calculated by dividing CT values from the test sample by the control sample values. Fold 
change values greater than one indicate an up regulation and fold change values less than one 
indicate down regulation. 
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6.3 Results  
6.3.1 Optimisation of western blotting for detection of the ATR1  
Initially, the soluble supernatant fraction of cellular lysis was analysed for expression of the 
angiotensin type I receptor (ATR1). At all protein concentrations tested no band corresponding 
to ATR1 expression (43kDa) was detected in these samples (Figure 6.2A), however detection of 
β-actin expression (42kDa) confirmed the successful transfer of proteins to the membrane 
(Figure 6.2B). 
Conversely, expression of ATR1 was detected in the whole cell lysates, containing both the 
soluble and insoluble proteins, at a level relative to the concentration of protein in the samples 
(Figure 6.3). This latter observation is indicative that the ATR1 is present in the insoluble fraction 
of the protein samples and whole cell lysates should be used for further experiments. 
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Figure 6.2 The ATR1 is absent from the soluble fraction of AC10 cardiomyocyte 
  cell lysates 
A. Western blot showing various concentrations of the soluble proteins from AC10-CM probed 
for the ATR1, expected band size 43kDa B. The same blot stripped and re-probed for β-actin, 
expected band size 42kDa. Protein concentration for each lane indicated on the top, arrows 
indicate location where bands would be expected, molecular markers for protein size are shown 
on the left.  
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Figure 6.3 The ATR1 is present in the insoluble fraction of AC10 cardiomyocyte cell 
  lysates 
Western blot showing various protein concentrations of the whole cell lysate from AC10-CM 
probed for the ATR1, expected band size 43kDa, arrow indicates location where bands would be 
expected. Protein concentration for each lane indicated on the top, molecular markers for 
protein size are shown on the left 
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6.3.2 Doxorubicin increases the expression of the ATR1 in AC10 
 cardiomyocytes 
The whole cell lysates of AC10-CMs treated with various concentrations of doxorubicin for 24 
hours showed an increase in the expression of ATR1 expression relative to vehicle control (Figure 
6.4A). Densitometric analyses of the ATR1/β-actin expression ratio shows that ATR1 expression 
is approximately 2-3 fold higher in AC10-CMs treated with doxorubicin, with the highest increase 
in expression in AC10-CMs treated with 250nM doxorubicin showing a 4.1 fold increase (Figure 
6.5). Although treatment with 500nM doxorubicin did increase ATR1 expression relative to 
vehicle control, the levels were lower than that observed with 250nM doxorubicin. This 
observation is similar to that observed when evaluating cytotoxicity (section 4.3.1), suggesting 
a relationship to cellular viability.    
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Figure 6.4 Doxorubicin increases the expression of the ATR1 in AC10  
  cardiomyocytes 
A. Representative western blot showing whole cell lysates of AC10-CMs treated with various 
concentrations of doxorubicin for 24 hours probed for the ATR1, B. The same blot stripped and 
re-probed for β-actin. Concentration of doxorubicin applied to AC10-CMs in each lane indicated 
on the top (VC = vehicle control), molecular markers for protein size are shown on the left, 
arrows indicate location where bands would be expected. All images are representative of n=4.  
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Figure 6.5 Doxorubicin treatment increases the expression of the ATR1 in AC10 
  cardiomyocytes – Densitometric analysis 
Densitometric analysis of 4 individual repeats of the western blot shown in Figure 6.4, showing 
fold change in ATR1 expression relative to vehicle control (normalised to β-actin expression)  
(n=4). Errors are calculated as standard errors of the mean.  
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6.3.3 Pre-array verification of cDNA quality  
Prior to conducting qRT-PCR gene arrays, the cDNA quality was ascertained by examining gene 
expression of a house-keeping gene in the control and treated samples using reverse 
transcriptase PCR (RT-PCR). Figure 6.6 shows that GAPDH was detected at visibly equal levels in 
cDNA samples generated from untreated and doxorubicin treated AC10-CMs and therefore is 
suitable for use in gene array experiments.  
 
 
 
Figure 6.6 GAPDH was detected at equal levels in cDNA generated from  
  untreated and doxorubicin treated AC10 cardiomyocytes 
Reverse-transcriptase PCR showing expression of GAPDH in cDNA generated from untreated and 
doxorubicin treated AC10-CMs, expected band size 598bp. Molecular markers for determination 
of product size shown on the left. 
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6.3.4 Doxorubicin alters expression of genes associated with 
 cardiotoxicity in AC10 cardiomyocytes 
Changes in gene expression in 84 genes involved in drug induced or chemical cardiotoxicity were 
assessed following exposure of AC10-CMs to 50nM doxorubicin for 24 hours, of which 21 genes 
showed greater than 2-fold changes to gene expression (Figure 6.7). This is outlined in figure 6.8 
and the full name and function of the proteins encoded by these genes is shown in table 6.2.  
 
Figure 6.7 Changes in gene expression profile of 84 genes involved in  
  cardiotoxicity following doxorubicin exposure in AC10 cardiomyocytes 
Out of 84 genes analysed, 21 showed more than a 2-fold change in gene expression. Increases 
in gene expression were recorded for 10 genes (green), and decreases in gene expression were 
recorded for 11 genes (blue) following exposure to 50nM doxorubicin for 24 hours 
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Figure 6.8 Doxorubicin alters expression of genes associated with cardiotoxicity in 
  AC10 cardiomyocytes 
Clustered bar graph showing genes with more than a 2-fold change in gene expression. Increases 
in gene expression were recorded for 10 genes (green), and decreases in gene expression were 
recorded for 11 genes (blue) following exposure to 50nM doxorubicin for 24 hours 
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Gene Full name Function 
UCP1 
Uncoupling protein 1 
(mitochondrial, proton carrier) 
Carries anions and protons between inner 
and outer mitochondrial membrane 
KLHL40 
Kelch repeat and BTB (POZ) 
domain containing 5 
Involved in protein-protein interactions, 
including actin and cullin 3 ubiquitin ligases 
HAMP Hepcidin antimicrobial peptide Iron regulation and metabolism 
PSMA2 
Proteasome (prosome, 
macropain) subunit, alpha 
type, 2 
Mediates ubiquitin-independent protein 
degradation 
CH25H Cholesterol 25-hydroxylase 
Lipid metabolism - Catalyses the formation 
of 25-hydroxycholesterol from cholesterol 
MT1F Metallothionein 1F 
Metal binding protein, plays a role in 
oxidative stress 
SPP1 Secreted phosphoprotein 1 Increased during myocardial dysfunction 
UXBN2A UBX domain protein 2A 
Ubiquitin regulatory proteins within the 
ubiquitination pathway 
POSTN 
Periostin, osteoblast specific 
factor 
ECM protein that supports cellular adhesion 
and migration  
VIM Vimentin Mesenchymal intermediate filament 
DUSP8 Dual specificity phosphatase 8 
Dephosphorylates and therefore inactivates 
target kinases, such as MAPKs which are 
involved in proliferation 
CCR1 
Chemokine (C-C motif) 
receptor 1 
GPCR involved in recruitment of immune 
cells to site of inflammation 
ADRA2A Adrenergic, alpha-2A-, receptor GPCR involved in adrenergic signalling 
TIAM1 
T-cell lymphoma invasion and 
metastasis 1 
Regulate RHO-like GTPases which are 
involved in actin dynamics 
SOX4 
SRY (sex determining region Y)-
box 4 
Transcription factor involved in embryonic 
development and determination of cell fate 
EGR1 Early growth response 1 Transcription factor 
CD14 CD14 molecule Immune system related co-receptor 
MCM6 
Minichromosome maintenance 
complex component 6 
Essential for DNA replication, part of DNA 
unwinding enzyme complex 
PVR Poliovirus receptor 
Involved in establishment of intercellular 
adherens junctions 
FCGR2B 
Fc fragment of IgG, low affinity 
IIb, receptor (CD32) 
Immune system related co-receptor 
ASH1L 
Ash1 (absent, small, or 
homeotic)-like (Drosophila) 
Transcriptional activator, regulates gene 
expression 
Table 6.2 Doxorubicin alters expression of genes associated with cardiotoxicity in 
  AC10 cardiomyocytes 
Full name and function of the genes with more than a 2-fold change in gene expression. 
Increases in gene expression were recorded for 10 genes (green), and decreases in gene 
expression were recorded for 11 genes (blue) following exposure to 50nM doxorubicin for 24 
hours 
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6.3.5 Doxorubicin alters expression of genes associated with GPCR 
 signalling in AC10 cardiomyocytes 
Changes in gene expression in 84 genes involved in G-protein coupled receptor (GPCR) signalling 
were assessed following exposure to 50nM doxorubicin for 24 hours, of which 40 genes showed 
greater than 2-fold changes to gene expression (Figure 6.9). This is outlined in figure 6.10 and 
the full name and function of the proteins encoded by these genes is shown in table 6.3. 
 
Figure 6.9 Changes in gene expression profile of 84 genes involved in GPCR  
  signalling following doxorubicin exposure in AC10 cardiomyocytes 
Out of 84 genes analysed, 40 showed more than a 2-fold change in gene expression. Increases 
in gene expression were recorded for 11 genes (green), and decreases in gene expression were 
recorded for 29 genes (blue) following exposure to 50nM doxorubicin for 24 hours. The gene 
shown in red was omitted due to the unusually large fold change recorded. 
 
 
 
 
 
235 
 
 
 
 
Figure 6.10 Doxorubicin alters expression of genes associated with GPCR signalling 
Clustered bar graph showing genes with more than a 2-fold change in gene expression. Increases 
in gene expression were recorded for 11 genes (green), and decreases in gene expression were 
recorded for 29 genes (blue) following exposure to 50nM doxorubicin for 24 hours. 
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Gene Full name Function 
VCAM1 Vascular cell adhesion molecule 1 
Cell adhesion molecule that is also 
involved in signal transduction in epithelial 
cells 
CRHR1 
Corticotropin releasing  
hormone receptor 1 
Important mediators in the stress 
response 
PTH1R Parathyroid hormone 1 receptor GPCR involved in calcium ion homeostasis 
VEGFA 
Vascular endothelial 
 growth factor A 
Signalling protein that stimulates 
angiogenesis 
MMP-9 Matrix metalloproteinase 9 
Involved in the degradation of the 
extracellular matrix 
SOCS1 
Suppressor of cytokine signalling 
1 
Down-regulate cytokine signalling  
RGS2 
Regulator of G-protein signalling 
2, 24kDa 
Increases activity of the Gα subunit  
SERPINE1 
Serpin peptidase inhibitor, clade 
E (nexin, plasminogen activator 
inhibitor type 1), member 1 
Inhibitor of tissue plasminogen activator 
(tPA) 
TSHR 
Thyroid stimulating hormone 
receptor 
Stimulates production of thyroxine and 
triiodothironine 
EDN1 Endothelin 1 
Precursor of the vasoconstrictor 
endothelin 
S1PR3 
Sphingosine-1-phosphate 
receptor 3 
GPCR involved in vascular endothelial cell 
function 
ELK1 
ELK1, member of ETS oncogene 
family 
Transcription factor involved in MAPK 
signalling 
JUNB Jun B proto-oncogene 
Component of the AP-1 transcription 
factor 
PDPK1 
3-phosphoinositide dependent 
protein kinase-1 
Kinase involved in signal transduction 
FOS 
FBJ murine osteosarcoma viral 
oncogene homolog 
Component of the AP-1 transcription 
factor 
CALCRL Calcitonin receptor-like GPCR involved in calcium ion homeostasis 
CASR Calcium sensing receptor GPCR involved in calcium ion homeostasis 
ADORA2A Adenosine A2a receptor GPCR involved in vasodilation 
CCNE1 Cyclin E1 Co-ordination of the cell cycle 
JUN Jun proto-oncogene Transcription factor  
IL1R1 Interleukin 1 receptor, type I 
Cytokine receptor involved in 
inflammatory response  
 
Table 6.3 Doxorubicin alters expression of genes associated with GPCR signalling 
  in AC10 cardiomyocytes (1) 
Full name and function of the genes with more than a 2-fold change in gene expression. 
Increases in gene expression were recorded for 11 genes (green), and decreases in gene 
expression were recorded for 29 genes (blue) following exposure to 50nM doxorubicin for 24 
hours. 
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Gene Full name Function 
GRM4 
Glutamate receptor, 
metabotropic 4 
Linked with inhibition of cyclic AMP 
signalling  
ADRB1 Adrenergic, beta-1-, receptor GPCR involved in adrenergic signalling 
CTGF Connective tissue growth factor 
ECM protein involved in cell adhesion, 
proliferation and migration 
GNAS GNAS complex locus Component of a G-protein alpha sub-unit  
GALR2 Galanin receptor 2  Neuromodulatory GPCR 
ICAM1 Intercellular adhesion molecule 1 Stabilises cell-cell interactions 
BCL2L1 BCL2-like 1 Apoptosis regulation 
COL1A1 Collagen, type I, alpha 1 Component of connective tissue 
GRM1 
Glutamate receptor, 
metabotropic 1 
Linked with inhibition of cyclic AMP 
signalling 
LPAR1 Lysophosphatidic acid receptor 1 GPCR involved in encouraging cell division 
EGR1 Early growth response 1 Transcription factor 
PRKCA Protein kinase C, alpha 
Protein kinase involved in diverse cellular 
signalling pathways 
GNAQ 
Guanine nucleotide binding 
protein (G protein), q polypeptide 
Involved in activation of G-protein subunits  
AGTRAP 
Angiotensin II receptor-
associated protein 
Negatively regulates angiotensin II 
signalling   
AKT1 
V-akt murine thymoma viral 
oncogene homolog 1 
Protein kinase involved in diverse cellular 
signalling pathways 
CFLAR 
CASP8 and FADD-like apoptosis 
regulator 
Regulator of apoptosis 
MAX MYC associated factor X Transcription factor 
CDKN1B 
Cyclin-dependent kinase inhibitor 
1B (p27, Kip1) 
Cell cycle inhibitor protein 
LPAR2 Lysophosphatidic acid receptor 2 GPCR involved in Calcium mobilisation 
 
Table 6.3 Doxorubicin alters expression of genes associated with GPCR signalling 
  in AC10 cardiomyocytes (2) 
Full name and function of the genes with more than a 2-fold change in gene expression. 
Increases in gene expression were recorded for 11 genes (green), and decreases in gene 
expression were recorded for 29 genes (blue) following exposure to 50nM doxorubicin for 24 
hours. 
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6.4 Discussion 
The purpose of this phase of the project was to build on evidence indicating that blockade of the 
angiotensin type 1 receptor (ATR1) reduces anthracycline-induced hypertrophy of in vitro 
cardiomyocyte models. By appreciating the molecular changes involved in these activities the 
objective is to better understand the interaction between angiotensin signalling and 
anthracycline-induced cardiotoxicity (AIC).  
The reduction in structural changes is thereby postulated to be due to direct interaction of 
angiotensin receptor blockers (ARB) with the ATR1 on cardiomyocytes. This is supported by 
observations in earlier phases of this study including angiotensin II induced hypertrophy of 
AC10-CMs and reduction of doxorubicin induced hypertrophy by angiotensin receptor blockade. 
Embedded within the cell membrane, the ATR1 is a G-protein coupled receptor (GPCR) 
responsible for mediating cellular responses to angiotensin II.76,231  
 
6.4.1 Analysis of ATR1 expression in AC10 cardiomyocytes  
In order to address this hypothesis is was thus important to evaluate selective expression of 
ATR1. The structural similarities between receptors that constitute the GPCR receptor family is 
reported to complicate their individual analysis, so this study evaluated ATR1 expression using 
an antibody against the extracellular N-terminus of the receptor, an epitope associated with part 
of ATR1 responsible for binding angiotensin II. Several studies have shown many of the residues 
that form this section of the receptor to be unique to ATR1,285 unlike other receptor areas (such 
as the intracellular loops and C-terminus), as these areas are more structurally similar to other 
GPCRs.286  
The ATR1 receptor protein was undetectable in the soluble fraction of the cell lysate of AC10-
CMs; however was easily detectable when the whole cell lysate (which contains both soluble 
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and insoluble proteins) was used, with bands of expected size detected in samples containing as 
little as 20µg of protein from the whole cell lysate of AC10-CMs. Analysis of the expression of 
the ATR1 following exposure of AC10-CMs to doxorubicin for 24 hours revealed that the 
expression of the ATR1 relative to the vehicle control was approximately 2-3 fold higher in AC10-
CMs treated with doxorubicin, with the highest increase in expression in AC10-CMs treated with 
250nM doxorubicin where a 4.1 fold increase was observed. Although treatment with 500nM 
doxorubicin did increase ATR1 expression relative to vehicle control, the levels were lower than 
that observed with 250nM doxorubicin. This observation is similar to that observed when 
evaluating cytotoxicity suggesting a relationship to cellular viability.  The increase in expression 
of the ATR1 in cells treated with doxorubicin may also cause increased levels of angiotensin 
signalling which will be discussed further later. 
A recent study conducted by Huang et al. also reported upregulation of the ATR1 following 
doxorubicin treatment in the rat myoblast H9c2 cell line.287 The increase in ATR1 expression was 
also found to occur in both a time dependent and dose dependent manner, albeit it at levels 
significantly higher than clinical cardiac exposures. These findings are in accordance with the 
results of the current study, however using a rodent rather than human derived cell line.  The 
rodent study also provided further direct evidence of an interaction between doxorubicin-
induced cardiotoxicity and increased angiotensin signalling, as levels of the G-protein Gαq also 
increased after doxorubicin treatment, substantiating the involvement of angiotensin signalling 
in doxorubicin induced cardiotoxicity.287 
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6.4.2 Molecular interactions between angiotensin signalling and 
 anthracycline-induced cardiotoxicity 
In order to elucidate the mechanisms by which anthracyclines facilitate angiotensin 
involvement, as being either direct induction of ATR1 or a consequence of perturbation of a 
subcellular signalling pathway, it was important to examine doxorubicin effects upon 
cardiomyocyte pathways. Changes in gene expression of 84 genes involved in drug induced or 
chemical cardiotoxicity were assessed following exposure of AC10-CMs to subclinical levels of 
doxorubicin, of which 21 genes showed greater than 2-fold changes to gene expression. 
Additionally, of the 84 genes involved in GPCR signalling evaluated, doxorubicin-induced greater 
than 2-fold changes relative to control cells in 40 genes. For the purposes of this project a 
selection of genes were chosen from each array and appraised with respect to their potential 
impact on anthracycline-induced cardiotoxicity (AIC) and relationship to angiotensin signalling.    
 
6.4.2.1  Gene changes relating to anthracycline-induced cardiotoxicity  
  mechanisms  
It is well reported that doxorubicin induces oxidative stress within cardiomyocytes.16,34,91 One of 
the highest changes in gene expression was observed in UCP1, an uncoupling protein and 
mitochondrial transporter responsible for decreasing the proton gradient associated with 
oxidative phosphorylation.288 Therefore, unsurprisingly, doxorubicin alters mitochondrial 
bioenergetics and alters proteins involved with physiological regulation of ROS.  
Similarly, doxorubicin increases expression of the regulator of iron homeostasis Hepcidin 
antimicrobial peptide (HAMP), involved in inhibiting the iron transport protein ferroportin and 
transport of iron outside the cell.289 Disruption of this gene is indicative of altered cardiomyocyte 
iron handling, culminating in formation of doxorubicin-iron complexes, formation of ROS 
through its association with the inner mitochondrial membrane (See section 1.7.1.1.1), further 
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adding to cardiomyocyte oxidative stress and the effects manifested through UCP1 
dysregulation. 
Doxorubicin changes in cardiomyocyte structure and subsequent cardiac hypertrophy are also 
reflected in genetic changes observed in treated AC10-CMs. The reduced expression of dual 
specificity phosphatase 8 (DUSP8) is associated with increased activity of MAPK signalling 
pathways, strongly associated with regulation of cardiac hypertrophy and remodelling in 
response to increased workload or pathological insults.290 Similarly, increased gene expression 
of the proteasomal subunit PSMA2 and proteins involved in the ubiquitination pathway 
(UXBN2A) following doxorubicin treatment indicates an increase in cellular proteolytic activities, 
linked to restructuring of contractile and structural proteins in cardiomyocytes.291 The 
observation that expression of the transcription factor SOX4 was downregulated also adds to 
the cardiac remodelling aspects of doxorubicin-induced toxicity, through its role in controlling 
cell fate and cardiac development, and thus cardiomyocyte differentiation and sensescence.292 
Transcriptional repression is also an effect of anthracycline treatment, which can affect the 
expression of critical genes in cardiomyocytes.293 For example, JUNB is reported to be essential 
in maintenance of sarcomeric Z-disc structure and therefore crucial in maintaining sarcomere 
architecture and function.294 Indeed in the current study the transcription factors ELK1, JUNB, 
FOS and EGR1 showed reduced expression which may relate to reductions in the expression of 
genes that are essential for cardiomyocyte function.  
 
6.4.2.2  Gene changes relating to anthracycline-induced cardiotoxicity and 
  angiotensin signalling 
The induction of matrix metalloproteinase-9 (MMP-9) gene expression by doxorubicin adds to 
the structural remodelling activities of doxorubicin. The MMPs are central mediators of cellular 
remodelling such as ventricular dilation in the clinic.295 Indeed, increased MMP activity is 
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associated with chronic doxorubicin cardiotoxicity and a recent study has linked acute 
doxorubicin treatment to increases in MMP-2 activity.296 Unfortunately, MMP-2 was not 
evaluated in the current study. Importantly for this study, angiotensin II treatment is also 
reported to increase expression of MMP-9 in a monocyte cell line,297 and also in rats in the 
context of cardiac hypertrophy298 thus the increase in MMP-9 gene expression in the current 
study supports synergism between AIC and angiotensin signalling.  
Corticotropin-releasing hormone receptor 1 (CRHR1) is also upregulated by doxorubicin in 
cardiomyocytes, with an involvement in the response to stress. Although this protein is primarily 
located in the nervous system, it is expressed at lower levels in other tissues including the 
heart.299 Many studies have related angiotensin II exposure increases expression of CRHR1 or its 
agonist corticotrophin releasing hormone (CRH), and found that antagonism of the ATR1 
reduces the levels of the receptor and agonist.300 In addition CRHR1 has been linked to local 
inflammatory responses,301 which links ATR1 activation with the occurrence of doxorubicin-
induced hypertrophy in the current study. 
One of the greatest genes upregulated in AC10-CMs following doxorubicin exposure when 
analysing the GPCR signalling pathway is vascular cell adhesion molecule 1 (VCAM1). This gene 
codes for an adhesion molecule on endothelial cells, with a central role in atherosclerotic lesion 
formation.302 Interestingly, Pueyo et al. have shown angiotensin II stimulates both gene and 
protein expression of VCAM-1 via signalling through the ATR1 and relates to induction of 
intracellular oxidative stress.303 Consequently, this suggests a mechanism for activation of the 
ATR1 as a response to doxorubicin independent of angiotensin II activity. As stimulation of 
VCAM-1 is associated with induction of intracellular oxidative stress which is a cardiotoxicity 
mechanism of anthracyclines this also suggests a link between angiotensin signalling and AIC. 
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6.4.2.3  Gene changes relating to angiotensin signalling  
Changes in gene expression of components required for angiotensin signalling were also 
observed following exposure to doxorubicin. For example the regulator of G-protein signalling 2 
(RGS2) which is involved in increasing activity of the Gα subunit304 showed increased expression. 
This is in agreement with the study by Huang et al. who reported that the levels of the G-protein 
Gαq increased after doxorubicin treatment, substantiating the involvement of angiotensin 
signalling in doxorubicin-induced cardiotoxicity.287 Similarly in the current study, expression of 
Angiotensin II receptor-associated protein (AGTRAP) decreased; AGTRAP is believed to 
negatively regulate angiotensin signalling305 therefore decreased expression suggests an 
increase in angiotensin signalling in response to doxorubicin treatment. However some genes 
that would be associated with increased angiotensin signalling decreased following doxorubicin 
treatment, such as GNAS and GNAQ which form components of G-protein alpha sub-units306 and 
are involved in the activation of G-protein subunits307 respectively.  
Genes usually stimulated by angiotensin II were also found to increase following doxorubicin 
treatment which suggests a link between angiotensin signalling and AIC. For example 
endothelin-1 gene expression increased following doxorubicin exposure; endothelin-1 is a 
vasoconstrictor that was found to be stimulated by angiotensin II in rat smooth muscle cells.308 
Similar to the study described above, angiotensin II has been found to stimulate expression of 
Parathyroid hormone receptor 1 (PTH1R) via the ATR1 in the kidney where it has damaging 
effects309 and angiotensin II also stimulates VEGF gene expression in rat heart endothelial cells, 
inhibited by addition of the ATR1 antagonist losartan.310 In this study, both PTHR1R and VEGFA 
were found to be upregulated following doxorubicin treatment, thereby providing further 
evidence for upregulation of angiotensin signalling as a consequence of doxorubicin therapy. 
A large decrease in gene expression of the α2A-adrenergic receptor (ADRA2A) and β1 adrenergic 
receptor (ADRB1) was reported in the current study following doxorubicin treatment. This may 
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also relate to angiotensin signalling as previous work in neonatal rat cardiomyocytes concluded 
that angiotensin II down-regulated mRNA levels of the α1A-adrenergic receptor, which was 
ATR1 dependent.311 This also suggests a mechanism for activation of the ATR1 as a response to 
doxorubicin independent of angiotensin II activity. 
Although some of the changes in gene expression are more difficult to specifically relate to 
angiotensin signalling or doxorubicin cardiotoxicity, the results in this section provide 
preliminary evidence that treatment of AC10-CMs with doxorubicin causes changes in gene 
expression that relate both to the cardiotoxicity mechanisms of anthracyclines and increased 
levels of angiotensin II signalling. In addition, there appears to be some areas of overlap between 
genes involved in anthracycline cardiotoxicity and genes stimulated by angiotensin signalling, 
which cause similar cellular effects (Figure 6.11). This implicates angiotensin signalling as having 
a direct effect on cardiomyocytes and potentiating the pathogenesis of doxorubicin mediated 
cardiotoxicity. As these results are preliminary, further work is needed to verify the changes in 
gene expression discussed, the work described herein is indicative of dysregulated pathways 
however further analyses are required to ascertain significance.  
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Figure 6.11 Molecular changes in doxorubicin treated AC10 cardiomyocytes that 
  potentially signify a relationship between anthracycline-induced  
  cardiotoxicity and the angiotensin signalling pathway via the ATR1 
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6.4.3 Conclusion 
The purpose of this phase of the project was to build on evidence from the previous chapter 
indicating that blockade of the angiotensin type I receptor (ATR1) reduces doxorubicin induced 
hypertrophy and increases survival of in vitro cardiomyocyte models. Treatment of AC10-CMs 
with doxorubicin caused a 2-3 fold increase in the level of ATR1, activation of which may occur 
due to the biomechanical stress caused by doxorubicin-induced hypertrophy. In addition to 
increased expression of the ATR1, doxorubicin treatment also caused changes in gene 
expression relating to the drug’s mechanisms of cardiotoxicity and indicative of induction of 
angiotensin signalling. 
In addition, there appears to be some areas of overlap between genes with altered expression 
that are involved in both anthracycline cardiotoxicity mechanisms and genes stimulated by 
angiotensin signalling; which cause similar cellular effects including increased oxidative stress, 
cellular remodelling and hypertrophy. Although further work is needed to verify and add to the 
changes in gene expression discussed, the work described implicates angiotensin signalling as 
having a direct effect on cardiomyocytes and potentiating the pathogenesis of doxorubicin 
mediated cardiotoxicity. This suggests synergism between doxorubicin induced cardiotoxicity 
and angiotensin signalling and supports the use of these pharmaceuticals such as angiotensin 
receptor blockers for protection against doxorubicin-induced cardiotoxicity.
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Chapter 7: Final discussion 
The cardioprotective potential of therapies that act on the angiotensin signalling pathway has 
been demonstrated in recent clinical studies,152 which strongly suggests that a relationship exists 
between anthracycline-induced cardiotoxicity (AIC) and angiotensin signalling (See table 1.2).  
Although a number of in vivo studies have added further support for the cardioprotective nature 
of these drugs,257,258,260,263 there is a lack of in vitro studies, and the molecular mechanisms 
underpinning the cardioprotective mechanisms are currently unclear. The overall aim of this 
study was to investigate the structural and functional cardiotoxicities caused by anthracyclines 
using in vitro models paired with impedance-based technology, and to ascertain if toxicity 
mitigation was detectable in these models upon concomitant administration of drugs that 
perturb angiotensin signalling.   
Initially the in vitro cardiomyocyte cell models (AC10 cardiomyocyte cell line (AC10-CMs) and 
hiPSC-derived cardiomyocytes (hiPSC-CMs)) were developed and qualified for use in the in vitro 
assessment of structural and functional drug-induced cardiotoxicity, using impedance-based 
methodologies.205,210 Changes in cellular viability, morphology and functionality were assessed 
using impedance-based detection (xCELLigence technology) in response to the cardiac 
regulatory factor angiotensin II and the anti-cancer drug sunitinib. Overall, both cell models 
responded as clinically expected to both agents and both structural cardiotoxicity and functional 
changes to cell behaviour were observed.        
As a well known mediator of cardiac hypertrophy angiotensin II was used to qualify the in vitro 
models for detection of structural cardiotoxicity.228 Changes in morphology indicative of a 
hypertrophic response was detected in AC10-CMs and hiPSC-CMs following addition of 
physiologically relevant doses of angiotensin II, and analysis of contractility of hiPSC-CMs 
uncovered functional disturbances immediately after angiotensin II addition. The increases in 
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beat number and decreases in beat amplitude observed immediately after angiotensin II 
addition are in agreement with previous studies which reported positive chronotropy and 
negative inotropy in isolated rat cardiomyocyte cultures following exposure to angiotensin II for 
a few minutes.230 
The anti-cancer drug sunitinib is associated with numerous cardiotoxicities including 
development of arrhythmias, hypertension and impairments to ventricular function.98 As a well 
known functional cardiotoxicant and mediator of cardiac hypertrophy, it was used to qualify the 
in vitro models used in this study for detection of functional and structural cardiotoxicity. 
Induction of dose-dependent hypertrophy was observed following repeated addition of clinically 
relevant concentrations of sunitinib in AC10-CMs and hiPSC-CMs, with all three concentrations 
of sunitinib causing an immediate and sustained increase in cell index. Analysis of contractility 
in the hiPSC-CMs revealed that sunitinib also caused dose-dependent decreases in beat number 
and increased beat amplitude with 500nM sunitinib following 72 hour exposure. The changes 
observed in cell morphology and contractility are in agreement with other studies, for example 
Doherty et al. reported an enlarged hypertrophic like cell shape of hiPSC-CMs following 
exposure to 3µM sunitinib for 48 hours, and dose-dependent reductions in beat rate following 
2 hours and 24 hours exposure to 625nM, 2.5µM and 10µM sunitinib.232 
This study is the first to demonstrate both angiotensin II induced hypertrophy and sunitinib 
induced hypertrophy using impedance based systems and the in vitro AC10-CM and hiPSC-CM 
using human derived cell models. Previously, many in vitro studies involving angiotensin II have 
been conducted on primary cardiomyocytes from animals. Therefore the findings from the 
current study possess significant 3R’s benefits as they demonstrate that the human derived in 
vitro models used are able to respond as expected to the hypertrophic mediator and therefore 
may replace or reduce the use of primary cardiomyocytes from animal sources for these 
purposes which require difficult culture techniques and animal sacrifice.218 
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In contrast to previous studies, where hypertrophy was detected at higher sunitinib 
concentrations, this study identified sunitinib hypertrophy at lower clinically relevant doses over 
prolonged periods that are more reflective of clinical exposures. This illustrates the utility of the 
xCELLigence systems to detect morphology changes to AC10-CMs and hiPSC-CMs in a manner 
that is translational to the clinical setting. The use of these in vitro models for detection of 
hypertrophy extends towards improved pre-clinical testing of pharmaceuticals as a means for 
early identification of structural cardiotoxicity. As mentioned in earlier chapters, the current 
method of pre-clinical testing for cardiac liabilities focusses narrowly on the ability of 
compounds to block the hERG potassium channel in vitro, followed by evaluation of the ability 
to prolong ventricular repolarisation and therefore prolong the QT-interval in vivo.177 This 
screening strategy completely overlooks the development of structural changes, which are 
associated with a number of cancer therapeutics with the potential to cause cardiovascular 
liabilities.29,34 Structural changes can have a huge impact on the pumping ability of the heart, 
therefore early identification of the problem is of crucial importance.    
Further qualification for the use of the methods developed in chapter 3 for identification of 
structural cardiotoxicity is necessary and could be achieved by comparison of the effects of a 
known cardiotoxicant (such as sunitinib) and a drug that is not associated with clinical 
cardiotoxicity using the methods developed in chapter 3. A recent paper by Sharma et al. used 
hiPSC-CMs generated from 11 healthy individuals and 2 patients receiving cancer treatment, to 
screen tyrosine kinase inhibitors (TKI) for cardiotoxicities by measuring alterations in 
cardiomyocyte viability, contractility, electrophysiology, calcium handling, and signalling. Using 
this data, a cardiac safety index was generated to reflect the cardiotoxicities of the TKIs tested.312 
In agreement with clinical observations and the current study, sunitinib was assigned a relatively 
low cardiac safety index score, indicating that it has a high association with cardiotoxicity. 
Interestingly axitinib, a TKI with similar therapeutic targets to sunitinib, was not associated with 
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any cardiotoxicity occurrence, and therefore may be a suitable choice for future studies to 
further qualify these models for identification of structural cardiotoxicity.  
Although cardiomyocytes are the cell type in the heart responsible for contraction and therefore 
gain a lot of attention in the area of pre-clinical screening for cardiotoxic effects, there are other 
cell types in the heart which may also be a target of drug-induced cardiotoxicity.53 Pericytes were 
identified as a cellular target associated with sunitinib cardiotoxicity by Chintalgattu et al., where 
sunitinib treated mice developed coronary microvascular dysfunction and exhibited an impaired 
cardiac response to stress. These physiological changes were accompanied by a substantial 
depletion of coronary microvascular pericytes; whose function is dependent on platelet derived 
growth factor receptor (PDGFR) signalling. Sunitinib induced pericyte depletion and coronary 
microvascular dysfunction were recapitulated by a structurally distinct PDGFR inhibitor 
therefore confirming the role of PDGFR in pericyte survival and PDGFR inhibition in pericyte 
related sunitinib induced cardiotoxicity.102 On a similar note, the co-culture of rat 
cardiomyocytes with fibroblasts was found to enhance cardiomyocyte hypertrophy in response 
to angiotensin II.229 These examples illustrate both the importance of paracrine signalling in 
normal physiological functioning of the heart and the crucial role of support cells such as 
fibroblasts and pericytes which are also a target for drug-induced cardiotoxicity. The inclusion 
of other cell types in addition to cardiomyocytes in pre-clinical cardiotoxicity screening would 
allow for a more complete assessment of the cardiotoxic potential of drugs, and would be useful 
to include within screening paradigms. 
The previously developed in vitro models and methods were used to determine if the structural 
and functional acute cardiotoxicity induced by the notoriously cardiotoxic anthracyclines can be 
recapitulated in vitro. Changes in cellular viability, morphology and functionality were assessed 
using impedance-based detection (xCELLigence technology) in response to the anthracyclines 
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doxorubicin, daunorubicin and epirubicin. Overall, all of the anthracyclines induced structural 
changes in both cell models and functional changes to cell behaviour were also observed.  
The induction of hypertrophy that was observed in AC10-CMs and hiPSC-CMs following 
exposure to clinically relevant doses of doxorubicin demonstrates the detection of structural 
cardiotoxicity which may relate to the inflammatory acute cardiotoxicity response of 
doxorubicin. This manifests as transient arrhythmias and inflammation and may be involved in 
increasing susceptibility to the more severe chronic forms of cardiotoxicity.141,144 The 
morphological changes to hiPSC-CMs were paired with altered contractility within 24 hours for 
all doses of doxorubicin used, and changes in contractility with the highest dose (250nM) applied 
were detected following just 6 hours exposure. Although the effects of doxorubicin on hiPSC-
CMs has been assessed by many groups previously, the main focus was primarily on identifying 
changes to beat parameters using higher doses of doxorubicin.249 This approach lacks clinical 
significance as the doses used are much higher than exposure levels in the body and are toxic to 
cells; therefore cell death occurs which makes acute toxicity responses such as hypertrophy 
difficult to ascertain. The results of the current work have shown that it is possible to detect 
both hypertrophy and contractile disturbances in human derived cell types using novel 
methodologies permissive of real-time and physiologically relevant analyses; with cellular 
changes occurring in response to clinically relevant concentrations of doxorubicin in as little as 
6 hours. Thus providing additional data to support the use of these cells on an impedance-based 
platform in screening assays for detection of structural toxicity. 
Very similar results were obtained when clinically relevant concentrations of doxorubicin, 
epirubicin and daunorubicin were compared using the same methodology.  Little distinction was 
observed between the toxicity profiles attained for these anthracyclines where studies revealed 
similar IC50 values in AC10-CMs, similar levels of hypertrophy in AC10-CMs and hiPSC-CMs and 
similar aberrations to contractility following 24 hours exposure to anthracyclines. The lack of 
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distinction between the severity of toxicity induced by the anthracyclines does not align with 
the current clinical view that epirubicin is less cardiotoxic than doxorubicin.237  However there 
are many additional factors, both pharmacokinetic and pharmacodynamic, that influence the 
development of clinical cardiotoxicity,253 which are not accounted for using in vitro 
cardiomyocyte models. An interesting addition to the current study would be to utilise 3D 
cardiomyocyte spheroid models and imaging techniques to assess if anthracycline treatment 
causes enlargement (hypertrophy) of the spheroids.198 Spheroid models more accurately 
recapitulate the in vivo cellular morphology and physiology than that of the more commonly 
used 2D cell models and are often developed to constitute different cell types (such as 
fibroblasts and endothelial cells).197 Studies in cardiomyocytes, endothelial cells and fibroblasts 
isolated from neonatal rat hearts found that fibroblasts and endothelial cells were more 
sensitive to doxorubicin-induced cardiotoxicity than cardiomyocytes, thus illustrating that 
adverse effects following anthracycline exposure also in occur in other cell types of the heart.255 
Therefore the use of multicellular spheroid models would allow for the influence of these cell 
types on anthracycline-induced hypertrophy in a physiologically relevant manner.   
Following detection of anthracycline-induced hypertrophy using in vitro cardiomyocyte models 
the possibility of using pharmaceuticals to reduce the hypertrophy and improve cell survival was 
explored. The mitigation of doxorubicin-induced cardiotoxicity using drugs that perturb 
angiotensin signalling has been investigated in both clinical studies135,152,164,166,167 and pre-
clinically in vivo257,258,260,263 with encouraging results, however the number of in vitro studies in 
this area remains limited. In addition, the direct effects upon and involvement of the cardiac 
system, as well as the molecular mechanism of cardioprotection have yet to be resolved.  To 
address these issues the formerly developed in vitro models and methods were used to 
determine if the previously elucidated structural and functional acute toxicity induced by 
doxorubicin in these models can be reduced by drugs that reduce angiotensin signalling. 
Changes in cellular viability, morphology and functionality were assessed using impedance-
253 
 
based detection (xCELLigence technology) in response to the doxorubicin alone and in 
combination with drugs that augment angiotensin signalling. Angiotensin receptor blockers 
(ARB) increased cell viability of AC10-CMs and reduced the hypertrophic responses of both cell 
models treated with doxorubicin, whereas angiotensin converting enzyme inhibitors (ACEi) had 
no protective effects.  
Due to the mechanism of action of ACEi it is unlikely that they would have been functionally 
active in the cell models used in this study (Discussed in section 5.4.2), therefore the protective 
effects that have been previously demonstrated in clinical and in vivo studies were not present 
in this in vitro study.  This is because in more complex models (in vivo) all of the elements 
required for angiotensin synthesis would be present, therefore in these models ACEi would be 
able to decrease angiotensin signalling, whereas in the current study the ACEi had no cellular 
target.231,268 The lack of direct interaction of ACEi with cardiomyocytes is illustrated in toxicity 
studies where the compounds alone exhibited negligible toxicity to AC10-CMs. In contrast, 
addition of the ARB telmisartan and losartan at 10µM yielded survival rates of 84% and 70% 
respectively which suggests direct interaction with the drugs’ target, the angiotensin type I 
receptor (ATR1).264 Indeed treatment with these ARB improved the viability of AC10-CMs 
treated with doxorubicin, whilst reducing hypertrophic responses in AC10-CMs and hiPSC-CMs, 
and importantly did not interfere with the efficacy of doxorubicin at killing cancer cells.       
Because the current study was conducted in vitro, unlike previous studies it is focussed on direct 
evaluation of cardiomyocyte behaviour independent of systemic effects. The reduction in 
cardiomyocyte hypertrophy and improved viability observed in this study demonstrates that 
perturbation of angiotensin signalling in the context of doxorubicin-induced cardiotoxicity has 
direct protective effects on cardiomyocytes. This may relate to a reduction in the acute 
cardiotoxicity response which potentially primes cardiomyocytes for the more severe forms of 
cardiotoxicity that involve cardiac remodelling and ventricular hypertrophy.113,144 Other work 
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has demonstrated that perturbation of angiotensin signalling is also useful for protecting 
endothelial cells from anthracycline-induced damage.313 Due to the crucial role of cardiac 
endothelial cells in maintaining heart function, protection of these cells from AIC provides and 
additional benefit of reducing angiotensin signalling in patients treated with anthracyclines; in 
addition to systemic effects and the direct effect on cardiomyocytes demonstrated in the 
current study.  
Further work to confirm that the reduction of doxorubicin-induced hypertrophy of 
cardiomyocytes by administration of ARB occurs via an ATR1 specific mechanism could 
encompass the use of siRNA to silence expression of the ATR1 in AC10-CMs, and then challenge 
the cells with doxorubicin and ARB in an identical manner. If the reduction in hypertrophy is 
absent and cell viability is not improved in cells with silenced ATR1 then this would illustrate that 
the protection afforded by ARB in doxorubicin-induced cardiotoxicity is ATR1 specific and further 
implicates angiotensin signalling in facilitation of the toxicity.  
Another interesting addition to the current work would be to utilise patient specific hiPSC-CMs. 
A recent paper by Burridge et al. demonstrated that patient specific hiPSC–CMs can recapitulate 
individual patients’ predilection to doxorubicin-induced cardiotoxicity at the cardiomyocyte 
level.314 Cells derived from breast cancer patients who suffered clinical doxorubicin-induced 
cardiotoxicity were consistently more sensitive to doxorubicin toxicity, demonstrating 
decreased cell viability, increased sarcomeric disarray and impairments to contractility 
compared to hiPSC–CMs from patients who did not experience doxorubicin-induced 
cardiotoxicity. With reference to the current study, it would be useful to use cells such as those 
derived by Burridge et al. to investigate whether the cells from patients who suffered 
doxorubicin-induced cardiotoxicity are a) More prone to doxorubicin-induced hypertrophy and 
b) If ARB therapy is able to reduce hypertrophy in all or just some patient cells. This would help 
to uncover how relevant doxorubicin-induced hypertrophy of hiPSC–CMs is and therefore also 
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the importance of the acute toxicity response with respect to the risk of developing clinical 
chronic cardiotoxicity, and to what extent ARB treatment may be helpful. Patient specific hiPSC–
CM models such as this would be a useful tool for continuation of work in this area in a 
translational manner to further clarify the role of angiotensin signalling in doxorubicin-induced 
cardiotoxicity.  
The response of the AC10 in vitro cardiomyocyte model to anthracyclines +/- ARBs in this study 
was evaluated using mainly a combination of the MTT cellular viability assay and impedance-
based technologies. As the toxicity mechanisms of anthracyclines involve perturbations to 
mitochondrial function (See section 1.7.1.1) and the MTT assay relies on mitochondrial 
conversion of tetrozolium to formazan as a measure of cell viability, the readings may not have 
been wholly accurate of viable cells as some cells may have still been viable but suffered reduced 
mitochondrial activity due to anthracycline treatment. Therefore, it may be useful to pair the 
MTT assay with other measures of cellular viability such as ATP assays, protease assays or trypan 
blue exclusion assays. Trypan blue exclusion assays allow identification of both viable and dead 
cells which would thereby complement and verify of the viability assessments from MTT assays. 
The response of hiPSC-CMs to anthracyclines +/- ARBs was evaluated using impedance-based 
technology only. As impedance readings are a measure of cellular contact with electrodes on 
the bottom of the wells, increases in impedance can represent either increased cell number or 
cell size, whereas decreases in impedance represent reductions in cell number or decreases in 
cell size. The occurrence of cellular hypertrophy of in vitro cardiomyocyte models upon 
anthracycline treatment and reduction with concomitant ARB treatment was a key finding from 
impedance-based technology in this study – Which in AC10-CMs was verified using a 
combination of the MTT assay and imaging. It would be worthwhile to perform similar studies 
with hiPSC-CMs to verify the occurrence of hypertrophy (i.e. check that the increased impedance 
is not due to increased cellular proliferation) as this would complement the hiPSC-CM data set 
presented in this study and confirm the findings. A further consideration for the use of 
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impedance-based technology for determination of cellular hypertrophy is that as well as 
increases in cellular dimensions on a 2D level (well plate surface) which is detectable by 
impedance changes, it is likely that cells would also increase on a 3D level (i.e. vertically). This 
would not be detectable by impedance-based technology therefore use of 3D spheroid models 
may be applicable for further work in this area.   
Because the mitigation of doxorubicin-induced cardiotoxicity by drugs that perturb angiotensin 
signalling suggests a direct role of angiotensin II in facilitating this toxicity, the effects of co-
administration of angiotensin II and doxorubicin with respect to changes in cellular viability, 
morphology and functionality were assessed in this study. Overall, the combination of 
angiotensin II and doxorubicin did not affect viability and morphology of AC10-CMs and hiPSC-
CMs any more than cells treated with doxorubicin alone. This may be due to the use of short 
exposure times that did not allow for the accumulation of further structural damage, or the use 
of simplistic in vitro models that do not fully represent the complexity of the cardiovascular 
system and human body. Altered contractility, however, was observed following 24 hours 
exposure to doxorubicin and angiotensin II, where a decrease in beat amplitude of hiPSC-CMs 
was seen compared to cells treated with doxorubicin only. As a decrease in beat amplitude 
relates to negative inotropy (reduced force of muscle contraction), the reduced beat amplitude 
may be due to increased impairment to the contractile machinery of the cells and myofibrillar 
loss, however more work would be needed to clarify this. 
Further work in elucidating the link between angiotensin signalling and doxorubicin-induced 
cardiotoxicity focussed on molecular changes that occur in AC10-CMs following doxorubicin 
treatment which may relate to angiotensin signalling, thereby indicating an interaction between 
angiotensin signalling and doxorubicin cardiotoxicity. Treatment of AC10-CMs with doxorubicin 
caused a 2-3 fold increase in the level of ATR1 expression and also induced changes in gene 
expression that relate both to the cardiotoxicity mechanisms of anthracyclines and increased 
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levels of angiotensin II signalling. In addition, there appears to be some areas of overlap between 
genes with altered expression that are involved in both anthracycline cardiotoxicity mechanisms 
and genes stimulated by angiotensin signalling; which cause similar cellular effects including 
increased oxidative stress, cellular remodelling and hypertrophy. Although further work is 
needed to verify and add to the changes in gene expression discussed, the work described 
implicates angiotensin signalling as having a direct effect on cardiomyocytes and potentiating 
the pathogenesis of doxorubicin mediated cardiotoxicity.  
As the current study was conducted in vitro, the cardiomyocytes were not exposed to circulating 
levels of angiotensin II that would ordinarily bind to the ATR1 and initiate signalling cascades. 
Evidence suggests that biomechanical stress (such as exposure to doxorubicin causing 
hypertrophy) to cardiomyocytes in vitro can induce changes to cardiomyocytes including the 
induction of ATR1 activation independent of agonist binding,272 which may also be responsible 
for ATR1 activation in the current study. Considering this, in addition to exposure of a patient’s 
myocardium to doxorubicin causing hypertrophy (biomechanical stress) and subsequent ATR1 
activation independent of angiotensin II, patients (unlike an in vitro system)  will also be exposed 
to circulating angiotensin II which will further magnify and become additive to effects caused by 
anthracyclines, further exaggerating cardiac stress. However, the observations described in this 
study are focused specifically on the direct effects upon the cardiomyocyte and thereby 
elucidate the underpinning molecular mechanisms. 
This has clinical implications as the level of angiotensin II that patients have is determined by 
the genotype of their angiotensin converting enzyme (ACE), which is responsible for the final 
step of angiotensin II production. There are three ACE genotypes: I/I, I/D and D/D, which are 
associated with low, medium and high levels of angiotensin II respectively.315 Evidence suggests 
that the D/D genotype is a risk factor for heart disease,316 and therefore this risk factor may 
extend to doxorubicin-induced cardiotoxicity. Therefore in addition to using patient derived 
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hiPSC-CMs for investigating if those who suffered doxorubicin-induced cardiotoxicity are more 
prone to doxorubicin-induced cardiomyocyte hypertrophy and evaluating if ARB therapy is able 
to reduce hypertrophy, it would also be useful to link this information to patient genotype and 
identify the impact of ACE genotype and angiotensin II levels to the risk of developing 
doxorubicin-induced cardiotoxicity.  
 
7.1 Conclusion         
The current study has qualified the AC10-CM and hiPSC-CM in vitro cardiomyocyte cell models 
for detection of structural and functional cardiotoxicity using impedance-based technologies 
and determined that anthracyclines induce hypertrophy of these cells which may relate to the 
acute cardiotoxicity response. The doxorubicin induced hypertrophy of in vitro cardiomyocyte 
models is associated with amplified expression of the ATR1 paired with increased expression of 
genes that would normally be stimulated by angiotensin II; therefore implicating angiotensin 
signalling as having a direct effect on cardiomyocytes and potentiating the pathogenesis of 
doxorubicin-induced cardiotoxicity. As it is possible that the observed cardioprotection occurs 
via an ATR1 independent mechanism, the aforementioned further work into clarifying the 
involvement of the ATR1 in the cardioprotective response is required and could be obtained 
using siRNA techniques. The mitigation of doxorubicin-induced hypertrophy by angiotensin 
blockade suggests that reduced angiotensin signalling protected cardiomyocytes from the 
additive toxicity caused by angiotensin signalling. This implicates synergism between 
doxorubicin induced cardiotoxicity and angiotensin signalling and further supports the use of 
these pharmaceuticals for protection against doxorubicin-induced cardiotoxicity. Furthermore, 
it is possible that the ACE genotype plays a role in susceptibility to doxorubicin-induced 
cardiotoxicity and may represent an additional risk factor that could be determined at the time 
of diagnosis to help guide appropriate cardioprotective strategies.  
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Appendix 1: Conference Abstracts 
Characterisation of novel molecular mechanisms involved in 
anthracycline-induced cardiotoxicity 
Rockley KL, Richardson G and Gill JH 
Cardiotoxicity is a major complication of many anticancer therapies, impacting the 
quality of life and overall survival of patients, manifesting as both an acute toxicity and 
frequently a chronic toxicity occurring months/years after conclusion of therapy. 
Consequently, greater understanding of the molecular mechanisms responsible for 
these toxicities, or identification of therapeutic strategies to mitigate and overcome 
these toxicities are significantly important.  Recently, clinical studies have demonstrated 
administration of angiotensin-converting enzyme inhibitors (ACEi) and/or β-blockers 
may reduce the cardiotoxicity of anthracyclines. However, despite showing promise, the 
molecular mechanisms responsible for toxicity mitigation are currently unknown. 
Furthermore, the majority of studies to date have either used inappropriate cell models 
or utilised end-point assays to evaluate this mechanism, both strategies that fail to 
account for the progressive nature of human toxicity development. In this study, using 
a human adult cardiomyocyte cell line and in vitro real-time impedance-based cell 
analyses (xCELLigence technology) we demonstrate the induction of cardiomyocyte 
hypertrophy by doxorubicin, and through its reduction by blockade of the angiotensin 
pathway, implicate synergism between doxorubicin-mediated toxicity and direct activity 
of angiotensin II upon cardiomyocytes. The methodologies in this study offer a robust 
clinically relevant model for assessing drug-induced cardiotoxicity, with the study 
identifying a novel mechanism for anthracycline-induced cardiotoxicity. 
 
Presented at the British toxicology society (BTS) annual symposium held in 
Manchester in April 2016 
Awarded a student bursary to attend the BTS annual symposium  
Won annual best poster presentation prize 
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Characterisation of novel molecular mechanisms involved in 
anthracycline-induced cardiotoxicity 
Rockley KL, Richardson G and Gill JH 
Recent advances in cancer treatment have improved cancer survivorship; however as a 
result the incidence of cancer therapy induced cardiotoxicity has increased. This major 
complication can present both as an acute toxicity or a chronic toxicity and can impose 
substantial detriment to both the quality of life and survival of patients. Consequently, 
greater understanding of the molecular mechanisms responsible for these toxicities, and 
identification of therapeutic strategies to mitigate and overcome these toxicities are 
significantly important.  Recently, clinical studies have demonstrated that 
administration of drugs that act upon the angiotensin system may reduce the 
cardiotoxicity of anthracyclines. However, despite showing promise, the molecular 
mechanisms responsible for toxicity mitigation are currently unknown. This study has 
utilised a variety of human cardiomyocyte in vitro models and real-time impedance-
based cell analyses (xCELLigence technology) to demonstrate induction of 
cardiomyocyte hypertrophy by doxorubicin, and through its reduction by blockade of 
the angiotensin pathway, implicates synergism between doxorubicin-mediated toxicity 
and angiotensin signalling in cardiomyocytes. Beat characteristics of iPSC derived 
cardiomyocytes have also been assessed using xCELLigence Cardio technology during 
exposure to doxorubicin alone and during angiotensin blockade in an attempt to 
elucidate the effects of cardiomyocyte hypertrophy on contractility of these cells. The 
methodologies used in this study offer a robust clinically relevant model for assessing 
drug-induced cardiotoxicity, with the study identifying a novel mechanism for 
anthracycline-induced cardiotoxicity. 
 
Presented at the Safety Pharmacology Society (SPS) annual meeting and the ACEA 
cardio symposium both held in Vancouver in September 2016 
Awarded a student travel bursary to attend the SPS annual meeting  
Awarded 1st place in the SPS junior investigator poster competition  
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In vitro assessment of anthracycline-induced cardiotoxicity and mitigation 
through angiotensin blockade 
Rockley KL, Pointon RA, Triffitt KL, Richardson G and Gill JH 
Cardiotoxicity is a major complication of many anticancer therapies, particularly 
anthracyclines, impacting the quality of life and overall survival of patients. 
Consequently, greater understanding of the molecular mechanisms responsible for 
these toxicities, and identification of therapeutic strategies to mitigate and overcome 
these toxicities are significantly important. Recently, clinical studies have demonstrated 
that administration of drugs that act upon the angiotensin system may reduce the 
cardiotoxicity of anthracyclines. However, despite showing promise, the molecular 
mechanisms responsible for toxicity mitigation are currently unknown. Furthermore, 
the majority of studies to date have either used inappropriate cell models or utilised 
end-point assays to evaluate this mechanism, both strategies that fail to account for the 
progressive nature of human toxicity development. This study has utilised a variety of 
human cardiomyocyte in vitro models and real-time impedance-based cell analyses 
(xCELLigence technology) to demonstrate induction of cardiomyocyte hypertrophy by 
anthracyclines. Through its reduction by blockade of the angiotensin pathway, a 
relationship between anthracycline-mediated toxicity and angiotensin signalling in 
cardiomyocytes is demonstrated. The effect of angiotensin and the anthracyclines is also 
shown to be independent of cardiomyocyte contractility, as assessed be changes in 
cellular impedance (xCELLigence Cardio technology). The methodologies used offer a 
model for assessing drug-induced cardiotoxicity that is robust, clinically relevant and 
animal-free, with the study identifying a novel mechanism for anthracycline-induced 
cardiotoxicity. 
Presented at the NC3Rs/Safety Pharmacology Society regional meeting: The use of human 
tissues for safety assessment held in Coventry in May 2017 
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The use of xCELLigence systems to detect structural and functional 
cardiotoxicities of cancer therapies 
Rockley KL, Brown S, Pointon RA and Gill JH 
Recent advances in cancer treatment have improved cancer survivorship; however the 
cardiac safety of cancer therapeutics has lagged behind in comparison. Accurate 
predication of structural and functional cardiac liabilities pre-clinically is therefore of 
crucial importance. Both of these toxicities can be detected using iPSC-derived 
cardiomyocytes (iPSC-CMs) on the xCELLigence cardio system, and the similar 
xCELLigence real-time cell analyser (RTCA) system can detect morphology changes to 
cardiomyocyte cell lines such as AC10 cardiomyocytes (AC10-CMs). Both of these 
systems have the advantage that long-term experiments can be conducted, thus 
allowing recapitulation of the progressive nature of human toxicity development. This 
study has utilised these systems to demonstrate induction of cardiomyocyte 
hypertrophy by the tyrosine kinase inhibitor sunitinib and the notoriously cardiotoxic 
anthracyclines, with changes in contractility also detected with sunitinib addition. The 
sensitivity of these systems at detecting changes in cellular morphology is evidenced by 
concurrent anthracycline and angiotensin receptor blocker (ARB) treatment, where 
reductions in hypertrophy were observed. Recent clinical studies have demonstrated 
that administration of drugs that act upon the angiotensin system may reduce the 
cardiotoxicity of anthracyclines, thus the reduction of anthracycline-induced 
hypertrophy by ARBs shows the translational potential of these systems. The 
methodologies used offer a model for assessing drug-induced cardiotoxicity that is 
robust, clinically relevant and animal-free, with the study identifying both structural and 
functional cardiotoxicities and a novel mechanism for anthracycline-induced 
cardiotoxicity. 
Presented at the ACEA cardio symposium held in Berlin in September 2017 
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The use of impedance-based systems to detect the structural and 
functional cardiotoxicity of cancer therapies 
 
Accurate predication of cardiac liabilities pre-clinically is of crucial importance, with 
current methodologies proving inadequate, evidenced by drug withdrawals and the 
association of many cancer therapeutics with occurrence of cardiotoxicity. The adverse 
effects of cancer therapies on the heart can be broadly classified into structural and 
functional cardiotoxicities, both of which can be detected using iPSC-derived 
cardiomyocytes (iPSC-CMs) on the real-time impedance-based xCELLigence cardio 
system. Due to the rapid data acquisition and ability to record the transient minute 
movements of iPSC-CMs via changes in impedance, information on overall cell health, 
morphology and contractility can be monitored. Using a similar system, the xCELLigence 
real-time cell analyser (RTCA), changes in morphology can be detected on 
cardiomyocyte cell lines such as AC10 cardiomyocytes (AC10-CMs), showing the 
potential of this platform for detection of structural cardiotoxicities. Both of these 
impedance-based systems have the advantage that long-term experiments can be 
conducted, thus allowing recapitulation of the progressive nature of human toxicity 
development. This study has utilised these real-time impedance-based xCELLigence 
systems to demonstrate induction of cardiomyocyte hypertrophy by the tyrosine kinase 
inhibitor sunitinib and the notoriously cardiotoxic anthracyclines, with changes in 
contractility also detected with sunitinib addition. The sensitivity of these systems at 
detecting changes in cellular morphology is evidenced by concurrent anthracycline and 
angiotensin receptor blocker (ARB) treatment, where reductions in hypertrophy were 
observed. Recent clinical studies have demonstrated that administration of drugs that 
act upon the angiotensin system may reduce the cardiotoxicity of anthracyclines, thus 
the reduction of anthracycline-induced hypertrophy by ARBs shows the translational 
potential of these systems. The methodologies used offer a model for assessing drug-
induced cardiotoxicity that is robust, clinically relevant and animal-free, with the study 
identifying both structural and functional cardiotoxicities and a novel mechanism for 
anthracycline-induced cardiotoxicity. 
Oral presentation at the IVTS annual meeting held in London in November 2017
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Appendix 2: Axol application note   
Similar to the qualification of Cor.4U hiPSC-CMs (axiogenesis) described in Chapter 3 (Section 
3.3.3), a study was conducted using Axol hiPSC-CMs which was published in Nature Methods 
Application Notes in November 2016.  
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Appendix 3: Publications 
Contributions in the form of experimental and analytical assistance using the MTT assay were 
made to a project resulting in the following research papers: 
 
Jasmine M. Cross, Tim R. Blower, Natalie Gallagher, Jason H. Gill, Kimberly L. Rockley and James 
W. Walton, Anticancer RuII and RhIII Piano‐Stool Complexes that are Histone Deacetylase 
Inhibitors. ChemPlusChem, 2016. 
 
Jasmine M. Cross, Natalie Gallagher, Jason H. Gill, Mohit Jain, Archibald W. McNeillis, Kimberly L. 
Rockley, Fiona H. Tscherny, Natasha J. Wirszycz, Dmitry S. Yufit and James W. Walton, 
Pyridylphosphinate metal complexes: synthesis, structural characterisation and biological activity. 
Dalton Transactions, 2016 
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Appendix 4: Solutions and gels  
Solution and gel compositions for Western blotting  
 
Composition of MRC lysis buffer 
Stock lysis buffer was stored at -20˚C until required 
Chemical Concentration  
Tris HCl pH 7.5 50mM 
EGTA 1mM 
EDTA 1mM 
Sodium orthovanadate 1mM 
β-glycerol phosphate 10mM 
Sodium fluoride 50mM 
Sodium pyrophosphate 5mM 
Sucrose 0.27M 
Triton x100 1% (v/v) 
β-mercaptoethanol 0.1% 
Mini protease inhibitor 
tablet (Roche, Germany) 
1 tablet per 50ml of 
lysis buffer   
 
 
Composition of 4x Sample buffer  
SDS-sample buffer was stored at room temperature and 10% (v/v) β-mercaptoethanol 
was added prior to use.  
Chemical Concentration 
Tris HCl pH 6.8 240mM 
SDS 8% (w/v) 
Glycerol  40% (v/v) 
Bromophenol blue 0.04% (w/v) 
 
 
Composition of 10% resolving gel 
Chemical Concentration 
Bis/acrylamide 10% (v/v) 
Tris HCl pH 8.8 375mM 
SDS 0.1% 
Ammonium persulfate 0.1% 
TEMED 0.4µl/ml 
Water  To volume  
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Composition of 5% stacking gel 
 
  
 
 
 
 
 
Composition of running buffer  
Chemical Concentration 
Trizma Base 250mM 
Glycine 190mM 
SDS 0.1% (w/v) 
Water To volume 
 
 
Composition of transfer buffer  
Chemical Concentration 
Trizma Base 20mM 
Glycine 150mM 
Methanol 20% (v/v) 
Water To volume 
 
 
Composition of Tris-buffered saline with Tween-20 (TBS-T) 
Chemical Concentration 
Trizma Base 20mM 
NaCl 150mM 
Tween-20 0.1% (v/v) 
 
 
 
 
 
 
Chemical Concentration 
Bis/acrylamide 5% (v/v) 
Tris HCl pH 6.8 125mM 
SDS 0.1% 
Ammonium persulfate 0.1% 
TEMED 1µl/ml 
Water To volume 
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Composition of Enhanced chemiluminescence solution (ECL) 
Prior to use solution 1 and solution 2 were mixed in equal volume 
 Chemical Concentration 
Solution 1 Luminol 2.5mM 
 p-Coumaric acid 0.4mM 
 Tris HCl pH 8.5 100mM 
 Water To volume  
Solution 2 H2O2 30% (v/v) 
 Tris HCl pH 8.5 100mM 
 Water To volume  
 
 
Composition of Acid Stripping Buffer  
pH to 2.2 with concentrated HCl 
Chemical Concentration 
Glycine 3% (w/v) 
SDS 0.2% (w/v) 
Tween-20 2% (v/v) 
Water  To volume  
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Appendix 5: Preliminary RT-PCR studies 
As discussed in Chapter 5 (Section 5.4.2) preliminary studies using reverse transcriptase 
polymerase chain reaction (RT-PCR)  detected gene expression of angiotensinogen, angiotensin 
converting enzyme (ACE) and the angiotensin type I receptor (ATR1) in AC10 cardiomyocytes 
(AC10-CMs), however expression of renin was not detected in the cells. 
The method used for RT-PCR can be found in Chapter 6 (Section 6.2.2.1 Production of cDNA from 
AC10 cardiomyocytes and Section 6.2.2.2 Pre-array verification of cDNA quality), except the cells 
were not exposed to doxorubicin. The same cycling conditions were used as outlined for analysis 
of GAPDH gene expression in section 6.2.2.2, however different annealing temperatures were 
optimised for each primer set.  
The primers used, annealing temperature, expected product size and example gel are shown 
below:  
Primer target Primer sequence 
Annealing 
temp (°C) 
Product 
size 
AC10-CM 
expression 
Angiotensinogen 
F   TCCACCTCGTCATCCACA 
R   GGCTCCCAGATAGAGAGA 
53 329 YES 
ACE 
F   CCGATCTGGCAGAACTTC 
R   GTGTTCCAGATCGTCCTC 
52 314, 408 YES 
ATR1 
F   GATGATTGTCCCAAAGCTGG 
R   TAGGTAATTGCCAAAGGGCC 
54 255 YES 
Renin 
F   AAATGAAGGGGGTGTCTGTGG 
R   AAGCCAATGCGGTTGTTACGC 
60* 397 NO 
 
 
*Annealing temperature from paper by Wagner et al. (1996), positive expression was 
not detected for renin in this study. 
